

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
23 June 2005 (23.06.2005)

PCT

(10) International Publication Number  
**WO 2005/056764 A2**

(51) International Patent Classification<sup>7</sup>: **C12N**  
(21) International Application Number:  
PCT/US2004/040885  
(22) International Filing Date: 6 December 2004 (06.12.2004)  
(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
60/527,886 5 December 2003 (05.12.2003) US

(71) Applicant (for all designated States except US): **COM-  
POUND THERAPEUTICS, INC.** [US/US]; 100 Beaver  
Street, Suite 300, Waltham, MA 02453 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEN, Yan**  
[US/—]. **GETMANOVA, Elena** [US/—]. **WRIGHT,  
Martin, C.** [GB/US]; 812 Memorial Drive, #1105, Cam-  
bridge, MA 02139 (US). **HARRIS, Ai** [US/US]; 197  
Haggetts Pond Road, Andover, MA 01810 (US). **LIM, Ai**  
**Ching**; Newton, MA. **GOKEMEIJER, Jochim**.

(74) Agents: **QUISEL, John, D.** et al.; Ropes & Gray LLP, One  
International Place, Boston, MA 02110-2624 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).



Published:

— without international search report and to be republished  
upon receipt of that report

[Continued on next page]

(54) Title: INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS

### CT-01 Blocks VEGFR-2 Signaling in Human Endothelial Cells



(57) Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS

### RELATED APPLICATIONS

5           This application claims the benefit of the filing date of U.S. Provisional Application No. 60/527,886, entitled "Inhibitors of Vascular Endothelial Growth Factor Receptors" and filed December 5, 2003. All of the teachings of the above-referenced application are incorporated herein by reference.

### 10   BACKGROUND OF THE INVENTION

          The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs).

          Angiogenesis is the process by which new blood vessels are formed from pre-  
15   existing capillaries or post capillary venules; it is an important component of many physiological processes including ovulation, embryonic development, wound repair, and collateral vascular generation in the myocardium. Angiogenesis is also central to a number of pathological conditions such as tumor growth and metastasis, diabetic retinopathy, and macular degeneration. In many instances, the process begins with the  
20   activation of existing vascular endothelial cells in response to a variety of cytokines and growth factors. In cancer, tumor released cytokines or angiogenic factors stimulate vascular endothelial cells by interacting with specific cell surface receptors. The activated endothelial cells secrete enzymes that degrade the basement membrane of the vessels, allowing invasion of the endothelial cells into the tumor tissue. Once situated,  
25   the endothelial cells differentiate to form new vessel offshoots of pre-existing vessels. The new blood vessels provide nutrients to the tumor, facilitating further growth, and also provide a route for metastasis.

          To date, numerous angiogenic factors have been identified, including the particularly potent factor VEGF. VEGF was initially purified from the conditioned  
30   media of folliculostellate cells and from a variety of cell lines. More recently a number of structural homologs and alternatively spliced forms of VEGF have been identified. The various forms of VEGF bind as high affinity ligands to a suite of VEGF receptors

(VEGFRs). VEGFRs are tyrosine kinase receptors, many of which are important regulators of angiogenesis. The VEGFR family includes 3 major subtypes: VEGFR-1, VEGFR-2 (also known as Kinase Insert Domain Receptor, "KDR", in humans), and VEGFR-3. Among VEGF forms, VEGF-A, VEGF-C and VEGF-D are known to bind  
5 and activate VEGFR-2.

VEGF, acting through its cognate receptors, can function as an endothelial specific mitogen during angiogenesis. In addition, there is substantial evidence that VEGF and VEGFRs are up-regulated in conditions characterized by inappropriate angiogenesis, such as cancer. As a result, a great deal of research has focused on the  
10 identification of therapeutics that target and inhibit VEGF or VEGFR.

Current therapeutic approaches that target or inhibit VEGF or VEGFR include antibodies, peptides, and small molecule kinase inhibitors. Of these, antibodies are the most widely used for in vivo recognition and inhibition of ligands and cellular receptors. Highly specific antibodies have been used to block receptor-ligand  
15 interaction, thereby neutralizing the biological activity of the components, and also to specifically deliver toxic agents to cells expressing the cognate receptor on its surface. Although effective, antibodies are large, complex molecules that rely on expression in recombinant mammalian cells for production. Antibodies also cause a variety of side effects that are often undesirable, including activation of complement pathways and  
20 antibody-directed cellular cytotoxicity. As a result, there remains a need for effective therapeutics that can specifically inhibit VEGF/VEGFR pathways as a treatment for disorders characterized by inappropriate angiogenesis, such as cancer.

#### SUMMARY OF THE INVENTION

25 In part, this disclosure provides novel, single domain polypeptides that bind to VEGFR-2 receptors, particularly human VEGFR-2 (also known as KDR) and mouse VEGFR-2 (also known as Flk-1). VEGFR-2 binding proteins described herein may be used, for example, to detect VEGFR-2 in vivo or in vitro. Additionally, certain VEGFR-2 binding proteins described herein may be used to treat diseases associated  
30 with VEGFR-2-mediated biological activity. For example, KDR mediates pro-angiogenic effects of VEGF, and accordingly, certain KDR binding proteins of the disclosure may be used to inhibit angiogenesis in a human patient. Certain VEGFR-2



binding proteins of the disclosure may be used to treat disorders such as cancers, inflammatory diseases, autoimmune diseases and retinopathies. Many disorders related to the hyperproliferation of cells of a tissue will include an angiogenic component, and thus it is expected that certain VEGFR-2 binding proteins described herein can be used  
5 to treat such disorders.

A single domain polypeptide described herein will generally be a polypeptide that binds to a target, such as VEGFR-2, and where target binding activity is situated within a single structural domain, as differentiated from, for example, antibodies and single chain antibodies, where antigen binding activity is generally contributed by both  
10 a heavy chain variable domain and a light chain variable domain. The disclosure also provides larger proteins that may comprise single domain polypeptides that bind to target. For example, a plurality of single domain polypeptides may be connected to create a composite molecule with increased avidity. Likewise, a single domain polypeptide may be attached (e.g., as a fusion protein) to any number of other  
15 polypeptides. In certain aspects a single domain polypeptide may comprise at least five to seven beta or beta-like strands distributed among at least two beta sheets, as exemplified by immunoglobulin and immunoglobulin-like domains. A beta-like strand is a string of amino acids that participates in the stabilization of a single domain polypeptide but does not necessarily adopt a beta strand conformation. Whether a beta-  
20 like strand participates in the stabilization of the protein may be assessed by deleting the string or altering the sequence of the string and analyzing whether protein stability is diminished. Stability may be assessed by, for example, thermal denaturation and renaturation studies. Preferably, a single domain polypeptide will include no more than two beta-like strands. A beta-like strand will not usually adopt an alpha-helical  
25 conformation but may adopt a random coil structure. In the context of an immunoglobulin domain or an immunoglobulin-like domain, a beta-like strand will most often occur at the position in the structure that would otherwise be occupied by the most N-terminal beta strand or the most C-terminal beta strand. An amino acid string which, if situated in the interior of a protein sequence would normally form a  
30 beta strand, may, when situated at a position closer to an N- or C-terminus, adopt a conformation that is not clearly a beta strand and is referred to herein as a beta-like strand.

In certain embodiments, the disclosure provides single domain polypeptides that bind to VEGFR-2. Preferably the single domain polypeptides bind to human KDR, mouse Flk-1, or both. A single domain polypeptide may comprise between about 80 and about 150 amino acids that have a structural organization comprising: at least seven  
5 beta strands or beta-like strands distributed between at least two beta sheets, and at least one loop portion connecting two beta strands or beta-like strands, which loop portion participates in binding to VEGFR-2. In other words a loop portion may link two beta strands, two beta-like strands or one beta strand and one beta-like strand. Typically, one or more of the loop portions will participate in VEGFR-2 binding, although it is  
10 possible that one or more of the beta or beta-like strand portions will also participate in VEGFR-2 binding, particularly those beta or beta-like strand portions that are situated closest to the loop portions. A single domain polypeptide may comprise a structural unit that is an immunoglobulin domain or an immunoglobulin-like domain. A single domain polypeptide may bind to any part of VEGFR-2, although polypeptides that bind  
15 to an extracellular domain of a VEGFR-2 are preferred. Binding may be assessed in terms of equilibrium constants (e.g., dissociation,  $K_D$ ) and in terms of kinetic constants (e.g., on rate constant,  $k_{on}$  and off rate constant,  $k_{off}$ ). A single domain polypeptide will typically be selected to bind to VEGFR-2 with a  $K_D$  of less than  $10^{-6}M$ , or less than  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$  or less than  $10^{-9}M$ . VEGFR-2 binding polypeptides may compete  
20 for binding with one, two or more members of the VEGF family, particularly VEGF-A, VEGF-C and VEGF-D and may inhibit one or more VEGFR-2-mediated biological events, such as proliferation of endothelial cells, permeabilization of blood vessels and increased motility in endothelial cells. VEGFR-2 binding polypeptides may be used for therapeutic purposes as well as for any purpose involving the detection or binding of  
25 VEGFR-2. Polypeptides for therapeutic use will generally have a  $K_D$  of less than  $5 \times 10^{-8}M$ , less than  $10^{-8}M$  or less than  $10^{-9}M$ , although higher  $K_D$  values may be tolerated where the  $k_{off}$  is sufficiently low or the  $k_{on}$  is sufficiently high. In certain embodiments, a single domain polypeptide that binds to VEGFR-2 will comprise a consensus VEGFR-2 binding sequence selected from the group consisting of: SEQ ID NO:1, SEQ  
30 ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. Preferably, such sequence will be situated in a loop, particularly the FG loop.

In certain embodiments, the single domain polypeptide comprises an immunoglobulin (Ig) variable domain. The Ig variable domain may, for example, be selected from the group consisting of: a human V<sub>L</sub> domain, a human V<sub>H</sub> domain and a camelid V<sub>HH</sub> domain. One, two, three or more loops of the Ig variable domain may participate in binding to VEGFR-2, and typically any of the loops known as CDR1, CDR2 or CDR3 will participate in VEGFR-2 binding.

In certain embodiments, the single domain polypeptide comprises an immunoglobulin-like domain. One, two, three or more loops of the immunoglobulin-like domain may participate in binding to VEGFR-2. A preferred immunoglobulin-like domain is a fibronectin type III (Fn3) domain. Such domain may comprise, in order from N-terminus to C-terminus, a beta or beta-like strand, A; a loop, AB; a beta strand, B; a loop, BC; a beta strand C; a loop CD; a beta strand D; a loop DE; a beta strand F; a loop FG; and a beta or beta-like strand G. See Figure 22 for an example of the structural organization. Optionally, any or all of loops AB, BC, CD, DE, EF and FG may participate in VEGFR-2 binding, although preferred loops are BC, DE and FG. A preferred Fn3 domain is an Fn3 domain derived from human fibronectin, particularly the 10<sup>th</sup> Fn3 domain of fibronectin, referred to as <sup>10</sup>Fn3. It should be noted that none of VEGFR-2 binding polypeptides disclosed herein have an amino acid sequence that is identical to native <sup>10</sup>Fn3; the sequence has been modified to obtain VEGFR-2 binding proteins, but proteins having the basic structural features of <sup>10</sup>Fn3, and particularly those retaining recognizable sequence homology to the native <sup>10</sup>Fn3 are nonetheless referred to herein as “<sup>10</sup>Fn3 polypeptides”. This nomenclature is similar to that found in the antibody field where, for example, a recombinant antibody V<sub>L</sub> domain generated against a particular target protein may not be identical to any naturally occurring V<sub>L</sub> domain but nonetheless the protein is recognizably a V<sub>L</sub> protein. A <sup>10</sup>Fn3 polypeptide may be at least 60%, 65%, 70%, 75%, 80%, 85%, or 90% identical to the human <sup>10</sup>Fn3 domain, shown in SEQ ID NO:5. Much of the variability will generally occur in one or more of the loops. Each of the beta or beta-like strands of a <sup>10</sup>Fn3 polypeptide may consist essentially of an amino acid sequence that is at least 80%, 85%, 90%, 95% or 100% identical to the sequence of a corresponding beta or beta-like strand of SEQ ID NO: 5, provided that such variation does not disrupt the stability of the polypeptide in physiological conditions. A <sup>10</sup>Fn3 polypeptide may have a sequence in each of the

loops AB, CD, and EF that consists essentially of an amino acid sequence that is at least 80%, 85%, 90%, 95% or 100% identical to the sequence of a corresponding loop of SEQ ID NO:5. In many instances, any or all of loops BC, DE, and FG will be poorly conserved relative to SEQ ID NO:5. For example, all of loops BC, DE, and FG  
5 may be less than 20%, 10%, or 0% identical to their corresponding loops in SEQ ID NO:5.

In certain embodiments, the disclosure provides a non-antibody polypeptide comprising a domain having an immunoglobulin-like fold that binds to VEGFR-2. The non-antibody polypeptide may have a molecular weight of less than 20 kDa, or less  
10 than 15 kDa and will generally be derived (by, for example, alteration of the amino acid sequence) from a reference, or “scaffold”, protein, such as an Fn3 scaffold. The non-antibody polypeptide may bind VEGFR-2 with a  $K_D$  less than  $10^{-6}M$ , or less than  $10^{-7}M$ , less than  $5 \times 10^{-8}M$ , less than  $10^{-8}M$  or less than  $10^{-9}M$ . The unaltered reference protein either will not meaningfully bind to VEGFR-2 or will bind with a  $K_D$  of greater  
15 than  $10^{-6}M$ . The non-antibody polypeptide may inhibit VEGF signaling, particularly where the non-antibody polypeptide has a  $K_D$  of less than  $5 \times 10^{-8}M$ , less than  $10^{-8}M$  or less than  $10^{-9}M$ , although higher  $K_D$  values may be tolerated where the  $k_{off}$  is sufficiently low (e.g., less than  $5 \times 10^{-4} s^{-1}$ ). The immunoglobulin-like fold may be a  $^{10}Fn3$  polypeptide.

20 In certain embodiments, the disclosure provides a polypeptide comprising a single domain having an immunoglobulin fold that binds to VEGFR-2. The polypeptide may have a molecular weight of less than 20 kDa, or less than 15 kDa and will generally be derived (by, for example, alteration of the amino acid sequence) from a variable domain of an immunoglobulin. The polypeptide may bind VEGFR-2 with a  
25  $K_D$  less than  $10^{-6}M$ , or less than  $10^{-7}M$ , less than  $5 \times 10^{-8}M$ , less than  $10^{-8}M$  or less than  $10^{-9}M$ . The polypeptide may inhibit VEGF signaling, particularly where the polypeptide has a  $K_D$  of less than  $5 \times 10^{-8}M$ , less than  $10^{-8}M$  or less than  $10^{-9}M$ , although higher  $K_D$  values may be tolerated where the  $k_{off}$  is sufficiently low or where the  $k_{on}$  is sufficiently high. In certain preferred embodiments, a single domain polypeptide  
30 having an immunoglobulin fold derived from an immunoglobulin light chain variable domain and capable of binding to VEGFR-2 may comprise an amino acid sequence selected from the group consisting of: SEQ ID NOs:241-310.

In certain preferred embodiments, the disclosure provides VEGFR-2 binding polypeptides comprising the amino acid sequence of any of SEQ ID NOs:192-194. In the case of a polypeptide comprising the amino acid sequence of SEQ ID NO:194, a PEG moiety or other moiety of interest, may be covalently bound to the cysteine at position 93. The PEG moiety may also be covalently bonded to an amine moiety in the polypeptide. The amine moiety may be, for example, a primary amine found at the N-terminus of a polypeptide or an amine group present in an amino acid, such as lysine or arginine. In certain embodiments, the PEG moiety is attached at a position on the polypeptide selected from the group consisting of: a) the N-terminus; b) between the N-terminus and the most N-terminal beta strand or beta-like strand; c) a loop positioned on a face of the polypeptide opposite the target-binding site; d) between the C-terminus and the most C-terminal beta strand or beta-like strand; and e) at the C-terminus.

In certain aspects, the disclosure provides short peptide sequences that mediate VEGFR-2 binding. Such sequences may mediate VEGFR-2 binding in an isolated form or when inserted into a particular protein structure, such as an immunoglobulin or immunoglobulin-like domain. Examples of such sequences include those disclosed as SEQ ID NOs:1-4 and other sequences that are at least 85%, 90%, or 95% identical to SEQ ID NOs:1-4 and retain VEGFR-2 binding activity. Accordingly, the disclosure provides substantially pure polypeptides comprising an amino acid sequence that is at least 85% identical to the sequence of any of SEQ ID NOs:1-4, wherein said polypeptide binds to a VEGFR-2 and competes with a VEGF species for binding to VEGFR-2. Examples of such polypeptides include a polypeptide comprising an amino acid sequence that is at least 80%, 85%, 90%, 95% or 100% identical to an amino acid sequence at least 85% identical to the sequence of any of SEQ ID NOs:6-183, 186-197, and 199. Preferably such polypeptide will inhibit a biological activity of VEGF and may bind to VEGFR-2 with a  $K_D$  less than  $10^{-6}M$ , or less than  $10^{-7}M$ , less than  $5 \times 10^{-8}M$ , less than  $10^{-8}M$  or less than  $10^{-9}M$ .

In certain embodiments, any of the VEGFR-2 binding polypeptides described herein may be bound to one or more additional moieties, including, for example, a moiety that also binds to VEGFR-2 (e.g., a second identical or different VEGFR-2 binding polypeptide), a moiety that binds to a different target (e.g., to create a dual-specificity binding agent), a labeling moiety, a moiety that facilitates protein

purification or a moiety that provides improved pharmacokinetics. Improved pharmacokinetics may be assessed according to the perceived therapeutic need. Often it is desirable to increase bioavailability and/or increase the time between doses, possibly by increasing the time that a protein remains available in the serum after dosing. In some instances, it is desirable to improve the continuity of the serum concentration of the protein over time (e.g., decrease the difference in serum concentration of the protein shortly after administration and shortly before the next administration). Moieties that tend to slow clearance of a protein from the blood include polyethylene glycol, sugars (e.g. sialic acid), and well-tolerated protein moieties (e.g., Fc fragment or serum albumin). The single domain polypeptide may be attached to a moiety that reduces the clearance rate of the polypeptide in a mammal (e.g., mouse, rat, or human) by greater than three-fold relative to the unmodified polypeptide. Other measures of improved pharmacokinetics may include serum half-life, which is often divided into an alpha phase and a beta phase. Either or both phases may be improved significantly by addition of an appropriate moiety. Where polyethylene glycol is employed, one or more PEG molecules may be attached at different positions in the protein, and such attachment may be achieved by reaction with amines, thiols or other suitable reactive groups. Pegylation may be achieved by site-directed pegylation, wherein a suitable reactive group is introduced into the protein to create a site where pegylation preferentially occurs. In a preferred embodiment, the protein is modified so as to have a cysteine residue at a desired position, permitting site directed pegylation on the cysteine. PEG may vary widely in molecular weight and may be branched or linear. Notably, the present disclosure establishes that pegylation is compatible with target binding activity of <sup>10</sup>F<sub>n</sub>3 polypeptides and, further, that pegylation does improve the pharmacokinetics of such polypeptides. Accordingly, in one embodiment, the disclosure provides pegylated forms of <sup>10</sup>F<sub>n</sub>3 polypeptides, regardless of the target that can be bound by such polypeptides.

In certain embodiments, the disclosure provides a formulation comprising any of the VEGFR-2 binding polypeptides disclosed herein. A formulation may be a therapeutic formulation comprising a VEGFR-2 binding polypeptide and a pharmaceutically acceptable carrier. A formulation may also be a combination



formulation, comprising an additional active agent, such as an anti-cancer agent or an anti-angiogenic agent.

In certain aspects, the disclosure provides methods for using a VEGFR-2 binding protein to inhibit a VEGF biological activity in a cell or to inhibit a biological activity mediated by VEGFR-2. The cell may be situated in vivo or ex vivo, and may be, for example, a cell of a living organism, a cultured cell or a cell in a tissue sample. The method may comprise contacting said cell with any of the VEGFR-2-inhibiting polypeptides disclosed herein, in an amount and for a time sufficient to inhibit such biological activity.

In certain aspects, the disclosure provides methods for treating a subject having a condition which responds to the inhibition of VEGF or VEGFR-2. Such a method may comprise administering to said subject an effective amount of any of the VEGFR-2 inhibiting polypeptides described herein. A condition may be one that is characterized by inappropriate angiogenesis. A condition may be a hyperproliferative condition. Examples of conditions (or disorders) suitable for treatment include autoimmune disorders, inflammatory disorders, retinopathies (particularly proliferative retinopathies), and cancers. Any of the VEGFR-2 inhibiting polypeptides described herein may be used for the preparation of a medicament for the treatment of a disorder, particularly a disorder selected from the group consisting of: an autoimmune disorder, an inflammatory disorder, a retinopathy, and a cancer.

In certain aspects, the disclosure provides methods for detecting VEGFR-2 in a sample. A method may comprise contacting the sample with a VEGFR-2 binding polypeptide described herein, wherein said contacting is carried out under conditions that allow polypeptide-VEGFR-2 complex formation; and detecting said complex, thereby detecting said VEGFR-2 in said sample. Detection may be carried out using any technique known in the art, such as, for example, radiography, immunological assay, fluorescence detection, mass spectroscopy, or surface plasmon resonance. The sample will often be a biological sample, such as a biopsy, and particularly a biopsy of a tumor, a suspected tumor or a tissue suspected of undergoing unwanted angiogenesis. The sample may be from a human or other mammal. The VEGFR-2 binding polypeptide may be labeled with a labeling moiety, such as a radioactive moiety, a

fluorescent moiety, a chromogenic moiety, a chemiluminescent moiety, or a hapten moiety. The VEGFR-2 binding polypeptide may be immobilized on a solid support.

Another aspect of the disclosure relates to a nucleic acid comprising a nucleic acid sequence encoding a polypeptide disclosed herein. In certain embodiments, a nucleic acid may comprise a nucleic acid sequence encoding a polypeptide selected from the group consisting of any of SEQ ID Nos. 6-183, 186-197, 199 and 241-528. In certain embodiments, a nucleic acid comprises a nucleic acid sequence that hybridizes in stringent conditions to a nucleic acid sequence of SEQ ID NO:184 and encodes a polypeptide that binds to human KDR with a KD of less than  $1 \times 10^{-6} \text{M}$ . In particular  
5  
10  
embodiments, nucleic acid may comprise a nucleic acid sequence selected from the group consisting of SEQ ID NO:184 and SEQ ID NO:185.

A further aspect of the disclosure relates to an expression vector comprising a nucleic acid operably linked with a promoter, wherein the nucleic acid encodes a polypeptide disclosed herein. Another aspect of the disclosure relates to a cell  
15  
comprising a nucleic acid disclosed herein. Also provided is a method of producing the polypeptide that binds VEGFR-2, e.g., KDR, comprising: expressing a nucleic acid encoding a polypeptide of the disclosure. In certain embodiments, the nucleic acid may comprise a sequence that encodes a polypeptide selected from the group consisting of any of SEQ ID Nos. 6-183, 186-197, 199 and 241-528. In certain embodiments, the  
20  
nucleic acid comprises a sequence that hybridizes in stringent conditions to a nucleic acid sequence of SEQ ID NO:184. In certain embodiments, the nucleic acid comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:184 and SEQ ID NO:185. In certain embodiments, the nucleic acid is expressed in a cell. Alternatively, the nucleic acid is expressed in a cell-free system.

25  
In certain aspects, the disclosure provides discoveries that may be applicable to any  $^{10}\text{Fn3}$  polypeptide, regardless of which target the polypeptide is engineered to bind. As noted above, the disclosure demonstrates that PEG can be used successfully to improve the pharmacokinetics of a  $^{10}\text{Fn3}$  polypeptide, while not interfering meaningfully with target binding. Accordingly, the disclosure provides pegylated  
30  
 $^{10}\text{Fn3}$  polypeptides that bind to target and have improved pharmacokinetics relative to the non-pegylated polypeptide. In a further embodiment, the disclosure demonstrates that a deletion of the first eight amino acids of a  $^{10}\text{Fn3}$  polypeptide can increase target



binding affinity. Accordingly, the disclosure provides <sup>10</sup>F<sub>n</sub>3 polypeptides lacking the initial eight amino acids (amino acids numbered in reference to the sequence of SEQ ID No:5). It is understood that one or two amino acids may be added back to the deleted form of the polypeptide so as to facilitate translation and proper processing. The disclosure demonstrates that subcutaneous administration of a <sup>10</sup>F<sub>n</sub>3 polypeptide results in a delayed release of polypeptide into the bloodstream and a decreased maximum serum concentration of the <sup>10</sup>F<sub>n</sub>3 polypeptide. Accordingly, the disclosure provides methods for administering a <sup>10</sup>F<sub>n</sub>3 polypeptide to a patient by a subcutaneous administration. This route of administration may be useful to achieve a delayed release relative to intravenous administration, and/or to decrease the maximum serum concentration of the <sup>10</sup>F<sub>n</sub>3 polypeptide by at least 25% or at least 50% relative to the maximum serum concentration achieved by intravenous administration of an equal dosage. The administered <sup>10</sup>F<sub>n</sub>3 polypeptide may be attached to a moiety that increases the serum half-life (or decreases clearance rate, or similarly affects another pharmacokinetic parameter) of the <sup>10</sup>F<sub>n</sub>3 polypeptide, such as a polyethylene glycol moiety. Preferably, the administered <sup>10</sup>F<sub>n</sub>3 polypeptide comprises an amino acid sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90% identical to SEQ ID NO:5.

In certain aspects, the disclosure provides single domain polypeptides that bind to a preselected target protein from a first mammal and to a homolog thereof from a second mammal. Such single domain polypeptides are particularly useful where the first mammal is a human and the second mammal is a desirable mammal in which to conduct preclinical testing, such as a mouse, rat, guinea pig, dog, or non-human primate. The disclosure demonstrates that single domain polypeptides can be engineered to have such dual specificity, and that the dual specificity simplifies drug development by allowing testing of the same polypeptide in human cells, human subjects and animal models. Preferably, the preselected target protein of the first mammal and the homolog thereof from the second mammal are sufficiently similar in amino acid sequence to allow generation of dual specificity polypeptides. For example, the preselected target protein and the homolog from the second mammal may share at least 80%, 90%, or 95% identity across a region of at least 50 amino acids, and optionally may share at least 80%, 90%, or 95% identity across the entire protein

sequence or across the sequence of the extracellular domain, in the case of a membrane protein. A single domain polypeptide with this type of dual specificity binding characteristic may comprise an immunoglobulin or immunoglobulin-like domain, and will preferably bind to both the preselected human target protein and to the homolog thereof with a dissociation constant of less than  $1 \times 10^{-6} \text{M}$ ,  $1 \times 10^{-7} \text{M}$ ,  $5 \times 10^{-8} \text{M}$ ,  $1 \times 10^{-8} \text{M}$  or  $1 \times 10^{-9} \text{M}$ .

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1D are graphs and images depicting the characterization of KDR-binding single clones from Round 6 of KDR selection. Figure 1A is a graph showing the specific binding of fibronectin-based binding proteins to 25 nM of KDR-Fc analyzed in radioactive equilibrium binding assay. Figure 1B is a graph showing the inhibition of specific binding of KDR-Fc and selected fibronectin based binding proteins in the presence of 100-fold excess of VEGF<sub>165</sub>. As shown in this figure, certain binding proteins bound KDR-Fc competitively with VEGF<sub>165</sub> while others, exemplified by clone 8, did not compete with VEGF<sub>165</sub>. Figure 1C is a graph showing the inhibition of KDR-Fc interaction with immobilized VEGF<sub>165</sub> in presence of selected fibronectin based binding proteins analyzed in BIAcore. Figure 1D is an image showing binding of VR28 to KDR-expressing and control cells detected by immunofluorescence.

Figure 2 is a graph showing the selection profile for the affinity maturation of VR28 KDR binder. Shown at left is binding of the VR28 clone to KDR-Fc and Flk1-Fc (very low, unlabeled bar). Shown at center is binding of a crude mutagenized pool and subsequent enrichment rounds to KDR-Fc. Shown at right is binding of further enrichment rounds to Flk-1-Fc. Binding was estimated in radioactive equilibrium binding assay as a percentage of input, using 1nM KDR-Fc or Flk1-Fc.

Figures 3A and 3B are graphs depicting the characterization of KDR-binding single clones from Round 4 of anti-KDR affinity maturation of VR28 binder. Figure 3A shows the saturation binding of VR28 (■) and affinity matured K1 (▲), K6 (▼), K9 (◆), K10 (●), K12 (□), K13 (△), K14 (▽), K15 (◇) to KDR-Fc in radioactive equilibrium binding assay. Figure 3B shows the binding of clones with and without N-terminal deletion to KDR-Fc. Deletion  $\Delta 1-8$  in the N-terminus of

fibronectin-based binding proteins improved binding to KDR-Fc. The data represents an average KDR-Fc binding of 23 independent clones with and without N-terminal deletion.

Figure 4 is a graph showing the binding of the selected clones to KDR and Flk-1. Specific binding of VR28 and selected clones after four rounds of affinity maturation to human KDR (K clones) and seven rounds of affinity maturation to human (KDR) and mouse (flk-1) (E clones). VEGFR-2-Fc chimeras were compared in radioactive equilibrium binding assay. The data represents an average of 3 independent experiments. As shown here, maturation against both mouse and human VEGFR-2 proteins produces binders that bind to both proteins.

Figures 5A and 5B are graphs showing the characterization of VEGFR-2-binding single clones from Round 7 of affinity maturation of VR28 binder. Saturation binding of VR28 (-■-) and specificity matured E3 (-▲-), E5 (-▼-), E6 (-◆-), E9 (-●-), E18 (-□-), E19 (-△-), E25 (-▽-), E26 (-◇-), E28 (-○-), E29 (-×-) clones to KDR (Figure 5A) and Flk1 (Figure 5B)-Fc chimeras was tested in radioactive equilibrium binding assay.

Figures 6A and 6B are graphs showing the characterization of VEGFR-2 binding by single clones from Round 7 of affinity maturation of the VR28 binder. Figure 6A shows the importance of arginine at positions 79 and 82 in binders with dual specificity to human and mouse VEGFR-2 for binding to mouse VEGFR-2 (Flk1). When either of these positions was replaced by amino acid other than R (X79 = E, Q, W, P; X82 = L, K), binding to Flk1 but not to KDR significantly decreased. Figure 6B shows the importance of all three variable loops (BC, DE and FG) of KDR fibronectin-based binding proteins for binding to the target in these proteins. Substitution of each loop at a time by NNS sequence affected binding to KDR and Flk1. The binding data is an average from E6 and E26 clones.

Figures 7A and 7B are graphs showing the binding of selected fibronectin-based binding proteins to CHO cells expressing human KDR receptor (Figure 7A) and EpoR-Flk1 chimera (Figure 7B). E18 (-■-), E19 (-▲-), E26 (-▼-), E29 (-◆-) and WT (-□-) fibronectin-based scaffold proteins were tested. No binding to control CHO cells was observed (data not shown).

Figures 8A and 8B are graphs showing the inhibition of VEGF-induced proliferation of Ba/F3-KDR (Figure 8A) and Ba/F3-Flk1 (Figure 8B) cells, expressing KDR and Flk1 in the presence of different amounts of fibronectin-based binding proteins: E18 (-■-), E19 (-▲-), E26 (-▼-), E29 (-◆-), M5 (-●-), WT (-□-) and anti-KDR or anti-flk-1 Ab (-△-). The data represents an average of 2 independent experiments.

Figure 9 is a graph showing the results of a HUVEC proliferation assay in the presence of different amounts of fibronectin-based scaffold proteins: E18 (-■-), E19 (-▲-), E26 (-▼-), E29 (-◆-), M5 (-●-), WT (-□-). The data represents an average of 2 independent experiments. As shown, the KDR binding proteins caused a decrease in proliferation by approximately 40%.

Figure 10 is a set of graphs showing the reversible refolding of M5FL in optimized buffer.

Figure 11 is an image showing SDS-PAGE analysis of pegylated forms of M5FL. M, molecular weight markers [Sea Blue Plus, Invitrogen]; -, M5FL alone; 20, M5FL with 20kD PEG; 40, M5FL with 40kD PEG.

Figure 12 is a graph showing the inhibition of VEGF-induced proliferation of Ba/F3-KDR cells with differing amounts of M5FL (-◆-), M5FL PEG20 (-■-) and M5FL PEG40(-▲-), respectively. Pegylation has little or no effect on M5FL activity in this assay.

Figure 13 shows western analysis of VEGFR-2 signaling in endothelial cells. Phospho VEGFR-2 – Visualization of phosphorylated VEGFR-2. VEGFR-2 – Sample loading control. Phospho ERK1/2 – Visualization of phosphorylated ERK1/2 (MAPK). ERK1 – Sample loading control. The results demonstrated that 130 pM CT-01 blocks VEGFR-2 activation and signaling by VEGF-A.

Figure 14 shows that various <sup>10</sup>F<sub>n</sub>3-derived molecules (e.g. M5FL, F10, CT-01) can block VEGF-A and VEGF-D signaling.

Figure 15 shows a comparison of <sup>125</sup>I native, pegylated CT-01 administered i.v. & i.p. CT-01 is a 12 kDa protein. It is rapidly cleared from the blood. Addition of a 40 kDa PEG reduces its clearance rate and increases the AUC by 10 fold. Half life of 16 hr in rats is equivalent to 2X dosing per week in humans. Administration route: i.p. CT-01-PEG40 has an AUC that is only 50% of an i.v. administration.

Figure 16 shows the tissue distribution of  $^{125}\text{I}$ -CT01PEG40 in normal rats. Tissue distribution of  $^{125}\text{I}$ -CT01PEG40 indicates secretion primarily via the liver and secondarily via the kidney. This is expected for the high molecular weight PEG form. No long term accumulation of CT-01PEG40 is detected.

5        Figure 17 is a schematic view of the Miles Assay that measures vascular permeability.

Figure 18 shows that CT-01 blocks VEGF in vivo using the Miles Assay. The results indicate that 5 mg/kg of CT01-PEG40 blocks VEGF challenge.

10       Figure 19 shows that CT-01 inhibits tumor growth using the B16-F10 Murine Melanoma Tumor Assay.

Figure 20 shows that CT-01 inhibits tumor growth using U87 Human Glioblastoma.

Figures 21A and 21B show the sequences of VEGFR binding polypeptides that are based on an antibody light chain framework/scaffold (SEQ ID NOs:241-310).

15       Figure 22 shows the structural organization for a single domain polypeptide having an immunoglobulin fold (a  $V_H$  domain of an immunoglobulin, left side) and a single domain polypeptide having an immunoglobulin-like fold (a  $^{10}\text{Fn3}$  domain, right side).

## 20       DETAILED DESCRIPTION OF THE INVENTION

### 1.       Overview

This specification describes, *inter alia*, the identification and production of novel, single domain polypeptides that bind to VEGFR-2 receptors. VEGFR-2, also called KDR in humans and Flk-1 in mice, is the primary mediator for the pro-  
25       angiogenic effects of VEGF signaling. VEGFR-2 is bound and activated by VEGF-A, VEGF-C and VEGF-D. In endothelial cells, VEGFR-2 activation stimulates cell proliferation and migration, and in vivo, VEGFR-2 activation triggers angiogenesis and increases the permeability of the vasculature. Increased angiogenesis is well-  
30       established as an important feature of tumor growth and various retinopathies, while increased permeability of the vasculature is a significant event in many inflammatory responses.

The present disclosure provides hundreds of single domain polypeptides that bind to VEGFR-2, many of which exhibit in vitro and/or in vivo VEGF antagonist activity. Single domain polypeptides having VEGF antagonist activity will be useful in numerous therapeutic applications. Anti-KDR antibodies have been established as having in vivo utility against diseases and conditions ranging from cancers and complications resulting from cancers to proliferative retinopathies, inflammatory disorders and fibrosis. Based on the in vivo and in vitro data presented here, it is expected that the single domain polypeptides will be useful in treating the same spectrum of disorders.

In addition to therapeutic applications, VEGFR-2-binding single domain polypeptides may be used in any circumstance where it is desirable to detect VEGFR-2. For example, many stem cells express VEGFR-2, including particularly useful cells of hematopoietic lineages. KDR-binding polypeptides may be used, particularly in a labeled format, to detect stem cells and facilitate cell sorting. In vivo, labeled VEGFR-2-binding polypeptides may be used to image tissues in which VEGFR-2 is expressed. Elevated VEGFR-2 expression may be characteristic of tissues experiencing particularly high levels of angiogenic or inflammatory activity. Histological analyses of tissue samples may also benefit from detection of VEGFR-2. For example, it may be desirable to detect VEGFR-2 expression in a tumor biopsy in order to assess the likely effectiveness of an anti-VEGFR-2 or anti-VEGF therapy. Interestingly, many of the VEGFR-2 binding proteins disclosed herein bind to VEGFR-2 with nanomolar dissociation constants and yet fail to have a significant effect on VEGFR-2 mediated biological events. Accordingly, such binding proteins, may be useful for in vivo visualization techniques or cell-labeling techniques, where it will often be desirable to selectively label cells that express a VEGFR-2 without causing a significant perturbation of VEGFR-2 mediated events.

This disclosure describes the use of an in vitro display technology, termed PROfusion<sup>TM</sup>, that exploits nucleic acid-protein fusions (RNA- and DNA-protein fusions) to identify novel single domain polypeptides and amino acid motifs that are important for binding to VEGFR-2. Nucleic acid-protein fusion technology is a display technology that covalently couples a protein to its encoding genetic information. PROfusion<sup>TM</sup> technology was used to screen collections of nucleic acids encoding



single domain polypeptides constructed using a scaffold based on the human fibronectin type three domain (<sup>10</sup>Fn3) or constructed from the variable domains of antibody light chains. The expressed polypeptides, termed a “library” of scaffold proteins, was screened for polypeptides that could bind VEGFR-2 with high affinity.

5 We isolated from this library of scaffold proteins novel single domain polypeptides that bind to VEGFR-2 and that, in some instances, inhibit VEGF biological activities. Furthermore, it was discovered that many independently randomized loops situated in immunoglobulin or immunoglobulin-like scaffolds tended to converge to a related set of consensus sequences that participated in VEGFR-2 binding. Therefore, it is  
10 expected that polypeptides having these consensus sequences will be useful as VEGFR-2 binding agents even when separated from the protein context in which they were identified. See, for example, SEQ ID Nos. 1-4. Such polypeptides may be used as independent, small peptide VEGFR-2 binding agents or may be situated in other proteins, particularly proteins that share an immunoglobulin or immunoglobulin-like  
15 fold.

As discussed above, the present disclosure demonstrates that single domain polypeptides having certain desirable properties, such as high affinity binding to VEGFR-2, antagonist effects with respect to one or more of VEGF-A, -C or -D and improved pharmacokinetics, can be used as effective anti-cancer agents. While it is  
20 expected that the effectiveness of such polypeptides as anti-cancer agents is related to the role of angiogenesis in cancer, we do not wish to be bound to any particular mechanism. It is formally possible that the present single domain polypeptides are effective against cancers for reasons unrelated to angiogenic processes.

To our knowledge, the present disclosure represents the first successful effort to  
25 use an Fn3-based polypeptide to achieve a therapeutic effect in vivo. Many of the improvements and discoveries made in achieving in vivo effectiveness will be broadly applicable to other Fn3-based polypeptides. In other words, although ligand binding properties of an Fn3-based polypeptide will generally be determined by a relatively small number of amino acids situated in solvent accessible loop regions, other features,  
30 such as pharmacokinetic features, of Fn3-based polypeptides will tend to be determined by the majority of the protein that is not directly involved in ligand binding and that is conserved from protein to protein regardless of the target protein. This has been the

case with antibodies, where a few loops, called CDR regions, mediate antigen binding, while other features of in vivo antibody behavior are largely dictated by the conserved framework regions and constant domains.

By “inhibit” is meant a measurable reduction in a phenomenon, often used  
5 herein in reference to any of the following: the interaction of VEGF with a VEGFR, VEGF- or VEGFR-mediated angiogenesis, angiogenesis, symptoms of angiogenesis, the viability of VEGFR-containing cells, the viability of VEGF-dependent Ba/F3 cells, or VEGF- or VEGFR-mediated cellular proliferation as compared to a control sample not treated with the polypeptide. A polypeptide will inhibit a VEGF- or VEGFR-2  
10 mediated activity if the reduction in activity or interaction is at least 10%, preferably 20%, 30%, 40%, or 50%, and more preferably 60%, 70%, 80%, 90% or more.

By “VEGF biological activity” is meant any function of any VEGF family member acting through any VEGF receptor, but particularly signaling through a VEGFR-2 receptor. The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-  
15 D, and placental growth factor (PIGF), as well as various alternatively spliced forms of VEGF including VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206 (Tischer et al., J. Biol. Chem, 266:11947-11954, 1991). The VEGFR family of tyrosine kinase receptors includes VEGFR-1 (also known as Flt-1), VEGFR-2 (also known as KDR (human form) or Flk-1 (mouse form)), and VEGFR-3 (also known as Flt-4). VEGF  
20 ligands bind to the VEGF receptors to induce, for example, angiogenesis, vasculogenesis, endothelial cell proliferation, vasodilation, and cell migration. VEGF ligands can also inhibit apoptosis through binding to their cognate receptors. VEGFR-2 is believed to be the VEGFR most involved in angiogenesis. A VEGFR-2 or KDR-mediated biological activity is any biological function in which VEGFR-2 or KDR  
25 participates in significantly, such that antagonism of VEGFR-2 or KDR causes a measurable decrease in the biological activity. The biological activity of VEGF and VEGFR can be measured by standard assays known in the art. Examples include ligand binding assays and Scatchard plot analysis; receptor dimerization assays; cellular phosphorylation assays; tyrosine kinase phosphorylation assays (see for example Meyer et al., Ann. N.Y. Acad. Sci. 995:200-207, 2003); endothelial cell proliferation assays  
30 such as BrdU labeling and cell counting experiments; VEGF-dependent cell proliferation assays; and angiogenesis assays. Methods for measuring angiogenesis are



standard, and are described, for example, in Jain et al. (Nat. Rev. Cancer 2:266-276, 2002). Angiogenesis can be assayed by measuring the number of non-branching blood vessel segments (number of segments per unit area), the functional vascular density (total length of perfused blood vessel per unit area), the vessel diameter, the formation of vascular channels, or the vessel volume density (total of calculated blood vessel volume based on length and diameter of each segment per unit area). Exemplary assays for VEGF-mediated proliferation and angiogenesis can be found in U.S.P.N. 6,559,126, Lyden et al, Nature Medicine 7:1194 (2001), Jacob et al, Exp. Pathol. 15:1234 (1978) and Bae et al, J. Biol. Chem. 275:13588 (2000). These assays can be performed using either purified receptor or ligand or both, and can be performed in vitro or in vivo. These assays can also be performed in cells using a genetically introduced or the naturally-occurring ligand or receptor or both. A polypeptide that inhibits the biological activity of VEGF will cause a decrease of at least 10%, preferably 20%, 30%, 40%, or 50%, and more preferably 60%, 70%, 80%, 90% or greater decrease in the biological activity of VEGF. The inhibition of biological activity can also be measured by the IC<sub>50</sub>. Preferably, a polypeptide that inhibits the biological activity of VEGF or VEGFR-2 will have an IC<sub>50</sub> of less than 100 nM, more preferably less than 10 nM and most preferably less than 1 nM.

## 2. Polypeptides

The methodology described herein has been successfully used to develop single domain VEGFR-2 binding polypeptides derived from two related groups of protein structures: those proteins having an immunoglobulin fold and those proteins having an immunoglobulin-like fold. By a "polypeptide" is meant any sequence of two or more amino acids, regardless of length, post-translation modification, or function.

"Polypeptide," "peptide," and "protein" are used interchangeably herein. Polypeptides can include natural amino acids and non-natural amino acids such as those described in U.S.P.N. 6,559,126, incorporated herein by reference. Polypeptides can also be modified in any of a variety of standard chemical ways (e.g., an amino acid can be modified with a protecting group; the carboxy-terminal amino acid can be made into a terminal amide group; the amino-terminal residue can be modified with groups to, e.g., enhance lipophilicity; or the polypeptide can be chemically glycosylated or otherwise

modified to increase stability or *in vivo* half-life). Polypeptide modifications can include the attachment of another structure such as a cyclic compound or other molecule to the polypeptide and can also include polypeptides that contain one or more amino acids in an altered configuration (i.e., R or S; or, L or D). The term “single domain polypeptide” is used to indicate that the target binding activity (e.g., VEGFR-2 binding activity) of the subject polypeptide is situated within a single structural domain, as differentiated from, for example, antibodies and single chain antibodies, where antigen binding activity is generally contributed by both a heavy chain variable domain and a light chain variable domain. It is contemplated that a plurality of single domain polypeptides of the sort disclosed herein could be connected to create a composite molecule with increased avidity. Likewise, a single domain polypeptide may be attached (e.g., as a fusion protein) to any number of other polypeptides, such as fluorescent polypeptides, targeting polypeptides and polypeptides having a distinct therapeutic effect.

Single domain polypeptides of either the immunoglobulin or immunoglobulin-like scaffold will tend to share certain structural features. For example, the polypeptide may comprise between about 80 and about 150 amino acids, which amino acids are structurally organized into a set of beta or beta-like strands, forming beta sheets, where the beta or beta-like strands are connected by intervening loop portions. Examples of the structural organization for the heavy chain variable domain and the <sup>10</sup>Fn3 domain are shown in Figure 22. The beta sheets form the stable core of the single domain polypeptides, while creating two “faces” composed of the loops that connect the beta or beta-like strands. As described herein, these loops can be varied to create customized ligand binding sites, and, with proper control, such variations can be generated without disrupting the overall stability of the protein. In antibodies, three of these loops are the well-known Complementarity Determining Regions (or “CDRs”).

Scaffolds for formation of a single domain polypeptides should be highly soluble and stable in physiological conditions. Examples of immunoglobulin scaffolds are the single domain V<sub>H</sub> or V<sub>L</sub> scaffold, as well as a single domain camelid V<sub>HH</sub> domain (a form of variable heavy domain found in camelids) or other immunoglobulin variable domains found in nature or engineered in the laboratory. In the single domain format disclosed herein, an immunoglobulin polypeptide need not form a dimer with a

second polypeptide in order to achieve binding activity. Accordingly, any such polypeptides that naturally contain a cysteine which mediates disulfide cross-linking to a second protein can be altered to eliminate the cysteine. Alternatively, the cysteine may be retained for use in conjugating additional moieties, such as PEG, to the single  
 5 domain polypeptide.

Other scaffolds may be non-antibody scaffold proteins. By “non-antibody scaffold protein or domain” is meant a non-antibody polypeptide having an immunoglobulin-like fold. By “immunoglobulin-like fold” is meant a protein domain of between about 80-150 amino acid residues that includes two layers of antiparallel  
 10 beta-sheets, and in which the flat, hydrophobic faces of the two beta-sheets are packed against each other. An example of such a scaffold is the “fibronectin-based scaffold protein”, by which is meant a polypeptide based on a fibronectin type III domain (Fn3). Fibronectin is a large protein which plays essential roles in the formation of extracellular matrix and cell-cell interactions; it consists of many repeats of three types  
 15 (types I, II, and III) of small domains (Baron et al., 1991). Fn3 itself is the paradigm of a large subfamily which includes portions of cell adhesion molecules, cell surface hormone and cytokine receptors, chaperoning, and carbohydrate-binding domains. For reviews see Bork & Doolittle, Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):8990-4; Bork et al., J Mol Biol. 1994 Sep 30;242(4):309-20; Campbell & Spitzfaden, Structure.  
 20 1994 May 15;2(5):333-7; Harpez & Chothia, J Mol Biol. 1994 May 13;238(4):528-39)..

Preferably, the fibronectin-based scaffold protein is a “<sup>10</sup>FN3” scaffold, by which is meant a polypeptide variant based on the tenth module of the human fibronectin type III protein in which one or more of the solvent accessible loops has  
 25 been randomized or mutated, particularly one or more of the three loops identified as the BC loop (amino acids 23-30), DE loop (amino acids 52-56) and FG loop (amino acids 77-87) (the numbering scheme is based on the sequence on the tenth Type III domain of human fibronectin, with the amino acids Val-Ser-Asp-Val-Pro representing amino acids numbers 1 – 5). The amino acid sequence of the wild-type tenth module of  
 30 the human fibronectin type III domain is:

VSDVPRDLEVVAATPTSLLISWDAPAVTVRYRITYGETGGNSPVQEFTVPGSK  
 STATISGLKPGVDYTITGYAVTGRGDSPASSKPISINYRT (SEQ ID NO:5). Thus,

the wild-type BC loop comprises the sequence of DAPAVTVR; the wild-type DE loop comprises the sequence of GSKST; the wild-type FG loop comprises the sequence of GRGDSPASSKP. The sequences flanking the BC, DE, and FG loops are also termed Frameworks 1, 2, 3, and 4, e.g., in Tables 1-3.

5           A variety of improved mutant <sup>10</sup>F<sub>n</sub>3 scaffolds have been identified. A modified Asp7, which is replaced by a non-negatively charged amino acid residue (e.g., Asn, Lys, etc.). Both of these mutations have the effect of promoting greater stability of the mutant <sup>10</sup>F<sub>n</sub>3 at neutral pH as compared to the wild-type form. A variety of additional alterations in the <sup>10</sup>F<sub>n</sub>3 scaffold that are either beneficial or neutral have been disclosed.

10       See, for example, Batori et al. Protein Eng. 2002 Dec;15(12):1015-20; Koide et al., Biochemistry 2001 Aug 28;40(34):10326-33.

          Additionally, several novel modifications to the <sup>10</sup>F<sub>n</sub>3 scaffold are disclosed here. Of particular significance, it was discovered that a deletion of the first 8 amino acids of the wild type human <sup>10</sup>F<sub>n</sub>3 led to roughly three-fold improved VEGFR-2

15       binding. Because the first 8 amino acids tend to fold into a position that is close to the BC, DE and FG loops, it is expected that this mutation will also improve target binding in other <sup>10</sup>F<sub>n</sub>3 scaffolds selected for binding to different targets. Accordingly, one may construct a library of nucleic acids encoding <sup>10</sup>F<sub>n</sub>3 scaffold that lack the first 8 amino acids and conduct screening in this improved library.

20           Both the variant and wild-type <sup>10</sup>F<sub>n</sub>3 proteins are characterized by the same structure, namely seven beta-strand domain sequences (designated A through and six loop regions (AB loop, BC loop, CD loop, DE loop, EF loop, and FG loop) which connect the seven beta-strand domain sequences. The beta strands positioned closest to the N- and C-termini may adopt a beta-like conformation in solution. In SEQ ID No:5,

25       the AB loop corresponds to residues 15-16, the BC loop corresponds to residues 22-30, the CD loop corresponds to residues 39-45, the DE loop corresponds to residues 51-55, the EF loop corresponds to residues 60-66, and the FG loop corresponds to residues 76-87. As shown in Fig. 22, the BC loop, DE loop, and FG loop are all located at the same end of the polypeptide. Similarly, immunoglobulin scaffolds tend to have at least seven

30       beta or beta-like strands, and often nine beta or beta-like strands.

          A single domain polypeptide disclosed herein may have at least five to seven beta or beta-like strands distributed between at least two beta sheets, and at least one

loop portion connecting two beta or beta-like strands, which loop portion participates in binding to VEGFR-2, particularly KDR, with the binding characterized by a dissociation constant that is less than  $1 \times 10^{-6} \text{M}$ , and preferably less than  $1 \times 10^{-8} \text{M}$ . As described herein, polypeptides having a dissociation constant of less than  $5 \times 10^{-9} \text{M}$  are particularly desirable for therapeutic use in vivo to inhibit VEGF signaling. Polypeptides having a dissociation constant of between  $1 \times 10^{-6} \text{M}$  and  $5 \times 10^{-9} \text{M}$  may be desirable for use in detecting or labeling, ex vivo or in vivo, VEGFR-2 proteins.

Optionally, the VEGFR-2 binding protein will bind specifically to VEGFR-2 relative to other related proteins from the same species. By “specifically binds” is meant a polypeptide that recognizes and interacts with a target protein (e.g., VEGFR-2) but that does not substantially recognize and interact with other molecules in a sample, for example, a biological sample. In preferred embodiments a polypeptide of the invention will specifically bind a VEGFR with a  $K_D$  at least as tight as 500 nM. Preferably, the polypeptide will specifically bind a VEGFR with a  $K_D$  of 1 pM to 500 nM, more preferably 1 pM to 100 nM, more preferably 1 pM to 10 nM, and most preferably 1 pM to 1 nM or lower.

In general, a library of scaffold single domain polypeptides is screened to identify specific polypeptide variants that can bind to a chosen target. These libraries may be, for example, phage display libraries or PROfusion<sup>TM</sup> libraries.

In an exemplary embodiment, we have exploited a novel in vitro RNA-protein fusion display technology to isolate polypeptides that bind to both human (KDR) and mouse (Flk-1) VEGFR-2 and inhibit VEGF-dependent biological activities. These polypeptides were identified from libraries of fibronectin-based scaffold proteins (Koide et al, JMB 284:1141 (1998)) and libraries of  $V_L$  domains in which the diversity of CDR3 has been increased by swapping with CDR3 domains from a population of  $V_H$  molecules. <sup>10</sup>F<sub>n</sub>3 comprises approximately 94 amino acid residues, as shown in SEQ ID NO:5.

In addition, as described above, amino acid sequences at the N-terminus of <sup>10</sup>F<sub>n</sub>3 can also be mutated or deleted. For example, randomization of the BC, DE, and FG loops can occur in the context of a full-length <sup>10</sup>F<sub>n</sub>3 or in the context of a <sup>10</sup>F<sub>n</sub>3 having a deletion or mutation of 1 – 8 amino acids of the N-terminus. For example, the L at position 8 can be mutated to a Q. After randomization to create a diverse library,

fibronectin-based scaffold proteins can be used in a screening assay to select for polypeptides with a high affinity for a protein, in this case the VEGFR. (For a detailed description of the RNA-protein fusion technology and fibronectin-based scaffold protein library screening methods see Szostak et al., U.S. Patent Nos.: 6,258,558; 5 6,261,804; 6,214,553; 6,281,344; 6,207,446; 6,518,018; PCT Publication Numbers WO 00/34784; WO 01/64942; WO 02/032925; and Roberts and Szostak, Proc Natl. Acad. Sci. 94:12297-12302, 1997, herein incorporated by reference.)

For the initial selection described herein, three regions of the <sup>10</sup>F<sub>n</sub>3 at positions 23-29, 52-55 and 77-86 were randomized and used for in vitro selection against the 10 extracellular domain of human VEGFR-2 (amino acids 1-764 of KDR fused to human IgG1Fc). Using mRNA display (RNA-protein fusion) and in vitro selection, we sampled a <sup>10</sup>F<sub>n</sub>3-based library with approximately ten trillion variants. The initial selection identified polypeptides with moderate affinity ( $K_D=10-200$  nM) that competed with VEGF for binding to KDR (human VEGFR-2). Subsequently, a single 15 clone ( $K_D=11-13$  nM) from the initial selection was subjected to mutagenesis and further selection. This affinity maturation process yielded new VEGFR binding polypeptides with dissociation constants between 60 pM to 2 nM. KDR binders are shown in Table 3. In addition, we also isolated polypeptides that could bind to Flk-1, the mouse KDR homolog, from mutagenized populations of KDR binders that initially 20 had no detectable binding affinity to Flk-1, resulting in the isolation of polypeptides that exhibit dual specificities to both human and mouse VEGFR-2. These polypeptides are shown to bind cells that display KDR or Flk-1 extracellular domains. They also inhibited cell growth in a VEGF-dependent proliferation assay. Polypeptides that bind to KDR and Flk-1 are shown in Table 2, while a selection of preferred KDR binders 25 and KDR/Flk-1 binders are shown in Table 1.

Using the VEGFR-2 binding polypeptides identified in these selections we determined FG loop amino acid consensus sequences required for the binding of the polypeptides to the VEGFR-2. The sequences are listed as SEQ ID NOs:1-4 below.

VEGFR-2 binding polypeptides, such as those of SEQ ID NOs:1-4, may be 30 formulated alone (as isolated peptides), as part of a <sup>10</sup>F<sub>n</sub>3 single domain polypeptide, as part of a full-length fibronectin, (with a full-length amino terminus or a deleted amino terminus) or a fragment thereof, in the context of an immunoglobulin (particularly a



single domain immunoglobulin), in the context of another protein having an immunoglobulin-like fold, or in the context of another, unrelated protein. The polypeptides can also be formulated as part of a fusion protein with a heterologous protein that does not itself bind to or contribute in binding to a VEGFR. In addition,  
 5 the polypeptides of the invention can also be fused to nucleic acids. The polypeptides can also be engineered as monomers, dimers, or multimers.

Sequences of the Preferred Consensus VEGFR-2 Binding Peptides:

10 SEQ ID NO:1 - (L/M)GXN(G/D)(H/R)EL(L/M)TP

[X can be any amino acid; ( / ) represents alternative amino acid for the same position]

SEQ ID NO:2 - XERNGRXL(L/M/N)TP

[X can be any amino acid; ( / ) represents alternative amino acid for the same position]

15

SEQ ID NO:3 - (D/E)GXNXRXXIP

[X can be any amino acid; ( / ) represents alternative amino acid for the same position]

SEQ ID NO:4 - (D/E)G(R/P)N(G/E)R(S/L)(S/F)IP

20 [X can be any amino acid; ( / ) represents alternative amino acid for the same position]

Sequences of the Preferred VEGFR-2 Binding <sup>10</sup>Fn3 Polypeptides:

SEQ ID NO:6

25 EVVAATPTSLLISWRHPHFTRYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
 PGVDYTITGYAVTMGLYGHELLTPISINYRT

SEQ ID NO:7

EVVAATPTSLLISWRHPHFTRYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
 30 PGVDYTITGYAVTDGENGQFLLVPISINYRT

SEQ ID NO:8

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTMGPNDNELLTPISINYRT

SEQ ID NO:9

5 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTAGWDDHELFIPISINYRT

SEQ ID NO:10

10 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTSGHNDHMLMIPISINYRT

SEQ ID NO:11

15 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTAGYNDQILMTPISINYRT

SEQ ID NO:12

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTFGLYGKELLIPISINYRT

20 SEQ ID NO:13  
EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTTGPNDRLLFVPISINYRT

SEQ ID NO:14

25 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTDVYNDHEIKTPISINYRT

SEQ ID NO:15

30 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTDGKDGRVLLTPISINYRT

SEQ ID NO:16



EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTEVHHDREIKTPISINYRT

SEQ ID NO:17

5 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTQAPNDRVLYTPISINYRT

SEQ ID NO:18

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
10 PGVDYTITGYAVTREENDHELLIPISINYRT

SEQ ID NO:19

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTVTHNGHPLMTPISINYRT

15

SEQ ID NO:20

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTLALKGHELLTPISINYRT

20 SEQ ID NO:21

VSDVPRDLEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPP  
TATISGLKPGVDYTITGYAVTVAQNDHELITPISINYRT

SEQ ID NO:22

25 VSDVPRDL/QEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQ  
PPAATISGLKPGVDYTITGYAVTMAQSGHELFTPISINYRT

SEQ ID NO:24

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
30 PGVDYTITGYAVTVERNGRVLMTTPISINYRT

SEQ ID NO:25

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTVERNGRHLMTPI SINYRT

SEQ ID NO:33

5 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTLERNGRELMTPISIN YRT

SEQ ID NO:45

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
10 PGVDYTITGYAVTEERNGRRTL RTPISIN YRT

SEQ ID NO:53

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTVERNDRVLFTPISIN YRT

15

SEQ ID NO:57

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTVERNGRELMTPISIN YRT

20 SEQ ID NO:62

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTLERNGRELMVPISIN YRT

SEQ ID NO:63

25 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTDGRNDRKLMVPISIN YRT

SEQ ID NO:68

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
30 PGVDYTITGYAVTDGQNGRLLNVPISIN YRT

SEQ ID NO:91

EVVAATPTSLLISWRHHPHFTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGL  
KPGVDYTITGYAVTVHWNGRELMTPISINYRT

SEQ ID NO:92

5 EVVAATPTSLLISWRHHPHFTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTEEWNGRVLMTTPISINYRT

SEQ ID NO:93

EVVAATPTSLLISWRHHPHFTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
10 PGVDYTITGYAVTVERNGHTLMTPISINYRT

SEQ ID NO:94

EVVAATPTSLLISWRHHPHFTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTVEENGRQLMTTPISINYRT

15

SEQ ID NO:95

EVVAATPTSLLISWRHHPHFTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTLERNQGVLFTPISINYRT

20 SEQ ID NO:96

EVVAATPTSLLISWRHHPHFTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTVERNGQVLYTPISINYRT

SEQ ID NO:97

25 EVVAATPTSLLISWRHHPHFTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTWGYKDHELLIPISINYRT

SEQ ID NO:98

EVVAATPTSLLISWRHHPHFTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
30 PGVDYTITGYAVTLGRNDRELLTPISINYRT

SEQ ID NO:99

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTDGPNDRLLNIPISINYRT

SEQ ID NO:100

5 EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTFARDGHEILTPISINYRT

SEQ ID NO:101

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
10 PGVDYTITGYAVTLEQNGRELMTPISINYRT

SEQ ID NO:102

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTVEENGRVLNTPISINYRT

15

SEQ ID NO:103

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTLEPNGRYLMVPISINYRT

20 SEQ ID NO:104

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITGYAVTEGRNGRELFIPISINYRT

SEQ ID NO:154

25 VSDVPRDLEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPP  
AATISGLKPGVDYTITGYAVTWERNGRELFTPISINYRT

SEQ ID NO:156

VSDVPRDLEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPP  
30 AATISGLKPGVDYTITGYAVTKERNGRELFTPISINYRT

SEQ ID NO:172

VSDVPRDLEVVAATPTSLLISWRHPHFPTHYYRITYGETGGNSPVQEFTVPLQP  
PAATISGLKPGVDYTITGYAVTTERTGRELFTPISINYRT

SEQ ID NO:173

5 VSDVPRDLEVVAATPTSLLISWRHPHFPTHYYRITYGETGGNSPVQEFTVPLQP  
PAATISGLKPGVDYTITGYAVTKERSGRELFTPISINYRT

SEQ ID NO:175

VSDVPRDLEVVAATPTSLLISWRHPHFPTHYYRITYGETGGNSPVQEFTVPLQP  
10 PAATISGLKPGVDYTITGYAVTLERDGRELFTPISINYRT

SEQ ID NO:177

VSDVPRDLEVVAATPTSLLISWRHPHFPTHYYRITYGETGGNSPVQEFTVPLQPP  
LATISGLKPGVDYTITG/VYAVTKERNGRELFTPISINYRT

15

SEQ ID NO:180

VSDVPRDLEVVAATPTSLLISWRHPHFPTHYYRITYGETGGNSPVQEFTVPLQP  
TTATISGLKPGVDYTITGYAVTWERNGRELFTPISINYRT

20 SEQ ID NO:181

VSDVPRDLEVVAATPTSLLISWRHPHFPTHYYRITYGETGGNSPVQEFTVPLQP  
TVATISGLKPGVDYTITGYAVTLERNDRRELFTPISINYRT

SEQ ID NO:186

25 MGEVVAATPTSLLISWRHPHFPTHYYRITYGETGGNSPVQEFTVPLQPPTATISG  
LKPGVDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPSQ

SEQ ID NO:187

MGEVVAATPTSLLISWRHPHFPTHYYRITYGETGGNSPVQEFTVPLQPPTATISG  
30 LKPGVDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPCQ

SEQ ID NO:188

MVSDVPRDLEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQ  
PPTATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPSQ

SEQ ID NO:189

5 MGEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISG  
LKPGVDYTITVYAVTDGWNGRLLSIPISINYRT

SEQ ID NO:190

MGEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISG  
10 LKPGVDYTITVYAVTEGPNERSLFIPISINYRT

SEQ ID NO:191

MVSDVPRDLEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQ  
PPTATISGLKPGVDYTITVYAVTEGPNERSLFIPISINYRT

15

SEQ ID NO:192 (A core form of the polypeptide referred to herein as CT-01):

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITVYAVTDGRNGRLLSIPISINYRT

The CT-01 molecule above has a deletion of the first 8 amino acids and may  
20 include additional amino acids at the N- or C- termini. For example, an additional MG  
sequence may be placed at the N-terminus. The M will usually be cleaved off, leaving  
a GEV... sequence at the N-terminus. The re-addition of the normal 8 amino acids at  
the N-terminus also produces a KDR binding protein with desirable properties. The N-  
terminal methionine is generally cleaved off to yield a sequence:

25 VSDVPRDLEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPP  
TATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRT (SEQ ID NO:193).

A polypeptide disclosed herein may be modified by one or more conservative  
substitutions, particularly in portions of the protein that are not expected to interact with  
a target protein. It is expected that as many as 5%, 10%, 20% or even 30% or more of  
30 the amino acids in an immunoglobulin or immunoglobulin-like domain may be altered  
by a conservative substitution without substantially altering the affinity of the protein  
for target. It may be that such changes will alter the immunogenicity of the polypeptide

in vivo, and where the immunogenicity is decreased, such changes will be desirable. As used herein, "conservative substitutions" are residues that are physically or functionally similar to the corresponding reference residues. That is, a conservative substitution and its reference residue have similar size, shape, electric charge, chemical  
5 properties including the ability to form covalent or hydrogen bonds, or the like. Preferred conservative substitutions are those fulfilling the criteria defined for an accepted point mutation in Dayhoff et al., *Atlas of Protein Sequence and Structure* 5:345-352 (1978 & Supp.). Examples of conservative substitutions are substitutions within the following groups: (a) valine, glycine; (b) glycine, alanine; (c) valine,  
10 isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine.

Polypeptides disclosed herein may also be modified in order to improve potency, bioavailability, chemical stability, and/or efficacy. For example, within one embodiment of the invention D-amino acid peptides, or retroenantio peptide sequences  
15 may be generated in order to improve the bioactivity and chemical stability of a polypeptide structure (see, e.g., Juvvadi et al., *J. Am. Chem. Soc.* 118: 8989-8997, 1996; Freidinger et al., *Science*, 210: 656-658, 1980). Lactam constraints (see Freidinger, *supra*), and/or azabicycloalkane amino acids as dipeptide surrogates can also be utilized to improve the biological and pharmacological properties of the native  
20 peptides (see, e.g., Hanessian et al., *Tetrahedron* 53:12789-12854, 1997).

Amide bond surrogates, such as thioamides, secondary and tertiary amines, heterocycles among others (see review in Spatola, A. F. in "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins" Wenstein, B. Ed. Marcel Dekker, New York, 1983 Vol. 7, pp 267-357) can also be utilized to prevent enzymatic  
25 degradation of the polypeptide backbone thereby resulting in improved activity. Conversion of linear polypeptides to cyclic polypeptide analogs can also be utilized to improve metabolic stability, since cyclic polypeptides are much less sensitive to enzymatic degradation (see generally, Veber, et al. *Nature* 292:55-58, 1981).

Polypeptides can also be modified utilizing end group capping as esters and  
30 amides in order to slow or prevent metabolism and enhance lipophilicity. Dimers of the peptide attached by various linkers may also enhance activity and specificity (see for example: Y. Shimohigashi et al, in *Peptide Chemistry 1988*, Proceedings of the 26th

Symposium on Peptide Chemistry, Tokyo, October 24-26, pgs. 47-50, 1989). For additional examples of polypeptide modifications, such as non-natural amino acids, see U.S.P.N. 6,559,126.

For use in vivo, a form suitable for pegylation may be generated. For example, a C-terminal tail comprising a cysteine was added and expressed, as shown below for a CT-01 form lacking the eight N-terminal amino acids (EIDKPCQ is added at the C-terminus).

GEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGL  
KPGVDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPCQ (SEQ ID NO:194). The  
pegylated form of this molecule is used in the in vivo experiments described below. A control form with a serine instead of a cysteine was also used:

GEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGL  
KPGVDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPSQ (SEQ ID NO:195).

The same C-terminal tails may also be added to CT-01 forms having the N-terminal eight amino acids, such as is shown in SEQ ID NO:193.

Additional variants with desirable KDR binding properties were isolated. The following core sequence has a somewhat different FG loop, and may be expressed with, for example, an N-terminal MG sequence, an N-terminal sequence that restores the 8 deleted amino acids, and/or a C-terminal tail to provide a cysteine for pegylation.

EVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITVYAVTEGPNERSLFIPIISINYRT (SEQ ID NO:196). Another such variant has the core sequence:

VSDVPRDLEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQEFTVPLQPP  
TATISGLKPGVDYTITVYAVTEGPNERSLFIPIISINYRT (SEQ ID NO:197).

Additionally, preferred single domain immunoglobulin polypeptides in a  $V_L$  framework were isolated by similar methodology and are disclosed in Figure 21.

Also included in the present invention are nucleic acid sequences encoding any of the polypeptides described herein. As appreciated by those skilled in the art, because of third base degeneracy, almost every amino acid can be represented by more than one triplet codon in a coding nucleotide sequence. In addition, minor base pair changes may result in a conservative substitution in the amino acid sequence encoded but are not expected to substantially alter the biological activity of the gene product.



Therefore, a nucleic acid sequence encoding a polypeptide described herein may be modified slightly in sequence and yet still encode its respective gene product.

In addition, the polypeptides of the present invention can be used as lead polypeptides that can be further mutated and screened for polypeptides that bind VEGFR with an even greater affinity. In one example, a polypeptide described herein is used as a lead polypeptide which is further mutated or randomized to produce polypeptides with amino acid mutations distinct from the lead polypeptide. The further randomized polypeptides can then be used to screen for polypeptides that inhibit VEGF biological activity as described herein (e.g., bind to a VEGFR and block binding of VEGF to the same receptor).

### 3. Nucleic Acids and Production of Polypeptides

Polypeptides of the present invention can be produced using any standard methods known in the art.

In one example, the polypeptides are produced by recombinant DNA methods by inserting a nucleic acid sequence (e.g., a cDNA) encoding the polypeptide into a recombinant expression vector and expressing the DNA sequence under conditions promoting expression. Examples of nucleic acid sequences encoding a CT-01 polypeptide disclosed herein are:

SEQ ID NO:184

atgggcgaagttgttgctgcgacccccaccagcctactgatcagctggcgccaccgcacttcccgactagatattacaggat  
cacttacggagaaacaggaggaaatagccctgtccaggagttcactgtgcctctgcagccccccacagctaccatcagcgg  
ccttaaacctggagttgattataccatcactgtgtatgctgtcactgacggccggaacggg'gcctcctgagcatcccaattcc  
attaattaccgcacagaaattgacaaacctatgccag

SEQ ID NO:185

Atgggcgaagttgttgctgcgacccccaccagcctactgatcagctggcgccaccgcacttcccgactagatattacagga  
tcacttacggagaaacaggaggaaatagccctgtccaggagttcactgtgcctctgcagccccccacagctaccatcagcgg  
ccttaaacctggagttgattataccatcactgtgtatgctgtcactgacggccggaacggg'gcctcctgagcatcccaattcc  
attaattaccgcaca

Nucleic acids encoding any of the various polypeptides disclosed herein may be synthesized chemically. Codon usage may be selected so as to improve expression in a cell. Such codon usage will depend on the cell type selected. Specialized codon usage

patterns have been developed for *E. coli* and other bacteria, as well as mammalian cells, plant cells, yeast cells and insect cells. See for example: Mayfield et al., *Proc Natl Acad Sci U S A.* 2003 Jan 21;100(2):438-42; Sinclair et al. *Protein Expr Purif.* 2002 Oct;26(1):96-105; Connell ND. *Curr Opin Biotechnol.* 2001 Oct;12(5):446-9; Makrides et al. *Microbiol Rev.* 1996 Sep;60(3):512-38; and Sharp et al. *Yeast.* 1991 Oct;7(7):657-78.

General techniques for nucleic acid manipulation are described for example in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Vols. 1-3, Cold Spring Harbor Laboratory Press, 2 ed., 1989, or F. Ausubel et al., *Current Protocols in Molecular Biology* (Green Publishing and Wiley-Interscience: New York, 1987) and periodic updates, herein incorporated by reference. The DNA encoding the polypeptide is operably linked to suitable transcriptional or translational regulatory elements derived from mammalian, viral, or insect genes. Such regulatory elements include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences that control the termination of transcription and translation. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants are additionally incorporated.

The recombinant DNA can also include any type of protein tag sequence that may be useful for purifying the protein. Examples of protein tags include but are not limited to a histidine tag, a FLAG tag, a myc tag, an HA tag, or a GST tag. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts can be found in *Cloning Vectors: A Laboratory Manual*, (Elsevier, New York, 1985), the relevant disclosure of which is hereby incorporated by reference.

The expression construct is introduced into the host cell using a method appropriate to the host cell, as will be apparent to one of skill in the art. A variety of methods for introducing nucleic acids into host cells are known in the art, including, but not limited to, electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (where the vector is an infectious agent).

Suitable host cells include prokaryotes, yeast, mammalian cells, or bacterial cells. Suitable bacteria include gram negative or gram positive organisms, for example,

E. coli or Bacillus spp. Yeast, preferably from the Saccharomyces species, such as S. cerevisiae, may also be used for production of polypeptides. Various mammalian or insect cell culture systems can also be employed to express recombinant proteins. Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, (Bio/Technology, 6:47, 1988). Examples of suitable mammalian host cell lines include endothelial cells, COS-7 monkey kidney cells, CV-1, L cells, C127, 3T3, Chinese hamster ovary (CHO), human embryonic kidney cells, HeLa, 293, 293T, and BHK cell lines. Purified polypeptides are prepared by culturing suitable host/vector systems to express the recombinant proteins. For many applications, the small size of many of the polypeptides disclosed herein would make expression in E. coli as the preferred method for expression. The protein is then purified from culture media or cell extracts.

Proteins disclosed herein can also be produced using cell- translation systems. For such purposes the nucleic acids encoding the polypeptide must be modified to allow in vitro transcription to produce mRNA and to allow cell-free translation of the mRNA in the particular cell-free system being utilized (eukaryotic such as a mammalian or yeast cell-free translation system or prokaryotic such as a bacterial cell-free translation system).

VEGFR-binding polypeptides can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). Modifications to the protein can also be produced by chemical synthesis.

The polypeptide of the present invention can be purified by isolation/purification methods for proteins generally known in the field of protein chemistry. Non-limiting examples include extraction, recrystallization, salting out (e.g., with ammonium sulfate or sodium sulfate), centrifugation, dialysis, ultrafiltration, adsorption chromatography, ion exchange chromatography, hydrophobic chromatography, normal phase chromatography, reversed-phase chromatography, gel filtration, gel permeation chromatography, affinity chromatography, electrophoresis, countercurrent distribution or any combinations of these. After purification, polypeptides may be exchanged into different buffers and/or concentrated by any of a variety of methods known to the art, including, but not limited to, filtration and dialysis.

The purified polypeptide is preferably at least 85% pure, more preferably at least 95% pure, and most preferably at least 98% pure. Regardless of the exact numerical value of the purity, the polypeptide is sufficiently pure for use as a pharmaceutical product.

5

#### 4. Post-Translational Modifications of Polypeptides

In certain embodiments, the binding polypeptides of the invention may further comprise post-translational modifications. Exemplary post-translational protein modification include phosphorylation, acetylation, methylation, ADP-ribosylation, ubiquitination, glycosylation, carbonylation, sumoylation, biotinylation or addition of a polypeptide side chain or of a hydrophobic group. As a result, the modified soluble polypeptides may contain non-amino acid elements, such as lipids, poly- or mono-saccharide, and phosphates. A preferred form of glycosylation is sialylation, which conjugates one or more sialic acid moieties to the polypeptide. Sialic acid moieties improve solubility and serum half-life while also reducing the possible immunogenicity of the protein. See, e.g., Raju et al. *Biochemistry*. 2001 Jul 31;40(30):8868-76. Effects of such non-amino acid elements on the functionality of a polypeptide may be tested for its antagonizing role in VEGFR-2 or VEGF function, e.g., its inhibitory effect on angiogenesis or on tumor growth.

In one specific embodiment of the present invention, modified forms of the subject soluble polypeptides comprise linking the subject soluble polypeptides to nonproteinaceous polymers. In one specific embodiment, the polymer is polyethylene glycol ("PEG"), polypropylene glycol, or polyoxyalkylenes, in the manner as set forth in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. Examples of the modified polypeptide of the invention include PEGylated M5FL and PEGylated CT-01.

PEG is a well-known, water soluble polymer that is commercially available or can be prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler and Karo, *Polymer Synthesis*, Academic Press, New York, Vol. 3, pages 138-161). The term "PEG" is used broadly to encompass any polyethylene glycol molecule, without regard to size or to modification at an end of the PEG, and can be represented by the formula:

X—O(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n-1</sub>CH<sub>2</sub>CH<sub>2</sub>OH (1), where n is 20 to 2300 and X is H or a terminal modification, e.g., a C<sub>1-4</sub> alkyl. In one embodiment, the PEG of the invention terminates on one end with hydroxy or methoxy, i.e., X is H or CH<sub>3</sub> (“methoxy PEG”). A PEG can contain further chemical groups which are necessary for binding reactions; which results from the chemical synthesis of the molecule; or which is a spacer for optimal distance of parts of the molecule. In addition, such a PEG can consist of one or more PEG side-chains which are linked together. PEGs with more than one PEG chain are called multiarmed or branched PEGs. Branched PEGs can be prepared, for example, by the addition of polyethylene oxide to various polyols, including glycerol, pentaerythriol, and sorbitol. For example, a four-armed branched PEG can be prepared from pentaerythriol and ethylene oxide. Branched PEG are described in, for example, EP-A 0 473 084 and U.S. Pat. No. 5,932,462. One form of PEGs includes two PEG side-chains (PEG2) linked via the primary amino groups of a lysine (Monfardini, C., et al., *Bioconjugate Chem.* 6 (1995) 62-69).

Although PEG is well-known, this is, to our knowledge, the first demonstration that a pegylated <sup>10</sup>F<sub>n</sub>3 polypeptide can be pegylated and retain ligand binding activity. In a preferred embodiment, the pegylated <sup>10</sup>F<sub>n</sub>3 polypeptide is produced by site-directed pegylation, particularly by conjugation of PEG to a cysteine moiety at the N- or C-terminus. Accordingly, the present disclosure provides a target-binding <sup>10</sup>F<sub>n</sub>3 polypeptide with improved pharmacokinetic properties, the polypeptide comprising: a <sup>10</sup>F<sub>n</sub>3 domain having from about 80 to about 150 amino acids, wherein at least one of the loops of said <sup>10</sup>F<sub>n</sub>3 domain participate in target binding; and a covalently bound PEG moiety, wherein said <sup>10</sup>F<sub>n</sub>3 polypeptide binds to the target with a K<sub>D</sub> of less than 100 nM and has a clearance rate of less than 30 mL/hr/kg in a mammal. The PEG moiety may be attached to the <sup>10</sup>F<sub>n</sub>3 polypeptide by site directed pegylation, such as by attachment to a Cys residue, where the Cys residue may be positioned at the N-terminus of the <sup>10</sup>F<sub>n</sub>3 polypeptide or between the N-terminus and the most N-terminal beta or beta-like strand or at the C-terminus of the <sup>10</sup>F<sub>n</sub>3 polypeptide or between the C-terminus and the most C-terminal beta or beta-like strand. A Cys residue may be situated at other positions as well, particularly any of the loops that do not participate in target binding. A PEG moiety may also be attached by other chemistry, including by conjugation to amines.

PEG conjugation to peptides or proteins generally involves the activation of PEG and coupling of the activated PEG-intermediates directly to target proteins/peptides or to a linker, which is subsequently activated and coupled to target proteins/peptides (see Abuchowski, A. et al, *J. Biol. Chem.*, 252, 3571 (1977) and *J. Biol. Chem.*, 252, 3582 (1977), Zalipsky, et al., and Harris et. al., in: Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications; (J. M. Harris ed.) Plenum Press: New York, 1992; Chap.21 and 22). It is noted that a binding polypeptide containing a PEG molecule is also known as a conjugated protein, whereas the protein lacking an attached PEG molecule can be referred to as unconjugated.

A variety of molecular mass forms of PEG can be selected, e.g., from about 1,000 Daltons (Da) to 100,000 Da (n is 20 to 2300), for conjugating to VEGFR-2 binding polypeptides. The number of repeating units "n" in the PEG is approximated for the molecular mass described in Daltons. It is preferred that the combined molecular mass of PEG on an activated linker is suitable for pharmaceutical use. Thus, in one embodiment, the molecular mass of the PEG molecules does not exceed 100,000 Da. For example, if three PEG molecules are attached to a linker, where each PEG molecule has the same molecular mass of 12,000 Da (each n is about 270), then the total molecular mass of PEG on the linker is about 36,000 Da (total n is about 820). The molecular masses of the PEG attached to the linker can also be different, e.g., of three molecules on a linker two PEG molecules can be 5,000 Da each (each n is about 110) and one PEG molecule can be 12,000 Da (n is about 270).

In a specific embodiment of the invention, a VEGFR-2 binding polypeptide is covalently linked to one poly(ethylene glycol) group of the formula:  $\text{—CO—(CH}_2\text{)}_x\text{—(OCH}_2\text{CH}_2\text{)}_m\text{—OR}$ , with the  $\text{—CO}$  (i.e. carbonyl) of the poly(ethylene glycol) group forming an amide bond with one of the amino groups of the binding polypeptide; R being lower alkyl; x being 2 or 3; m being from about 450 to about 950; and n and m being chosen so that the molecular weight of the conjugate minus the binding polypeptide is from about 10 to 40 kDa. In one embodiment, an binding polypeptide's  $\epsilon$ -amino group of a lysine is the available (free) amino group.

The above conjugates may be more specifically presented by formula (II):  $\text{P—NHCO—(CH}_2\text{)}_x\text{—(OCH}_2\text{CH}_2\text{)}_m\text{—OR}$  (II), wherein P is the group of a binding polypeptide as described herein, (i.e. without the amino group or amino groups which



form an amide linkage with the carbonyl shown in formula (II); and wherein R is lower alkyl; x is 2 or 3; m is from about 450 to about 950 and is chosen so that the molecular weight of the conjugate minus the binding polypeptide is from about 10 to about 40 kDa. As used herein, the given ranges of "m" have an orientational meaning. The  
5 ranges of "m" are determined in any case, and exactly, by the molecular weight of the PEG group.

One skilled in the art can select a suitable molecular mass for PEG, e.g., based on how the pegylated binding polypeptide will be used therapeutically, the desired dosage, circulation time, resistance to proteolysis, immunogenicity, and other  
10 considerations. For a discussion of PEG and its use to enhance the properties of proteins, see N. V. Katre, Advanced Drug Delivery Reviews 10: 91-114 (1993).

In one embodiment of the invention, PEG molecules may be activated to react with amino groups on a binding polypeptide, such as with lysines (Bencham C. O. et al., Anal. Biochem., 131, 25 (1983); Veronese, F. M. et al., Appl. Biochem., 11, 141  
15 (1985).; Zalipsky, S. et al., Polymeric Drugs and Drug Delivery Systems, adrs 9-110 ACS Symposium Series 469 (1999); Zalipsky, S. et al., Europ. Polym. J., 19, 1177-1183 (1983); Delgado, C. et al., Biotechnology and Applied Biochemistry, 12, 119-128 (1990)).

In one specific embodiment, carbonate esters of PEG are used to form the PEG-  
20 binding polypeptide conjugates. N,N'-disuccinimidylcarbonate (DSC) may be used in the reaction with PEG to form active mixed PEG-succinimidyl carbonate that may be subsequently reacted with a nucleophilic group of a linker or an amino group of a binding polypeptide (see U.S. Pat. No. 5,281,698 and U.S. Pat. No. 5,932,462). In a similar type of reaction, 1,1'-(dibenzotriazolyl)carbonate and di-(2-pyridyl)carbonate  
25 may be reacted with PEG to form PEG-benzotriazolyl and PEG-pyridyl mixed carbonate (U.S. Pat. No. 5,382,657), respectively.

Pegylation of a <sup>10</sup>F<sub>n</sub>3 polypeptide can be performed according to the methods of the state of the art, for example by reaction of the binding polypeptide with electrophilically active PEGs (supplier: Shearwater Corp., USA,  
30 www.shearwatercorp.com). Preferred PEG reagents of the present invention are, e.g., N-hydroxysuccinimidyl propionates (PEG-SPA), butanoates (PEG-SBA), PEG-succinimidyl propionate or branched N-hydroxysuccinimides such as mPEG2-NHS



(Monfardini, C., et al., *Bioconjugate Chem.* 6 (1995) 62-69). Such methods may be used to pegylate at an  $\epsilon$ -amino group of a binding polypeptide lysine or the N-terminal amino group of the binding polypeptide.

5 In another embodiment, PEG molecules may be coupled to sulfhydryl groups on a binding polypeptide (Sartore, L., et al., *Appl. Biochem. Biotechnol.*, 27, 45 (1991); Morpurgo et al., *Biocon. Chem.*, 7, 363-368 (1996); Goodson et al., *Bio/Technology* (1990) 8, 343; U.S. Patent No. 5,766,897). U.S. Patent Nos. 6,610,281 and 5,766,897 describes exemplary reactive PEG species that may be coupled to sulfhydryl groups.

10 In some embodiments where PEG molecules are conjugated to cysteine residues on a binding polypeptide, the cysteine residues are native to the binding polypeptide, whereas in other embodiments, one or more cysteine residues are engineered into the binding polypeptide. Mutations may be introduced into a binding polypeptide coding sequence to generate cysteine residues. This might be achieved, for example, by mutating one or more amino acid residues to cysteine. Preferred amino acids for  
15 mutating to a cysteine residue include serine, threonine, alanine and other hydrophilic residues. Preferably, the residue to be mutated to cysteine is a surface-exposed residue. Algorithms are well-known in the art for predicting surface accessibility of residues based on primary sequence or a protein. Alternatively, surface residues may be predicted by comparing the amino acid sequences of binding polypeptides, given that  
20 the crystal structure of the framework based on which binding polypeptides are designed and evolved has been solved (see Himanen et al., *Nature*. (2001) 20-27;414(6866):933-8) and thus the surface-exposed residues identified. In one embodiment, cysteine residues are introduced into binding polypeptides at or near the N- and/or C-terminus, or within loop regions.

25 In some embodiments, the pegylated binding polypeptide comprises a PEG molecule covalently attached to the alpha amino group of the N-terminal amino acid. Site specific N-terminal reductive amination is described in Pepinsky et al., (2001) JPET, 297,1059, and U.S. Pat. No. 5,824,784. The use of a PEG-aldehyde for the reductive amination of a protein utilizing other available nucleophilic amino groups is  
30 described in U.S. Pat. No. 4,002,531, in Wieder et al., (1979) *J. Biol. Chem.* 254,12579, and in Chamow et al., (1994) *Bioconjugate Chem.* 5, 133.

In another embodiment, pegylated binding polypeptide comprises one or more

PEG molecules covalently attached to a linker, which in turn is attached to the alpha amino group of the amino acid residue at the N-terminus of the binding polypeptide. Such an approach is disclosed in U.S. Patent Publication No. 2002/0044921 and in WO94/01451.

5           In one embodiment, a binding polypeptide is pegylated at the C-terminus. In a specific embodiment, a protein is pegylated at the C-terminus by the introduction of C-terminal azido-methionine and the subsequent conjugation of a methyl-PEG-triarylphosphine compound via the Staudinger reaction. This C-terminal conjugation method is described in Cazalis et al., C-Terminal Site-Specific PEGylation of a  
10   Truncated Thrombomodulin Mutant with Retention of Full Bioactivity, *Bioconjug Chem.* 2004;15(5):1005-1009.

          Monopegylation of a binding polypeptide can also be produced according to the general methods described in WO 94/01451. WO 94/01451 describes a method for preparing a recombinant polypeptide with a modified terminal amino acid alpha-carbon  
15   reactive group. The steps of the method involve forming the recombinant polypeptide and protecting it with one or more biologically added protecting groups at the N-terminal alpha-amine and C-terminal alpha-carboxyl. The polypeptide can then be reacted with chemical protecting agents to selectively protect reactive side chain groups and thereby prevent side chain groups from being modified. The polypeptide is then  
20   cleaved with a cleavage reagent specific for the biological protecting group to form an unprotected terminal amino acid alpha-carbon reactive group. The unprotected terminal amino acid alpha-carbon reactive group is modified with a chemical modifying agent. The side chain protected terminally modified single copy polypeptide is then deprotected at the side chain groups to form a terminally modified recombinant  
25   single copy polypeptide. The number and sequence of steps in the method can be varied to achieve selective modification at the N- and/or C-terminal amino acid of the polypeptide.

          The ratio of a binding polypeptide to activated PEG in the conjugation reaction can be from about 1:0.5 to 1:50, between from about 1:1 to 1:30, or from about 1:5 to  
30   1:15. Various aqueous buffers can be used in the present method to catalyze the covalent addition of PEG to the binding polypeptide. In one embodiment, the pH of a buffer used is from about 7.0 to 9.0. In another embodiment, the pH is in a slightly

basic range, *e.g.*, from about 7.5 to 8.5. Buffers having a pKa close to neutral pH range may be used, *e.g.*, phosphate buffer.

Conventional separation and purification techniques known in the art can be used to purify PEGylated binding polypeptide, such as size exclusion (*e.g.* gel  
5 filtration) and ion exchange chromatography. Products may also be separated using SDS-PAGE. Products that may be separated include mono-, di-, tri- poly- and un-pegylated binding polypeptide, as well as free PEG. The percentage of mono-PEG conjugates can be controlled by pooling broader fractions around the elution peak to increase the percentage of mono-PEG in the composition. About ninety percent mono-  
10 PEG conjugates represents a good balance of yield and activity. Compositions in which, for example, at least ninety-two percent or at least ninety-six percent of the conjugates are mono-PEG species may be desired. In an embodiment of this invention the percentage of mono-PEG conjugates is from ninety percent to ninety-six percent.

In one embodiment, PEGylated binding polypeptide of the invention contain  
15 one, two or more PEG moieties. In one embodiment, the PEG moiety(ies) are bound to an amino acid residue which is on the surface of the protein and/or away from the surface that contacts the target ligand. In one embodiment, the combined or total molecular mass of PEG in PEG- binding polypeptide is from about 3,000 Da to 60,000 Da, optionally from about 10,000 Da to 36,000 Da. In a one embodiment, the PEG in  
20 pegylated binding polypeptide is a substantially linear, straight-chain PEG.

In one embodiment of the invention, the PEG in pegylated binding polypeptide is not hydrolyzed from the pegylated amino acid residue using a hydroxylamine assay, *e.g.*, 450 mM hydroxylamine (pH 6.5) over 8 to 16 hours at room temperature, and is thus stable. In one embodiment, greater than 80% of the composition is stable mono-  
25 PEG-binding polypeptide, more preferably at least 90%, and most preferably at least 95%.

In another embodiment, the pegylated binding polypeptides of the invention will preferably retain at least 25%, 50%, 60%, 70% least 80%, 85%, 90%, 95% or 100% of the biological activity associated with the unmodified protein. In one embodiment,  
30 biological activity refers to its ability to bind to VEGFR-2, as assessed by KD,  $k_{on}$  or  $k_{off}$ . In one specific embodiment, the pegylated binding polypeptide protein shows an increase in binding to VEGFR relative to unpegylated binding polypeptide.

The serum clearance rate of PEG-modified polypeptide may be decreased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or even 90%, relative to the clearance rate of the unmodified binding polypeptide. The PEG-modified polypeptide may have a half-life ( $t_{1/2}$ ) which is enhanced relative to the half-life of the unmodified protein. The half-life of PEG- binding polypeptide may be enhanced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 400% or 500%, or even by 1000% relative to the half-life of the unmodified binding polypeptide. In some embodiments, the protein half-life is determined in vitro, such as in a buffered saline solution or in serum. In other  
10      embodiments, the protein half-life is an *in vivo* half life, such as the half-life of the protein in the serum or other bodily fluid of an animal.

#### 5.      Therapeutic Formulations and Modes of Administration

The present invention features methods for treating conditions or preventing  
15      pre-conditions which respond to an inhibition of VEGF biological activity. Preferred examples are conditions that are characterized by inappropriate angiogenesis. Techniques and dosages for administration vary depending on the type of specific polypeptide and the specific condition being treated but can be readily determined by the skilled artisan. In general, regulatory agencies require that a protein reagent to be  
20      used as a therapeutic is formulated so as to have acceptably low levels of pyrogens. Accordingly, therapeutic formulations will generally be distinguished from other formulations in that they are substantially pyrogen free, or at least contain no more than acceptable levels of pyrogen as determined by the appropriate regulatory agency (e.g., FDA).

25      Therapeutic compositions of the present invention may be administered with a pharmaceutically acceptable diluent, carrier, or excipient, in unit dosage form. Administration may be parenteral (e.g., intravenous, subcutaneous), oral, or topical, as non-limiting examples. In addition, any gene therapy technique, using nucleic acids encoding the polypeptides of the invention, may be employed, such as naked DNA  
30      delivery, recombinant genes and vectors, cell-based delivery, including ex vivo manipulation of patients' cells, and the like.

The composition can be in the form of a pill, tablet, capsule, liquid, or sustained release tablet for oral administration; or a liquid for intravenous, subcutaneous or parenteral administration; gel, lotion, ointment, cream, or a polymer or other sustained release vehicle for local administration.

5           Methods well known in the art for making formulations are found, for example, in "Remington: The Science and Practice of Pharmacy" (20th ed., ed. A.R. Gennaro AR., 2000, Lippincott Williams & Wilkins, Philadelphia, PA). Formulations for parenteral administration may, for example, contain excipients, sterile water, saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or  
10   hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Nanoparticulate formulations (e.g., biodegradable nanoparticles, solid lipid nanoparticles, liposomes) may be used to control the biodistribution of the compounds. Other potentially useful parenteral  
15   delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. The concentration of the compound in the formulation varies depending upon a number of factors, including the dosage of the drug to be administered, and the route of administration.

          The polypeptide may be optionally administered as a pharmaceutically  
20   acceptable salt, such as non-toxic acid addition salts or metal complexes that are commonly used in the pharmaceutical industry. Examples of acid addition salts include organic acids such as acetic, lactic, pamoic, maleic, citric, malic, ascorbic, succinic, benzoic, palmitic, suberic, salicylic, tartaric, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like; polymeric acids such as tannic acid, carboxymethyl  
25   cellulose, or the like; and inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid phosphoric acid, or the like. Metal complexes include zinc, iron, and the like. In one example, the polypeptide is formulated in the presence of sodium acetate to increase thermal stability.

          Formulations for oral use include tablets containing the active ingredient(s) in a  
30   mixture with non-toxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose and sorbitol), lubricating agents,

glidants, and anti-adhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc).

Formulations for oral use may also be provided as chewable tablets, or as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, or as  
5 soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium.

A therapeutically effective dose refers to a dose that produces the therapeutic effects for which it is administered. The exact dose will depend on the disorder to be treated, and may be ascertained by one skilled in the art using known techniques. In  
10 general, the polypeptide is administered at about 0.01  $\mu\text{g/kg}$  to about 50 mg/kg per day, preferably 0.01 mg/kg to about 30 mg/kg per day, most preferably 0.1 mg/kg to about 20 mg/kg per day. The polypeptide may be given daily (e.g., once, twice, three times, or four times daily) or less frequently (e.g., once every other day, once or twice weekly, or monthly). In addition, as is known in the art, adjustments for age as well as the body  
15 weight, general health, sex, diet, time of administration, drug interaction, and the severity of the disease may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.

#### 6. Exemplary Uses

20 The VEGFR-2 binding proteins described herein and their related variants are useful in a number of therapeutic and diagnostic applications. These include the inhibition of the biological activity of VEGF by competing for or blocking the binding to a VEGFR-2 as well as the delivery of cytotoxic or imaging moieties to cells, preferably cells expressing VEGFR-2.

25 The small size and stable structure of these molecules can be particularly valuable with respect to manufacturing of the drug, rapid clearance from the body for certain applications where rapid clearance is desired or formulation into novel delivery systems that are suitable or improved using a molecule with such characteristics.

On the basis of their efficacy as inhibitors of VEGF biological activity, the  
30 polypeptides of the invention are effective against a number of conditions associated with inappropriate angiogenesis, including but not limited to autoimmune disorders (e.g., rheumatoid arthritis, inflammatory bowel disease or psoriasis); cardiac disorders



(e.g., atherosclerosis or blood vessel restenosis); retinopathies (e.g., proliferative retinopathies generally, diabetic retinopathy, age-related macular degeneration or neovascular glaucoma), renal disease (e.g., diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes; transplant rejection; inflammatory renal disease; glomerulonephritis; mesangioproliferative glomerulonephritis; haemolytic-uraemic syndrome; and hypertensive nephrosclerosis); hemangioblastoma; hemangiomas; thyroid hyperplasias; tissue transplantations; chronic inflammation; Meigs's syndrome; pericardial effusion; pleural effusion; autoimmune diseases; diabetes; endometriosis; chronic asthma; undesirable fibrosis (particularly hepatic fibrosis) and cancer, as well as complications arising from cancer, such as pleural effusion and ascites. Preferably, the VEGFR-binding polypeptides of the invention can be used for the treatment of prevention of hyperproliferative diseases or cancer and the metastatic spread of cancers. Non-limiting examples of cancers include bladder, blood, bone, brain, breast, cartilage, colon kidney, liver, lung, lymph node, nervous tissue, ovary, pancreatic, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital tract, ureter, urethra, uterus, or vaginal cancer. Additional treatable conditions can be found in U.S.P.N. 6,524,583, herein incorporated by reference. Other references describing uses for VEGFR-2 binding polypeptides include: McLeod DS et al., Invest Ophthalmol Vis Sci. 2002 Feb;43(2):474-82; Watanabe et al. Exp Dermatol. 2004 Nov;13(11):671-81; Yoshiji H et al., Gut. 2003 Sep;52(9):1347-54; Verheul et al., Oncologist. 2000;5 Suppl 1:45-50; Boldicke et al., Stem Cells. 2001;19(1):24-36.

As described herein, angiogenesis-associated diseases include, but are not limited to, angiogenesis-dependent cancer, including, for example, solid tumors, blood born tumors such as leukemias, and tumor metastases; benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; inflammatory disorders such as immune and non-immune inflammation; chronic articular rheumatism and psoriasis; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation and wound healing;



telangiectasia psoriasis scleroderma, pyogenic granuloma, coronary collaterals, ischemic limb angiogenesis, corneal diseases, rubeosis, arthritis, diabetic neovascularization, fractures, vasculogenesis, hematopoiesis.

5 A VEGFR-2 binding polypeptide can be administered alone or in combination with one or more additional therapies such as chemotherapy radiotherapy, immunotherapy, surgical intervention, or any combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above.

10 In certain embodiments of such methods, one or more polypeptide therapeutic agents can be administered, together (simultaneously) or at different times (sequentially). In addition, polypeptide therapeutic agents can be administered with another type of compounds for treating cancer or for inhibiting angiogenesis.

In certain embodiments, the subject therapeutic agents of the invention can be used alone. Alternatively, the subject agents may be used in combination with other conventional anti-cancer therapeutic approaches directed to treatment or prevention of proliferative disorders (e.g., tumor). For example, such methods can be used in prophylactic cancer prevention, prevention of cancer recurrence and metastases after surgery, and as an adjuvant of other conventional cancer therapy. The present invention recognizes that the effectiveness of conventional cancer therapies (e.g., chemotherapy, radiation therapy, phototherapy, immunotherapy, and surgery) can be enhanced through the use of a subject polypeptide therapeutic agent.

A wide array of conventional compounds have been shown to have anti-neoplastic activities. These compounds have been used as pharmaceutical agents in chemotherapy to shrink solid tumors, prevent metastases and further growth, or decrease the number of malignant cells in leukemic or bone marrow malignancies. Although chemotherapy has been effective in treating various types of malignancies, many anti-neoplastic compounds induce undesirable side effects. It has been shown that when two or more different treatments are combined, the treatments may work synergistically and allow reduction of dosage of each of the treatments, thereby reducing the detrimental side effects exerted by each compound at higher dosages. In other instances, malignancies that are refractory to a treatment may respond to a combination therapy of two or more different treatments.

When a polypeptide therapeutic agent of the present invention is administered in combination with another conventional anti-neoplastic agent, either concomitantly or sequentially, such therapeutic agent may be found to enhance the therapeutic effect of the anti-neoplastic agent or overcome cellular resistance to such anti-neoplastic agent.

5 This allows decrease of dosage of an anti-neoplastic agent, thereby reducing the undesirable side effects, or restores the effectiveness of an anti-neoplastic agent in resistant cells.

Pharmaceutical compounds that may be used for combinatory anti-tumor therapy include, merely to illustrate: aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.

Certain chemotherapeutic anti-tumor compounds may be categorized by their mechanism of action into, for example, following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate antagonists and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine)); antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristin, vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents

(actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, melphalan, merchlorhetamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, teniposide, triethylenethiophosphoramide and etoposide (VP16)); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes - dacarbazine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents (breveldin); immunosuppressives (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); anti-angiogenic compounds (TNP-470, genistein) and growth factor inhibitors (e.g., VEGF inhibitors, fibroblast growth factor (FGF) inhibitors); angiotensin receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies (trastuzumab); cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prednisolone); growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers and caspase activators; and chromatin disruptors.

In certain embodiments, pharmaceutical compounds that may be used for combinatory anti-angiogenesis therapy include: (1) inhibitors of release of “angiogenic molecules,” such as bFGF (basic fibroblast growth factor); (2) neutralizers of angiogenic molecules, such as an anti- $\beta$ bFGF antibodies; and (3) inhibitors of endothelial cell response to angiogenic stimuli, including collagenase inhibitor, basement membrane turnover inhibitors, angiostatic steroids, fungal-derived angiogenesis inhibitors, platelet factor 4, thrombospondin, arthritis drugs such as D-penicillamine and gold thiomalate, vitamin D<sub>3</sub> analogs, alpha-interferon, and the like. For additional proposed inhibitors of angiogenesis, see Blood et al., *Bioch. Biophys. Acta.*, 1032:89-118 (1990), Moses et al., *Science*, 248:1408-1410 (1990), Ingber et al., *Lab. Invest.*, 59:44-51 (1988), and U.S. Pat. Nos. 5,092,885, 5,112,946, 5,192,744, 5,202,352, and 6,573,256. In addition, there are a wide variety of compounds that can be used to inhibit angiogenesis, for example, endostatin protein or derivatives, lysine binding fragments of angiostatin, melanin or melanin-promoting compounds, plasminogen fragments (e.g., Kringles 1-3 of plasminogen), tropoin subunits, antagonists of vitronectin  $\alpha_v\beta_3$ , peptides derived from Saposin B, antibiotics or analogs (e.g., tetracycline, or neomycin), dienogest-containing compositions, compounds comprising a MetAP-2 inhibitory core coupled to a peptide, the compound EM-138, chalcone and its analogs, and naaladase inhibitors. See, for example, U.S. Pat. Nos. 6,395,718, 6,462,075, 6,465,431, 6,475,784, 6,482,802, 6,482,810, 6,500,431, 6,500,924, 6,518,298, 6,521,439, 6,525,019, 6,538,103, 6,544,758, 6,544,947, 6,548,477, 6,559,126, and 6,569,845.

Depending on the nature of the combinatory therapy, administration of the polypeptide therapeutic agents of the invention may be continued while the other therapy is being administered and/or thereafter. Administration of the polypeptide therapeutic agents may be made in a single dose, or in multiple doses. In some instances, administration of the polypeptide therapeutic agents is commenced at least several days prior to the conventional therapy, while in other instances, administration is begun either immediately before or at the time of the administration of the conventional therapy.

The VEGFR-2 binding proteins described herein can also be detectably labeled and used to contact cells expressing VEGFR-2 for imaging applications or diagnostic

applications. For diagnostic purposes, the polypeptide of the invention is preferably immobilized on a solid support. Preferred solid supports include columns (for example, affinity columns, such as agarose-based affinity columns), microchips, or beads.

In one example of a diagnostic application, a biological sample, such as serum  
5 or a tissue biopsy, from a patient suspected of having a condition characterized by inappropriate angiogenesis is contacted with a detectably labeled polypeptide of the invention to detect levels of VEGFR-2. The levels of VEGFR-2 detected are then compared to levels of VEGFR-2 detected in a normal sample also contacted with the labeled polypeptide. An increase of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%,  
10 80%, or 90% in the levels of the VEGFR-2 may be considered a diagnostic indicator of a condition characterized by inappropriate angiogenesis.

In certain embodiments, the VEGFR-2 binding polypeptides of the invention are further attached to a label that is able to be detected (e.g., the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor). The active moiety  
15 may be a radioactive agent, such as: radioactive heavy metals such as iron chelates, radioactive chelates of gadolinium or manganese, positron emitters of oxygen, nitrogen, iron, carbon, or gallium,  $^{43}\text{K}$ ,  $^{52}\text{Fe}$ ,  $^{57}\text{Co}$ ,  $^{67}\text{Cu}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{123}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{132}\text{I}$ , or  $^{99}\text{Tc}$ . A binding agent affixed to such a moiety may be used as an imaging agent and is administered in an amount effective for diagnostic use in a mammal such as a human  
20 and the localization and accumulation of the imaging agent is then detected. The localization and accumulation of the imaging agent may be detected by radioscintigraphy, nuclear magnetic resonance imaging, computed tomography or positron emission tomography. Immunoscintigraphy using VEGFR-2 binding polypeptides directed at VEGFR may be used to detect and/or diagnose cancers and  
25 vasculature. For example, any of the binding polypeptide against the VEGFR-2 marker labeled with  $^{99}\text{Tc}$ ,  $^{111}\text{In}$ , or  $^{125}\text{I}$  may be effectively used for such imaging. As will be evident to the skilled artisan, the amount of radioisotope to be administered is dependent upon the radioisotope. Those having ordinary skill in the art can readily formulate the amount of the imaging agent to be administered based upon  
30 the specific activity and energy of a given radionuclide used as the active moiety. Typically 0.1-100 millicuries per dose of imaging agent, preferably 1-10 millicuries, most often 2-5 millicuries are administered. Thus, compositions according to the

present invention useful as imaging agents comprising a targeting moiety conjugated to a radioactive moiety comprise 0.1-100 millicuries, in some embodiments preferably 1-10 millicuries, in some embodiments preferably 2-5 millicuries, in some embodiments more preferably 1-5 millicuries.

5           The VEGFR-2 binding polypeptides of the present invention can also be used to deliver additional therapeutic agents (including but not limited to drug compounds, chemotherapeutic compounds, and radiotherapeutic compounds) to a cell or tissue expressing VEGFR-2. In one example, the VEGFR-2 binding polypeptide is fused to a chemotherapeutic agent for targeted delivery of the chemotherapeutic agent to a tumor  
10 cell or tissue expressing VEGFR-2.

          The VEGFR-2 binding polypeptides of the present invention are useful in a variety of applications, including research, diagnostic and therapeutic applications. For instance, they can be used to isolate and/or purify receptor or portions thereof, and to study receptor structure (e.g., conformation) and function.

15           In certain aspects, the various binding polypeptides of the present invention can be used to detect or measure the expression of VEGFR-2, for example, on endothelial cells (e.g., venous endothelial cells), or on cells transfected with a VEGFR-2 gene. Thus, they also have utility in applications such as cell sorting and imaging (e.g., flow cytometry, and fluorescence activated cell sorting), for diagnostic or research purposes.

20           In certain embodiments, the binding polypeptides or fragments thereof can be labeled or unlabeled for diagnostic purposes. Typically, diagnostic assays entail detecting the formation of a complex resulting from the binding of a binding polypeptide to VEGFR-2. The binding polypeptides or fragments can be directly labeled, similar to antibodies. A variety of labels can be employed, including, but not  
25 limited to, radionuclides, fluorescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors and ligands (e.g., biotin, haptens). Numerous appropriate immunoassays are known to the skilled artisan (see, for example, U.S. Pat. Nos. 3,817,827; 3,850,752; 3,901,654; and 4,098,876). When unlabeled, the binding polypeptides can be used in assays, such as agglutination assays. Unlabeled binding  
30 polypeptides can also be used in combination with another (one or more) suitable reagent which can be used to detect the binding polypeptide, such as a labeled antibody reactive with the binding polypeptide or other suitable reagent (e.g., labeled protein A).



In one embodiment, the binding polypeptides of the present invention can be utilized in enzyme immunoassays, wherein the subject polypeptides are conjugated to an enzyme. When a biological sample comprising a VEGFR-2 protein is combined with the subject binding polypeptides, binding occurs between the binding polypeptides and the VEGFR-2 protein. In one embodiment, a sample containing cells expressing a VEGFR protein (e.g., endothelial cells) is combined with the subject antibodies, and binding occurs between the binding polypeptides and cells bearing a VEGFR-2 protein recognized by the binding polypeptide. These bound cells can be separated from unbound reagents and the presence of the binding polypeptide-enzyme conjugate specifically bound to the cells can be determined, for example, by contacting the sample with a substrate of the enzyme which produces a color or other detectable change when acted on by the enzyme. In another embodiment, the subject binding polypeptides can be unlabeled, and a second, labeled polypeptide (e.g., an antibody) can be added which recognizes the subject binding polypeptide.

In certain aspects, kits for use in detecting the presence of a VEGFR-2 protein in a biological sample can also be prepared. Such kits will include an VEGFR-2 binding polypeptide which binds to a VEGFR-2 protein or portion of said receptor, as well as one or more ancillary reagents suitable for detecting the presence of a complex between the binding polypeptide and the receptor protein or portions thereof. The polypeptide compositions of the present invention can be provided in lyophilized form, either alone or in combination with additional antibodies specific for other epitopes. The binding polypeptides and/or antibodies, which can be labeled or unlabeled, can be included in the kits with adjunct ingredients (e.g., buffers, such as Tris, phosphate and carbonate, stabilizers, excipients, biocides and/or inert proteins, e.g., bovine serum albumin). For example, the binding polypeptides and/or antibodies can be provided as a lyophilized mixture with the adjunct ingredients, or the adjunct ingredients can be separately provided for combination by the user. Generally these adjunct materials will be present in less than about 5% weight based on the amount of active binding polypeptide or antibody, and usually will be present in a total amount of at least about 0.001% weight based on polypeptide or antibody concentration. Where a second antibody capable of binding to the binding polypeptide is employed, such antibody can be provided in the kit, for instance in a separate vial or container. The second antibody,



if present, is typically labeled, and can be formulated in an analogous manner with the antibody formulations described above.

Similarly, the present invention also relates to a method of detecting and/or quantitating expression of VEGFR-2, wherein a composition comprising a cell or fraction thereof (e.g., membrane fraction) is contacted with a binding polypeptide which binds to a VEGFR-2 or portion of the receptor under conditions appropriate for binding thereto, and the binding is monitored. Detection of the binding polypeptide, indicative of the formation of a complex between binding polypeptide and VEGFR-2 or a portion thereof, indicates the presence of the receptor. Binding of a polypeptide to the cell can be determined by standard methods, such as those described in the working examples. The method can be used to detect expression of VEGFR-2 on cells from an individual. Optionally, a quantitative expression of VEGFR-2 on the surface of endothelial cells can be evaluated, for instance, by flow cytometry, and the staining intensity can be correlated with disease susceptibility, progression or risk.

The present invention also relates to a method of detecting the susceptibility of a mammal to certain diseases. To illustrate, the method can be used to detect the susceptibility of a mammal to diseases which progress based on the amount of VEGFR-2 present on cells and/or the number of VEGFR-2-positive cells in a mammal. In one embodiment, the invention relates to a method of detecting susceptibility of a mammal to a tumor. In this embodiment, a sample to be tested is contacted with a binding polypeptide which binds to a VEGFR-2 or portion thereof under conditions appropriate for binding thereto, wherein the sample comprises cells which express VEGFR-2 in normal individuals. The binding and/or amount of binding is detected, which indicates the susceptibility of the individual to a tumor, wherein higher levels of receptor correlate with increased susceptibility of the individual to a tumor.

#### EXAMPLES:

The following examples are for the purposes of illustrating the invention, and should not be construed as limiting.

#### Example 1. Initial identification of KDR binding molecules

A library of approximately  $10^{13}$  RNA-protein fusion variants was constructed based on the scaffold of the tenth type 3 domain of human fibronectin with three randomized regions at positions 23-29, 52-55 and 77-86 (amino acid nos. are referenced to SEQ ID NO:5) (three loop library; Xu et al, Chemistry & Biology 9:933-942, 2002). Similar libraries were constructed containing randomized regions only at positions 23-29 and 77-86 (two loop library) or only at positions 77-86 (one loop library). A mixture of these three libraries was used for in vitro selection against the extracellular domain of human VEGFR-2 (KDR, extracellular domain, residues 1-764 fused to human IgG1 Fc). For the purposes of this application, the amino acid positions of the loops will be defined as residues 23-30 (BC Loop), 52-56 (DE Loop) and 77-87 (FG Loop). The target binding population was analyzed by DNA sequencing after six rounds of selection and was found to be diverse, with some replicates present. Proteins encoded by fifteen independent clones were screened for binding to KDR, (Figure 1A) and the best binders were subsequently analyzed for inhibition of target binding in the presence of VEGF (Figure 1B). Multiple clones were identified that inhibited KDR-VEGF binding, suggesting that these clones bound KDR at or near the natural ligand (VEGF) binding site. The ability of two of the binding molecules (VR28 and VR12) to directly inhibit VEGF-KDR interaction was evaluated in a BIAcore assay using immobilized VEGF and a mobile phase containing KDR-Fc with or without a selected binding protein. VR28 and, to a lesser extent, VR12, but not a non-competing clone (VR17), inhibited KDR binding to VEGF in a dose dependent manner (Figure 1C). Finally, in addition to binding to purified recombinant KDR, VR28 also appeared to bind to KDR-expressing recombinant CHO cells, but not to control CHO cells (Figure 1D).

The sequence of the binding loops of the VR28 clone is shown in the first row of Table 4.

While VR28 was not the most abundant clone in the sequenced binding population (one copy out of 28 sequenced clone), its binding affinity to KDR was the best among the tested clones from this binding population, with a dissociation constant of 11-13 nM determined in a radioactive equilibrium binding assay (Figure 3 and Table 5) and BIAcore assays (Table 7). There were no changes from wild type  $^{10}$ F<sub>n</sub>3 in the remaining scaffold portion of the molecule (following correction of an incidental

scaffold change at position 69 that had no effect on binding). However, VR28 showed little inhibition of VEGF-KDR signaling in a VEGF-dependent cell proliferation assay. Thus, while the selection from the naïve library yielded antibody mimics that interfered with the interaction between VEGF and KDR in biochemical binding studies, affinity improvements were useful for neutralizing function in a biological signal transduction assay.

#### Example 2. Affinity Maturation of Clone VR28

A mutagenesis strategy focusing on altering sequences only in the binding loops was employed. To initially test which loops were more likely to result in improvement, loop-directed hypermutagenic PCR was carried out to introduce up to 30% mutations independently into each loop of VR28. After three rounds of selection against KDR, multiple clones with improved binding to KDR-Fc were observed. Sequence analysis of the selection pools revealed that the majority of mutations were accumulated in the FG loop while the BC and DE loops remained almost intact. This result indicated that the FG loop was the most suitable target for further modification.

Consequently, a new library of approximately  $10^{12}$  variants was constructed by altering the sequence of VR28 in the FG loop using oligonucleotide mutagenesis. For each of the FG loop positions (residues 77-86 [VAQNDHELIT (SEQ ID NO:198)] as well as the following Proline [residue 87]), a 50:50 mixture of the VR28-encoding DNA and NNS was introduced at each position. DNA sequence analysis of a random sample of approximately 80 clones revealed an average of six amino acid changes per clone as expected. Lower KDR-Fc concentrations were utilized during selection to favor clones with better affinities to the target. The profile of target binding during the four rounds of selection is shown in Figure 2. After four rounds of selection the binding population was subcloned and analyzed. Table 5 and Figure 3A summarize affinity measurements of individual binding clones. The measured binding constants to KDR-Fc ranged from  $<0.4$  to  $<1.8$  nM, a 10-30 improvement over VR28 (11 nM).

Sequence analysis, some of which is shown in Table 4 (K clones), revealed that while the binding population was diverse, several consensus motifs could be identified among the clones. Most noticeably, Pro87 and Leu84 were found in nearly all clones (as in VR28), suggesting that these residues may be essential for the structure of the

binding site. A positively charged amino acid at position 82 appears to be required since only H82K or H82R changes were seen in the sequenced clones and an aliphatic amino acid was predominant at position 78. D81 was often mutated to a G, resulting in the loss of negative charge at this position and a gain in flexibility. In addition, the overall mutation rate in the selected population was comparable to the pool prior to selection, which suggested that the FG loop is very open to changes.

Several residues in the N-terminus of the <sup>10</sup>F<sub>n</sub>3 domain of human fibronectin are located in close proximity to the FG loop, as suggested by structural determinations (Main et al, Cell 71:671-678, 1992). The close proximity of the two regions could potentially have a negative impact on target binding. Two incidental mutations in the N-terminal region, L8P and L8Q, resulted in better binding to KDR in a number of selected clones, presumably due to a change of the location of the N-terminus relative to the FG loop. To further test the impact of the N-terminus, we created binding molecules for 23 different KDR binders in which the N-terminal first eight residues before the  $\beta$ -sheet were deleted. We then compared target binding to the non-deleted counterparts. On average, binding to KDR-Fc was about 3-fold better with the deletion, as shown in Figure 3B.

Example 3. Selection of binders with dual specificities to human (KDR) and mouse (Flk-1) VEGFR-2.

VR28 and most of the affinity matured variants (K clones) failed to bind the mouse homolog of KDR, Flk1, as shown in Figure 4. However, since KDR and Flk1 share a high level of sequence identity (85%, Claffey et al., J. Biol. Chem. 267:16317-16322 (1992), Shima et al., J. Biol. Chem. 271:3877-3883 (1996)), it is conceivable to isolate antibody mimics that can bind both KDR and Flk1. Such dual binders were desirable because they would allow the same molecule to be tested in functional studies in animal models and subsequently in humans.

The population of clones following FG loop mutagenesis and selection against KDR for four rounds was further selected against Flk1 for an additional three rounds. As shown in Figure 2 an increase in binding to Flk1 was observed from Round 5 to Round 7, indicating enrichment of Flk1 binders. Analysis of binding for multiple individual clones revealed that in contrast to the clones selected against KDR only (K

clones), most clones derived from additional selection against Flk1 (E clones) are able to interact with both KDR and Flk1. The binding constants to both targets, as determined using a radioactive equilibrium binding assay (Table 6 and Figure 5) and BIAcore (Table 7), indicate that individual clones were able to bind both targets with  
5 high affinities.

For example, E19 has a  $K_d$  of 60 pM to KDR, and 340 pM to Flk-1. These results demonstrate that a simple target switch strategy in the selection process, presumably through selection pressures exerted by both targets, has allowed the isolation of molecules with dual binding specificities to both KDR and Flk-1 from a  
10 mutagenized population of VR28, a moderate KDR binder that was not able to bind Flk-1. The selected fibronectin-based binding proteins are highly specific to VEGFR-2 (KDR) as no substantial binding to VEGFR1 was observed at high target concentration.

Sequence analysis revealed some motifs similar to those observed in the KDR binder pool (Leu and Pro at residues 84 and 87 respectively; positively charged amino  
15 acid at residue 82, predominantly Arg) and some that were not maintained (aliphatic at position 78). In addition, the motif ERNGR (residues 78-82) was present in almost all clones binding to Flk-1 (Table 4); this motif was barely discernable in the KDR binding pool. R79 and R82 appear to be particularly important for high affinity binding to Flk-1, since binding to Flk-1, but not KDR, is greatly reduced when a different residue is  
20 present at this position (Figure 6A). To determine the importance of each loop in binding to KDR and Flk-1, the loops of clones E6 and E26 shown in Table 4, were substituted one loop at a time by NNS randomized sequence. As shown in Figure 6B, after the substitution, the proteins are no longer able to bind either KDR or Flk-1. These results indicate that each loop is required for binding to the targets, suggesting a  
25 cooperative participation of all three loops in interacting with the targets.

An alternative mutagenesis strategy was independently employed to produce clones capable of binding to both targets. The clone 159Q(8)L (Table 4), the product of hypermutagenic PCR affinity maturation of VR28 that binds KDR with high affinity ( $K_d=2$  nM; Table 7) and Flk-1 with poor affinity ( $K_d>3000$  nM), was chosen as a  
30 starting point. The first six amino acids of the FG loop were fully randomized (NNS), leaving the following five residues (ELFTP) intact. After six rounds of selection against Flk-1, the binding pool was re-randomized at the DE loop (positions 52-56) and

the selection was performed for three additional rounds against Flk-1 and one round against KDR. A number of high affinity binding molecules to both KDR and Flk-1 were thus obtained (Tables 4 and Figure 4). For example, clone M5FL, while retaining high binding affinity to KDR ( $K_d=890$  pM), can bind Flk-1 at a  $K_d$  of 2.1 nM, a 1000-  
5 fold improvement over the original clone. Interestingly, the ERNGR motif, found in Flk-1 binding molecules selected from a mutagenized population of VR28, was also present in multiple clones derived from clone 159Q(8)L mutagenesis and selection, despite a full randomization of this region of the FG loop. The isolation of similar binding molecules from two independent libraries suggests that the affinity maturation  
10 process is robust for isolating optimal Flk-1 binding motifs located in the FG loop.

#### Example 4. Cell surface binding and neutralization of VEGF activity in vitro

The functionality of KDR and Flk-1 binding molecules in a cell culture model system was evaluated with *E. coli* produced binding molecules. Using a detection  
15 system consisting of anti-His6 tag murine antibody (the *E. coli* expressed proteins were expressed with a His tag) and an anti-murine fluorescently labeled antibody the binding molecules were shown to bind specifically to mammalian cells expressing KDR or Flk-1 with low nanomolar EC50s, (Figure 7 and Table 8).

More importantly, using recombinant BA/F3 cells (DSMZ-Deutsche Sammlung  
20 von Mikroorganismen und Zellkulturen GmbH) expressing the extracellular KDR or Flk-1 domain linked to the erythropoietin receptor signaling domain, these molecules inhibited VEGF-stimulated cell proliferation in a dose dependent fashion, with IC50 3-12 nM for KDR expressing cells, and 2-5 nM for Flk-1 expressing cells. The potency of inhibition appears to be similar to control anti-KDR and anti-Flk-1 monoclonal  
25 antibodies, as shown in Figure 8 and Table 9.

A number of clones were further tested for VEGF-inhibition of the growth of HUVEC cells (Human Umbilical Vein Endothelial Cells). HUVEC cells are natural human cells that are closely related to cells in the body that respond to VEGF. As shown in Figure 9 and Table 10, the fibronectin-based binding proteins were also active  
30 in inhibiting VEGF activity in this human-derived cell system while the wild type fibronectin-based scaffold protein was inactive.



### Example 5. Thermal Stability and Reversible Refolding of M5FL Protein

The thermal stability of KDR-binder M5FL was established using differential scanning calorimetry (DSC). Under standard PBS buffer conditions (sodium phosphate pH 7.4, 150 mM NaCl), M5FL was found to have a single non-reversible thermal melting transition at 56°C. Subsequently, sodium acetate pH 4.5 was identified as a favorable buffer for M5FL protein solubility. DSC experiments in this buffer (100 mM) demonstrated that M5FL is more stable under these conditions ( $T_m = 67-77^\circ\text{C}$ ) and that the melting transition is reversible (Figure 10). Reversible thermal transitions have been used to identify favorable conditions that support long-term storage of protein therapeutics (Remmele et al, Biochemistry 38:5241 (1999), so Na-acetate pH 4.5 has been identified as an optimized buffer for storing the M5FL protein.

### Example 6. In Vitro Binding and Cell-Based Activity of PEGylated M5FL Protein

The M5FL protein was produced in an E. coli expression system with a C-terminal extension to yield the following protein sequence (C-terminal extension underlined with Cys100 shaded; a significant percentage of protein is produced with the initial methionine removed):

MGVSDVPRDLEVVAATPTSLLISWRHPHFPTRYYYRITYGETGGNSPVQE  
FTVPLQPPLATISGLKPGVDYTITVYAVTKERNGRELFTPIISINYRTEIDKPCQHH  
HHHH (SEQ ID NO:199)

The single sulfhydryl of the cysteine residue at position 100 was used to couple to PEG variants using standard maleimide chemistry to yield two different PEGylated forms of M5FL. Both a linear 20 kD PEG and a branched 40 kD PEG (Shearwater Corporation) were conjugated to M5FL to produce M5FL-PEG20 and M5FL-PEG40, respectively. The PEGylated protein forms were purified from unreacted protein and PEG by cation exchange chromatography. Covalent linkage of the two PEG forms of M5FL was verified by SDS-PAGE (Figure 11) and mass spectroscopy.

In vitro affinity measurements were made using surface plasmon resonance (SPR) (BIAcore) with both the human and mouse VEGF-receptor target proteins immobilized via amide chemistry on the BIAcore chip. For both target proteins, both



the 20 and 40 kD PEGylated M5FL forms were found to have slower on-rates ( $k_a$ ) relative to unmodified M5FL with little effect on off-rates ( $k_d$ ; Table 11).

The functionality of the PEGylated M5FL preparations was tested using the Ba/F3 system described in Example 4. Figure 12 shows a plot of A490 (representing the extent of cell proliferation) as a function of concentration of each of the binders. The curves were nearly identical, indicating there was little effect of PEGylation on the biological activity of either of the PEGylated forms.

The  $k_{on}$ ,  $k_{off}$  and  $K_D$  were analyzed for a subset of KDR-binding polypeptides and compared to the EC50 for the BaF3 cell-based VEGF inhibition assay. Scatter plots showed that the  $k_{on}$  was well-correlated with the EC50, while  $k_{off}$  was poorly correlated. Greater than 90% of KDR-binding proteins with a  $k_{on}$  of  $10^5 s^{-1}$  or greater had an EC50 of 10nM or less.  $K_D$  is a ratio of  $k_{on}$  and  $k_{off}$ , and, as expected, exhibits an intermediate degree of correlation with EC50.

Many of the KDR-binding proteins, including CT-01, were assessed for binding to VEGFR-1, VEGFR-2 and VEGFR-3. The proteins showed a high degree of selectivity for VEGFR-2.

#### Example 6: Preparation of KDR Binding Protein CT-01 Blocks VEGFR-2 Signaling in Human Endothelial Cells.

Following the methodologies described in the preceding Examples, additional  $^{10}F_n3$ -based KDR binding proteins were generated. As described for the development of the M5FL protein in Example 5, above, proteins were tested for  $K_D$  against human KDR and mouse Flk-1 using the BIAcore binding assay and for IC50 in a Ba/F3 assay. A protein termed CT-01 exhibited desirable properties in each of these assays and was used in further analysis.

The initial clone from which CT-01 was derived had a sequence:  
GEVVAATPTSLLISWRHPHFTRYRITYGETGGNSPVQEFTVPLQPPTATISGL  
KPGVDYTITVYAVTDDGWNGRLLSIPISINYRT (SEQ ID NO:200). The FG loop sequence is underlined.

Affinity maturation as described above produced a core form of CT-01:  
EVVAATPTSLLISWRHPHFTRYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITVYAVTDGRNGRLLSIPISINYRT (SEQ ID NO:192).

The CT-01 molecule above has a deletion of the first 8 amino acids and may include additional amino acids at the N- or C- termini. For example, an additional MG sequence may be placed at the N-terminus. The M will usually be cleaved off, leaving a GEV... sequence at the N-terminus. The re-addition of the normal 8 amino acids at the N-terminus also produces a KDR binding protein with desirable properties. The N-terminal methionine is generally cleaved off to yield a sequence:

VSDVPRDLEVVAATPTSLLISWRHPHFPTTRYRITYGETGGNSPVQEFTVPLQPP  
TATISGLKPGVDYTITVYAVTDGRNGRLLSIPISINYRT (SEQ ID NO:193).

For use in vivo, a form suitable for PEGylation may be generated. For example, a C-terminal tail comprising a cysteine was added and expressed, as shown below for a form lacking the eight N-terminal amino acids.

GEVVAATPTSLLISWRHPHFPTTRYRITYGETGGNSPVQEFTVPLQPPTATISGL  
KPGVDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPCQ (SEQ ID NO:194). The

PEGylated form of this molecule is used in the in vivo experiments described below. A control form with a serine instead of a cysteine was also used:

GEVVAATPTSLLISWRHPHFPTTRYRITYGETGGNSPVQEFTVPLQPPTATISGL  
KPGVDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPSQ (SEQ ID NO:195).

The same C-terminal tails may also be added to CT-01 forms having the N-terminal eight amino acids, such as is shown in SEQ ID NO:193.

Additional variants with desirable KDR binding properties were isolated. The following core sequence has a somewhat different FG loop, and may be expressed with, for example, an N-terminal MG sequence, an N-terminal sequence that restores the 8 deleted amino acids, and/or a C-terminal tail to provide a cysteine for PEGylation.

EVVAATPTSLLISWRHPHFPTTRYRITYGETGGNSPVQEFTVPLQPPTATISGLK  
PGVDYTITVYAVTEGPNERSLFIPIISINYRT (SEQ ID NO:196). Another such variant has the core sequence:

VSDVPRDLEVVAATPTSLLISWRHPHFPTTRYRITYGETGGNSPVQEFTVPLQPP  
TATISGLKPGVDYTITVYAVTEGPNERSLFIPIISINYRT (SEQ ID NO:197).

A comparison of these variants shows a consensus sequence for the FG loop of: D/E)GXNXRXXIP (SEQ ID NO:3). With greater particularity, the consensus sequence may be expressed as (D/E)G(R/P)N(G/E)R(S/L)(S/F)IP (SEQ ID NO:4).

Example 7: CT-01 Blocks VEGFR-2 Signaling in Human Endothelial Cells.

As shown in Figure 13, VEGF-A signaling through VEGFR-2 is mediated by phosphorylation of the intracellular domain of VEGFR-2, followed by activation of pathway involving phospholipase C gamma (PLC $\gamma$ ), Protein Kinase C (PKC), Raf-1,  
5 MEK1/2, ERK1/2, leading to endothelial cell proliferation.

To assess whether KDR binders disclosed herein inhibited activation of this signaling pathway, Human Microvascular Endothelial Cells were treated with a VEGFR binding polypeptide (e.g., CT-01) for 30 min and stimulated with VEGF-A for 5 min. Total cell lysates were analyzed by SDS-PAGE and western analysis, using  
10 antibodies specific to phospho-VEGFR-2, non-phospho-VEGFR-2, phosphor-ERK1/2 and non-phospho-ERK1/2.

As shown in Figure 13, 130 pM CT-01 inhibits formation of phosphor-VEGFR-2 and also decreases the formation of the downstream phosphorylated ERK1/2. Phosphorylated ERK1/2 is not entirely eliminated, probably due to the fact that  
15 ERK1/2 receives signals from a number of additional signaling pathways.

Example 8: Fibronectin-based KDR Binding Proteins Disrupt Signaling by VEGF-A and VEGF-D.

VEGFR-2 is a receptor for three VEGF species, VEGF-A, VEGF-C and VEGF-D. Experiments were conducted to evaluate the effects of fibronectin-based KDR  
20 binding proteins on VEGF-A and VEGF-D mediated signaling through KDR.

A Ba/F3 cell line dependent on Flk-1 mediated signaling was generated. As shown in the left panel of Figure 14, cell viability could be maintained by treating the cells with VEGF-A or VEGF-D, although significantly higher levels of VEGF-D were  
25 required.

As shown in the middle panel of Figure 14, cells were maintained in the presence of 15 ng/ml of VEGF-A and contacted with the M5FL or CT-01 proteins disclosed herein, or with the DC-101 anti-Flk-1 antibody. Each reagent reversed the VEGF-A-mediated cell viability, indicating that VEGF-A signaling through Flk-1 was  
30 blocked.

As shown in the right panel of Figure 14, cells were maintained in the presence of 300 ng/ml of VEGF-D and contacted with the M5FL or F10 proteins disclosed

herein, or with an anti-VEGF-A antibody. M5FL and F10 reversed the VEGF-D-mediated cell viability, indicating that VEGF-D signaling through Flk-1 was blocked. The anti-VEGF-A antibody had no effect, demonstrating the specificity of the assay.

## 5 Example 9: Pharmacokinetics

Pharmacokinetic Studies: Native CT-01 or a pegylated form (40 kDa PEG, CT-01PEG40) were iodinated with  $^{125}\text{I}$ . 10-20 mCi of iodinated proteins were injected into adult male rats either i.v. or i.p. and iodinated proteins levels were determined at the indicated times. For tissue distribution studies, rats were sacrificed at 15 min, 2 hr and  
10 6 hr and radioactivity levels determined. See Figures 15 and 16. Unmodified CT-01 is a 12 kDa protein that is rapidly cleared from the blood. The area-under-curve value (AUC) value is 14.6 hr\*mg/mL with a clearance of 69.9 mL/hr/kg, a maximum serum concentration of 9.1 mg/mL. The initial half-life ( $\alpha$ ) is 0.3 hours and the second phase half-life ( $\beta$ ) is 13.5 hours. By comparison, i.v. PEGylated CT-01 has greatly increased  
15 presence in the blood, mostly because of a dramatic decrease in the initial phase of clearance. The AUC is increased greater than 10 fold to 193, the clearance rate is decreased by greater than 10 fold to 5.2, the Cmax is 12.9 mg/mL. The  $\alpha$  half-life is increased to 1 hour, and the  $\beta$  is increased to 16.2 hours. These pharmacokinetics in rats are equivalent to a twice-weekly dosing regimen in humans, a rate of dosing that is  
20 well within acceptable ranges.

Intraperitoneal (i.p.) administration of PEGylated CT-01 had reservoir-like pharmacokinetics. There was no initial spike in the blood concentration of CT-01. Instead, the amount of CT-01 built up more slowly and decreased slowly. Such pharmacokinetics may be desirable where there is concern about side effects from the  
25 initial spike in CT-01 concentration upon intravenous administration. It is likely that other  $^{10}\text{FN3}$ -based agents would exhibit similar behavior in i.p. administration. Accordingly, this may be a generalizable mode for achieving a time-delayed dosing effect with  $^{10}\text{FN3}$ -based agents.

As shown in Figure 16, the liver is the primary route for secretion of the  
30 PEGylated form of CT-01. No long term accumulation of CT-01 was detected.

Similar results were obtained using a CT-01 conjugated to a 20kDa PEG moiety.

#### Example 10: In Vivo Efficacy of CT-01

The Miles assay, as outlined in Figure 17, is used to evaluate Dose, Schedule and Administration parameters for the tumor efficacy studies. Balb/c female mice were  
5 injected i.p. with buffer or CT-01PEG40 at 1, 5 and 20 mg/kg 4 hr prior to VEGF challenge. Intradermal focal administration of VEGF-A into the back skin induces vessel leakage of Evans blue dye (Figure 17 and 18).

Mice treated with a KDR binding agent showed a statistically significant decrease in the level of VEGF-mediated vessel leakage. Both 5mg/kg and 20mg/kg  
10 dosages with CT-01 showed significant results. Therefore, a 5mg/kg dosage was selected for mouse tumor model studies.

#### Example 11: CT-01 Inhibits Tumor Growth

##### B16-F10 Murine Melanoma Tumor Assay:

15  $2 \times 10^6$  B16-F10 murine melanoma tumor cells were implanted subcutaneously into C57/BL male mice at Day 1. At day 6 a palpable mass was detected. On day 8 when tumors were of measurable size, daily i.p. injections of either Vehicle control, 5, 15, or 40 mg/kg CT-01PEG40 were started. The lowest dose 5 mg/kg decreased tumor growth. At day 18, mice treated with 15 and 40 mg/kg showed 50 % and 66%  
20 reduction in tumor growth. See Figure 19.

##### U87 Human Glioblastoma Assay:

5  $5 \times 10^6$  U87 human glioblastoma tumor cells were implanted subcutaneously into nude male mice. When tumor volume reached approximately 50 mm<sup>3</sup> treatment started (day 0). Vehicle control, 3, 10, or 30 mg/kg CT-01PEG40 were injected i.v.  
25 every other day (EOD). The anti-Flk-1 antibody DC101 was injected at 40 mg/kg twice a week as published for its optimal dose schedule. The lowest dose 3 mg/kg decreased tumor growth. At day 12, mice treated with 10 and 30 mg/kg showed 50 % reduction in tumor growth. See Figure 20. Effectiveness is comparable to that of the anti-Flk-1 antibody.

30

The following materials and methods were used for the experiments described in Examples 1-11.

## Recombinant proteins:

Recombinant human VEGF<sub>165</sub>, murine VEGF<sub>164</sub>, human neurotrophin-4 (NT4), human and mouse vascular endothelial growth factor receptor-2 Fc chimeras (KDR-Fc and Flk-1-Fc) were purchased from R&D systems (Minneapolis, MN). Biotinylation of the target proteins was carried out in 1xPBS at 4 °C for 2 hours in the presence of EZ-Link™ Sulfo-NHS-LC-LC-Biotin (Pierce, IL). Excess of EZ-Link™ Sulfo-NHS-LC-LC-Biotin was removed by dialysis against 1x PBS. The level of biotinylation was determined by mass spectroscopy and target protein concentrations were determined using Coomassie Protein Plus Assay (Pierce, IL).

## Primers:

The following oligonucleotides were prepared by chemical synthesis for eventual use in library construction and mutagenesis of selected clones.

15

T7 TMV Fn: 5' GCG TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG GTT TCT GAT GTT CCG AGG 3' (SEQ ID NO:201)

20

T7 TMV N-terminus deletion: 5' GCG TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG GAA GTT GTT GCT GCG ACC CCC ACC AGC CTA 3' (SEQ ID NO:202)

25

MK165-4 A20: 5' TTT TTT TTT TTT TTT TTT TTA AAT AGC GGA TGC CTT GTC GTC GTC GTC CTT GTA GTC 3' (SEQ ID NO:203)

N-terminus forward: 5' ATG GTT TCT GAT GTT CCG AGG GAC CTG GAA GTT GTT GCT GCG ACC CCC ACC AGC CTA CTG ATC AGC TGG 3' (SEQ ID NO:204)

30

BCDE reverse: 5' AGG CAC AGT GAA CTC CTG GAC AGG GCT ATT TCC TCC TGT TTC TCC GTA AGT GAT CCT GTA ATA TCT 3' (SEQ ID NO:205)

BCDE forward: 5' AGA TAT TAC AGG ATC ACT TAC GGA GAA ACA GGA  
GGA AAT AGC CCT GTC CAG GAG TTC ACT GTG CCT 3' (SEQ ID NO:206)

DEFG reverse: 5' AGT GAC AGC ATA CAC AGT GAT GGT ATA ATC AAC TCC  
5 AGG TTT AAG GCC GCT GAT GGT AGC TGT 3' (SEQ ID NO:207)

DEFG forward: 5' ACA GCT ACC ATC AGC GGC CTT AAA CCT GGA GTT GAT  
TAT ACC ATC ACT GTG TAT GCT GTC ACT 3' (SEQ ID NO:208)

10 C-terminus polyA: 5' TTT TTT TTT TTT TTT TTT TAA ATA GCG GAT GCC TTG  
TCG TCG TCG TCC TTG TAG TCT GTT CGG TAA TTA ATG GAA AT 3' (SEQ  
ID NO:209)

Hu3'FLAGSTOP: 5' TTT TAA ATA GCG GAT GCC TTG TCG TCG TCG TCC  
15 TTG TAG TCT GTT CGG TAA TTA ATG G 3' (SEQ ID NO:210)

VR28FG-50: 5' GTG TAT GCT GTC ACT 123 145 463 665 165 465 163 425 625 645  
447 ATT TCC ATT AAT TAC 3', (SEQ ID NO:211), where 1 = 62.5%G + 12.5%A +  
12.5%T + 12.5%C; 2 = 2.5%G + 12.5%A + 62.5%T + 12.5%C; 3 = 75%G + 25%C; 4  
20 = 12.5%G + 12.5%A + 12.5%T + 62.5%C; 5 = 25%G + 75%C; 6 = 12.5%G + 62.5%A  
+ 12.5%T + 12.5%C; 7: 25%G + 50%A + 25%C

F1U2: 5' TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT  
CTA TCA ATA CAA TGG TGT CTG ATG TG CCG 3' (SEQ ID NO:212)

25

F2: 5' CCA GGA GAT CAG CAG GGA GGT CGG GGT GGC AGC CAC CAC TTC  
CAG GTC GCG CGG CAC ATC AGA CAC CAT TGT 3' (SEQ ID NO:213)

F3159: 5' ACC TCC CTG CTG ATC TCC TGG CGC CAT CCG CAT TTT CCG  
30 ACC CGC TAT TAC CGC ATC ACT TAC G 3' (SEQ ID NO:214)



F4: 5' CAC AGT GAA CTC CTG GAC CGG GCT ATT GCC TCC TGT TTC GCC  
GTA AGT GAT GCG GTA ATA GCG 3' (SEQ ID NO:215)

5 F5159: 5' CGG TCC AGG AGT TCA CTG TGC CGC TGC AGC CGC CGG CGG  
CTA CCA TCA GCG GCC TTA AAC C 3' (SEQ ID NO:216)

F5-X5: 5' CG GTC CAG GAG TTC ACT GTG CCG NNS NNS NNS NNS NNS GCT  
ACC ATC AGC GGC CTT AAA CC 3' (SEQ ID NO:217)

10 F6: 5' AGT GAC AGC ATA CAC AGT GAT GGT ATA ATC AAC GCC AGG TTT  
AAG GCC GCT GAT GGT AG 3' (SEQ ID NO:218)

F7X6159: 5' ACC ATC ACT GTG TAT GCT GTC ACT NNS NNS NNS NNS NNS  
NNS GAA CTG TTT ACC CCA ATT TCC ATC AAC TAC CGC ACA GAC TAC  
15 AAG 3' (SEQ ID NO:219)

F8: 5' AAA TAG CGG ATG CGC GTT TGT TCT GAT CTT CCT TAT TTA TGT  
GAT GAT GGT GGT GAT GCT TGT CGT CGT CGT CCT TGT AGT CTG TGC  
GGT AGT TGA T 3' (SEQ ID NO:220)

20

C2asaiA20: 5' TTT TTT TTT TTT TTT TTT TTA AAT AGC GGA TGC GCG TTT  
GTT CTG ATC TTC 3' (SEQ ID NO:221)

C2RT: 5' GCG CGT TTG TTC TGA TCT TCC 3' (SEQ ID NO:222)

25

hf01 BC reverse: 5' TGCC TCC TGT TTC GCC GTA AGT GAT GCG GTA ATA  
GCG SNN SNN SNN SNN SNN SNN SNN CCA GCT GAT CAG CAG 3' (SEQ ID  
NO:223)

30 hf01 DE reverse: 5' GAT GGT AGC TGT SNN SNN SNN SNN AGG CAC AGT  
GAA CTC CTG GAC AGG GCT ATT GCC TCC TGT TTC GCC 3' (SEQ ID  
NO:224)

hf01 FG reverse: 5' GT GCG GTA ATT AAT GGA AAT TGG SNN SNN SNN SNN  
SNN SNN SNN SNN SNN SNN AGT GAC AGC ATA CAC 3' (SEQ ID NO:225)

5 BCDE rev: 5' CCT CCT GTT TCT CCG TAA GTG 3' (SEQ ID NO:226)

BCDEfor: 5' CAC TTA CGG AGA AAC AGG AGG 3' (SEQ ID NO:227)

hf01 DE-FG forward: 5' ACA GCT ACC ATC AGC GGC CTT AAA CCT GGC GTT  
10 GAT TAT ACC ATC ACT GTG TAT GCT GTC ACT 3' (SEQ ID NO:228)

Front FG reverse: 5' AGT GAC AGC ATA CAC AGT 3' (SEQ ID NO:229)

hf01 RT Flag PolyA reverse: 5' TTT TTT TTT TTT TTT TTT TTA AAT AGC GGA  
15 TGC CTT GTC GTC GTC GTC CTT GTA GTC TGT GCG GTA ATT AAT GGA 3'  
(SEQ ID NO:230)

5-RI-hKDR-1B: 5' TAG AGA ATT CAT GGA GAG CAA GGT GCTG 3' (SEQ ID  
NO:231)

20

3-EPO/hKDR-2312B: 5' AGG GAG AGC GTC AGG ATG AGT TCC AAG TTC  
GTC TTT TCC 3' (SEQ ID NO:232)

5-RI-mKDR-1: 5' TAG AGA ATT CAT GGA GAG CAA GGC GCT G 3' (SEQ ID  
25 NO:233)

3-EPO/mKDR-2312: 5' AGG GAG AGC GTC AGG ATG AGT TCC AAG TTG  
GTC TTT TCC 3' (SEQ ID NO:234)

30 5-RI-hTrkB-1: 5' TAG AGA ATT CAT GAT GTC GTC CTG GAT AAG GT 3' (SEQ  
ID NO:235)

3-EpoR/hTrkB-1310: 5' AGG GAG AGC GTC AGG ATG AGA TGT TCC CGA  
CCG GTT TTA 3' (SEQ ID NO:236)

5-hKDR/EPO-2274B: 5' GGA AAA GAC GAA CTT GGA ACT CAT CCT GAC  
5 GCT CTC CCT 3' (SEQ ID NO:237)

5-mKDR/EPO-2274: 5' GGA AAA GAC CAA CTT GGA ACT CAT CCT GAC  
GCT CTC CCT 3' (SEQ ID NO:238)

10 3-XHO-EpoR-3066: 5' TAG ACT CGA GTC AAG AGC AAG CCA CAT AGCT 3'  
(SEQ ID NO:239)

5'hTrkB/EpoR-1274: 5' TAA AAC CGG TCG GGA ACA TCT CAT CCT GAC GCT  
CTC CCT 3' (SEQ ID NO:240)

15

#### Buffers

The following buffers were utilized in the experiments described herein. Buffer A (100 mM TrisHCl, 1M NaCl, 0.05% Tween-20, pH 8.0); Buffer B (1X PBS, 0.02% Triton X100); Buffer C (100 mM TrisHCl, 60 mM EDTA, 1M NaCl, 0.05% Triton  
20 X100, pH 8.0); Buffer Ca (100 mM TrisHCl, 1M NaCl, 0.05% Triton X100, pH 8.0); Buffer D (2M NaCl, 0.05% Triton); Buffer E (1X PBS, 0.05% Triton X100, pH 7.4); Buffer F (1X PBS, 0.05% Triton X100, 100 mM imidazole, pH 7.4); Buffer G (50 mM HEPES, 150 mM NaCl, 0.02% TritonX-100, 1 mg/ml bovine serum albumin, 0.1  
25 mg/ml salmon sperm DNA, pH 7.4); Buffer H (50 mM HEPES, 150 mM NaCl, 0.02% TritonX-100, pH 7.4); Buffer I (1xPBS, 0.02% TritonX-100, 1 mg/ml bovine serum albumin, 0.1 mg/ml salmon sperm DNA, pH 7.4); Buffer J (1xPBS, 0.02% TritonX-100, pH 7.4); Buffer K (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.5 M NaCl, 5% glycerol, 5 mM CHAPS, 25 mM imidazole, 1x Complete™ Protease Inhibitor Cocktail (Roche), pH 8.0); Buffer L (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.5 M NaCl, 5% glycerol, 25 mM imidazole, pH 8.0); Buffer M  
30 (1xPBS, pH 7.4, 25 mM imidazole, pH 7.4); Buffer N (1xPBS, 250 mM imidazole, pH 7.4); Buffer O (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, pH 7.4).

Primary library construction:

The construction of the library using the tenth domain of human fibronectin as a scaffold was previously described (Xu et al, 2002, *supra*). Three loop regions, corresponding to positions 23-29, 52-55, and 77-86, respectively, were randomized using NNS (standard nucleotide mixtures, where N = equimolar mixture of A, G, T, C; S = equimolar mixture of G and C) as the coding scheme. Similar libraries were constructed containing randomized regions only at positions 23-29 and 77-86 (two loop library) or only at positions 77-86 (one loop library). These libraries were mixed in approximately equimolar amounts. This mixed library contained  $\sim 1 \times 10^{13}$  clones and was used in the KDR selection that identified VR28.

Mutagenic library construction:

Hypermutagenic PCR. Scaffold mutation T(69)I in VR28 clone was corrected back to wild type sequence by PCR (see below) and no change in binding characteristics of VR28 binder to KDR was observed. Mutations were introduced into the loop regions of VR28 using conditions described previously (Vartanian et al, *Nuc. Acid Res.* 24:2627-2631, 1996). Three rounds of hypermutagenic PCR were conducted on a VR28 template using primer pairs flanking each loop (N-terminus forward/ BCDE reverse, BCDE forward/ DEFG reverse, DEFG forward/ C-terminus polyA). The resulting fragments were assembled using overlap extension and PCR with flanking primers T7TMV Fn and MK165-4 A20. DNA sequencing of the clones from the final PCR reaction confirmed correct assembly of the library. Up to 30% mutagenesis rate was observed in the loop regions, as compared to 1.5 % in the scaffold regions.

Oligo mutagenesis. Oligo mutagenesis of the FG loop of VR28 by PCR utilized the VR28FG-50 primer, DEFG reverse primer and flanking primers. At each nucleotide position encoding the FG loop, primer VR28FG-50 contained 50% of the VR28 nucleotide and 50% of an equimolar mixture of all four nucleotides (N) or of G or C (S). This scheme was designed to result in approximately 67% of the amino acids of the VR28 FG loop being randomly replaced by another amino acid which was confirmed by DNA sequencing.

159 (Q8L) randomized sub-libraries. Oligo mutagenesis of the FG loop of Clone 159 (Q8L) clone, a three-step extension and amplification was performed. For the first extension, pairs of primers (a: F1U2/ F2, b: F3159/ F4, c: F5159/ F6, d: F7X6159/ F8) were mixed in equal concentrations (100 pmol each) and amplified for 10 cycles. For the second extension, 1/20 of the first reactions were combined (a/b and c/d) and amplification was continued for another 10 cycles. To bias the amplification in favor of extension rather than re-annealing of fully complementary fragments, a linear amplification of the half-construct products (0.5 pmol each) was performed for an additional 20 cycles using 50 pmol of either F1U2 forward primer for fragment ab, or the C2asaiA20 reverse primer for fragment cd. Finally, the extended half-construct fragments ab and cd were combined and amplified for 20 cycles without any additional components. Primer F7X6159 contained NNS at each of the first 6 coding positions of Clone 159 (Q8L) and was otherwise identical to Clone 159 (Q8L). Correct assembly of the library 159 (Q8L)-FGX6 was confirmed by DNA sequencing of clones from the final PCR reaction. The sub-library contained  $\sim 1 \times 10^9$  clones.

For randomization of the DE loop of post round 6 (PR6) selection pool of the 159 (Q8L)-FGX6 library, two half-construct fragments were prepared by PCR using primers F1U2/ F4 and F5X5/ C2asaiA20. The F5X5 primer contained NNS at the four positions of the DE loop as well as at position 56. Then, the extended fragments ab and cd were combined and amplified for 20 cycles without any additional components.

Introduction of point mutations, deletion and random (NNS) loop sequences into fibronectin-based scaffold proteins:

Scaffold mutation T(69)I of VR28 binder was corrected back to wild type sequence in two-step PCR using VR28 clone as a template. Half-construct fragments, obtained with primers N-terminus forward/ DEFG reverse and DEFG forward/ C-terminus polyA, were combined and the whole VR28 (I69T) clone (designated as VR28 in the text) was constructed using primers T7TMV Fn and MK165-4 A20. Correction of N-terminus mutations in clone 159 (Q8 to L) was performed by PCR with primers N-terminus forward/ C-terminus polyA followed by extension with primers T7TMV Fn and MK165-4 A20.

Introduction of deletion  $\Delta 1-8$  into the N-terminus of fibronectin-based scaffold proteins was performed by amplification using primers T7 TMV N-terminus deletion and MK165-4 A20.

Construction of the chimeras of E clones containing NNS loop sequences was performed by two-step PCR. Loop regions were amplified using primers T7 TMV N-terminus deletion/ BCDE rev (a: BC loop of E clones); N-terminus forward/ hf01 BC reverse (b: BC NNS); BCDE for/ Front FG reverse (c: DE loop of E clones); BCDE for/ hf01 DE reverse (d: DE NNS); hf01 DE-FG forward/ hf01 RT-Flag PolyA reverse (e: FG of E clones); hf01 DE-FG forward/ hf01 FG reverse (f: FG NNS). Fragments b/c/e, a/d/e, a/c/f were combined and the whole pools were constructed by extension and amplification using primers T7Tmv N-terminus deletion and hf01 RTFlag PolyA reverse.

All constructs were verified and/or analyzed by DNA sequencing. All constructs and mutagenic libraries contained T7 TMV promoter at the 5' flanking region and Flag tag or His<sub>6</sub> tag sequences at 3' flanking region for RNA-protein fusion production and purification *in vitro*.

#### RNA-protein fusion production

For each round of selection PCR DNA was transcribed using MegaScript transcription kit (Ambion) at 37°C for 4 hours. Template DNA was removed by DNase I (Ambion) digestion at 37°C for 20 minutes. RNA was purified by phenol/chloroform extraction followed by gel filtration on a NAP-25 column (Amersham). The puromycin linker PEG 6/10 (5' Pso u agc gga ugc XXX XXX CC Pu 3', where Pso = C6-Psoralen, u,a,g,c = 2'OMe-RNA, C = standard amidities, X: Spacer Phosphoramidite 9 (9-O-Dimethoxytrityl-triethylene glycol,1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite); Pu = Puromycin-CPG) was synthesized as described previously (Kurz et al, *Nuc. Acid Res.* 28:83, 2000). The linker was annealed to the library RNA in 0.1 M NaCl, 25 mM TrisHCl, pH 7.0, by gradient temperature decrease from 85°C to 4°C. The linker and RNA were then cross linked by exposing to UV light (365 nm) for 15 minutes. The cross-linked mixture (600 pmol RNA) was included in an *in vitro* translation reaction using rabbit reticulocyte lysate translation kit (Ambion) in the presence of <sup>35</sup>S-labeled methionine at 30°C for 60 minutes. To enhance fusion

formation, 0.5 M KCl and 0.05 M MgCl<sub>2</sub> were added to the reaction and incubated for 30 minutes at 4°C. Fusion molecules were purified using oligo-dT cellulose (Sigma) chromatography as follows. The translation and fusion mix was diluted into buffer A (100 mM TrisHCl, 1M NaCl, 0.05% Tween-20, pH 8.0) and added to oligo dT  
5 cellulose. The slurry was rotated at 4°C for 1 hour and transferred to a spin column. Oligo dT cellulose beads were washed on the column with 10 column volumes of buffer A and eluted with 3 column volumes of H<sub>2</sub>O. Reverse transcription reaction was conducted with SuperScript II Reverse Transcription kit (Invitrogen) for 1 hour at 42°C using primer Hu3'FLAGSTOP. To decrease potential non-specific binding through  
10 reactive cysteines the thiol groups were reacted with 1 mM of 2-nitro-5-thiocyanatobenzoic acid (NTCB) or N-ethylmaleimide (NEM) alternatively over the course of the selection. The reaction was carried out for 1 hour at room temperature. Fusion molecules were further purified by anti-FLAG affinity chromatography using M2 agarose (Sigma). The M2 beads were added to the reaction and rotated in buffer B  
15 (1X PBS, 0.02% Triton X100) for 1 hour at 4°C. Then the beads were applied to a spin column, washed with 5 column volumes of buffer B and fusion molecules were eluted with 3 column volumes of 100 µM Flag peptide DYKDDDDK (Sigma) in buffer G. Fusion yield was calculated based on specific activity measured by scintillation counting of <sup>35</sup>S-methionine in the samples.

20 For the 159 (Q8L) randomized library, RNA-protein fusion was prepared using a streamlined, semi-automated procedure in a Kingfisher<sup>TM</sup> (ThermoLabSystems). The steps were similar to the procedure described above except for several steps described below. Purification of the RNA-protein fusion molecules was performed in buffer C (100 mM TrisHCl, 60 mM EDTA, 1M NaCl, 0.05% Triton X100, pH 8.0) on magnetic  
25 oligo dT beads (GenoVision). The beads were washed with 10 reaction volumes of buffer Ca (100 mM TrisHCl, 1M NaCl, 0.05% Triton X100, pH 8.0) and fusion proteins were eluted with one volume of H<sub>2</sub>O. Reverse transcription (RT) was conducted using primer C2RT. Fusion proteins were further purified by His-tag affinity chromatography using Ni-NTA magnetic beads (Qiagen). The RT reaction was  
30 incubated with Ni-NTA beads in buffer D (2M NaCl, 0.05% Triton) for 20 minutes at room temperature, the beads were then washed with 10 reaction volumes of buffer E



(1X PBS, 0.05% Triton X100, pH 7.4) and fusion molecules were eluted with one volume of buffer F (1X PBS, 0.05% Triton X100, 100 mM imidazole, pH 7.4).

#### Selection:

5           Primary selection against KDR. Fusion library ( $\sim 10^{13}$  clones in 1 ml) was incubated with 150  $\mu$ l of Protein A beads (Dyna) which was pre-immobilized with 200 nM of human IgG1 for 1 hour at 30°C prior to selection to reduce non-specific binding to both Protein A beads and Fc protein (preclear). The supernatant was then incubated in buffer G (50 mM HEPES, 150 mM NaCl, 0.02% TritonX-100, 1 mg/ml bovine  
10   serum albumin, 0.1 mg/ml salmon sperm DNA, pH 7.4) with KDR-Fc chimera for 1 hour at 30°C with end-over-end rotation. Final concentrations of KDR-Fc were 250 nM for Round 1, 100 nM for rounds 2 – 4 and 10 nM for rounds 5 and 6. The target was captured on 300  $\mu$ l of Protein A beads (Round 1) or 100  $\mu$ l of Protein A beads (Rounds 2-6) for 30 minutes at 30°C with end-over-end rotation and beads were washed  
15   5 times with 1 ml of buffer G (50 mM HEPES, 150 mM NaCl, 0.02% TritonX-100, pH 7.4). Bound fusion molecules were eluted with 100  $\mu$ l of 0.1 M KOH into 50  $\mu$ l of 1 M TrisHCl, pH 8.0. DNA was amplified from elution by PCR using flanking primers T7TMV Fn and MK165-4 A20.

20           Affinity and specificity maturation of KDR binder VR28. Clone VR28 was mutagenized by hypermutagenic PCR or oligo-directed mutagenesis as described above and fusion sub-libraries were constructed. Following pre-clear with Protein A beads selection was performed in buffer I (1xPBS, 0.02% TritonX-100, 1 mg/ml bovine serum albumin, 0.1 mg/ml salmon sperm DNA, pH 7.4) for four rounds according to  
25   procedure described above. DNA was amplified from elution by PCR using primers T7TMV Fn and MK165-4 A20. Lower target concentrations (0.1 nM KDR for first four rounds of selection) were used for libraries derived from oligo mutagenesis and then 1 nM mouse VEGF-R2 (Flk-1) was introduced for three additional rounds of selection. Primers T7 TMV N-terminus deletion and MK165-4 A20 were used for PCR  
30   in the last 3 rounds.

For specificity maturation of KDR binder 159 first 6 positions of the FG loop of clone 159 Q(8)L were randomized by PCR as described above. Binding of the fusion

sub-library to biotinylated mouse VEGF-R2 (70 nM) was performed in buffer I at room temperature for 30 minutes. The rest of the selection procedure was continued in Kingfisher™ (ThermoLabSystems). The biotinylated target was captured on 50 µl of streptavidin-coated magnetic beads (Dyna) and the beads were washed with 10  
5 volumes of buffer I and one volume of buffer J (1xPBS, 0.02% TritonX-100, pH 7.4). Bound fusion molecules were eluted with 100 µl of 0.1 M KOH into 50 µl of 1 M TrisHCl, pH 8.0. DNA was amplified from elution by PCR using primers F1U2 and C2asaiA20. After four rounds of selection an off-rate/rebinding selection against 7 nM Flk-1 was applied for another two rounds as follows. After the binding reaction with  
10 biotinylated mouse Flk-1 had progressed for 30 minutes, a 100-fold excess of non-biotinylated Flk-1 was added and the reaction continued for another 6 hours to allow time for the weak binders to dissociate. The biotinylated target was captured on 50 µl of streptavidin beads (Dyna) and beads were washed 5 times with 1 ml of buffer J. Bound fusion molecules were eluted by incubation at 75 °C for 5 minutes. Supernatant  
15 was subjected to re-binding to 7 nM Flk-1 and standard selection procedure was continued. DNA from the final elution pool was subjected to DE loop randomization (see above) and fusion sub-library was selected against 7 nM mouse VEGF-R2 for three rounds. At the fourth round an off-rate selection was applied with re-binding to 1 nM human VEGF-R2. Final DNA was amplified from elution by PCR using primers  
20 F1U2 and C2asaiA20.

#### Radioactive Equilibrium Binding Assay

To prepare <sup>35</sup>S-labeled binding proteins for analysis, mRNA was prepared as described above for RNA-protein fusion production but the linker ligation step was  
25 omitted. The mRNA was expressed using rabbit reticulocyte lysate translation kit (Ambion) in the presence of <sup>35</sup>S-labeled Met at 30°C for 1 hour. Expressed protein was purified on M2-agarose Flag beads (Sigma) as described above. This procedure produced the encoded protein without the nucleic acid tail. In a direct binding assay, VEGF-R2-Fc fusions in concentrations ranging from 0 to 200 nM were added to a  
30 constant concentration of the purified protein (0.2 or 0.5 nM) and incubated at 30°C for 1 hour in buffer B. The receptor-binder complexes were captured using Protein A magnetic beads for another 10 minutes at room temperature using a Kingfisher™. The

beads were washed with six reaction volumes of buffer B. The protein was eluted from the beads with 100  $\mu$ L of 0.1 M KOH. 50  $\mu$ L of the reaction mixture and elution were dried onto a LumaPlate-96 (Packard) and the amount of  $^{35}$ S on the plate was measured using a TopCount NXT instrument (Packard). The amount of fibronectin-based scaffold protein bound to the target was estimated as a percent of radioactivity eluted from Protein A magnetic beads compare to radioactivity in the reaction mixture. Nonspecific binding of fibronectin-based scaffold proteins to the beads was determined by measuring binding in the absence of KDR-Fc and represented less than 1-2% of the input. Specific binding was obtained through subtraction of nonspecific binding from total binding. Data was analyzed using the GraphPad Prizm software (GraphPad Software, Inc, San Diego, CA), fitted using a one site, non-linear binding equation.

#### Expression and purification of soluble fibronectin-based scaffold protein binders:

For expression in *E. coli* residues 1-101 of each clone followed by the His<sub>6</sub> tag were cloned into a pET9d-derived vector and expressed in *E. coli* BL21 (DE3) pLysS cells (Invitrogen). 20 ml of overnight culture was used to inoculate 1 liter of LB medium containing 50  $\mu$ g/mL kanamycin and 34  $\mu$ g/mL chloromphenicol. The culture was grown at 37 °C until A<sub>600</sub> 0.4-0.6. After induction with 1 mM isopropyl- $\beta$ -thiogalactoside (IPTG, Invitrogen) the culture was grown for another 3 hours at 37°C and harvested by centrifugation for 30 minutes at 3,000 g at 4 °C. The cell pellet was resuspended in 50 mL of lysis buffer K (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.5 M NaCl, 5% glycerol, 5 mM CHAPS, 25 mM imidazole, 1x Complete™ Protease Inhibitor Cocktail (Roche), pH 8.0) BufferL and sonicated on ice at 80 W for four 15 second pulses separated by ten-second pauses. The soluble fraction was separated by centrifugation for 30 minutes at 30,000 g at 4 °C. The supernatant was rotated for 1 hour at 4 °C with 10 mL of TALON™ Superflow™ Metal Affinity Resin (Clontech) pre-equilibrated with wash buffer L (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.5 M NaCl, 5% glycerol, 25 mM imidazole, pH 8.0). The resin was then washed with 10 column volumes of buffer L and 30 column volumes of buffer M (1xPBS, pH 7.4, 25 mM imidazole, pH 7.4). Protein was eluted with 5 column volumes of buffer N (1xPBS, 250 mM imidazole, pH 7.4) and dialyzed against 1xPBS at 4 °C. Any precipitate was removed by filtering at 0.22  $\mu$ m (Millipore).

#### BIAcore analysis of the soluble fibronectin-based scaffold proteins:

The binding kinetics of fibronectin-based scaffold proteins binding proteins to the target was measured using BIAcore 2000 biosensor (Pharmacia Biosensor). Human and mouse VEGF-R2-Fc fusions were immobilized onto a CM5 sensor chip and soluble binding proteins were injected at concentrations ranging from 0 to 100 nM in  
5 buffer O (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, pH 7.4). Sensorgrams were obtained at each concentration and were evaluated using a program, BIA Evaluation 2.0 (BIAcore), to determine the rate constants  $k_a$  ( $k_{on}$ ) and  $k_d$  ( $k_{off}$ ). The affinity constant,  $K_D$  was calculated from the ratio of rate constants  $k_{off} / k_{on}$ .

For inhibition experiments, human VEGF<sub>165</sub> was immobilized on a surface of  
10 CM-5 chip and KDR-Fc was injected at a concentration of 20 nM in the presence of different concentrations of soluble binding proteins ranging from 0 to 100 nM.  $IC_{50}$  was determined at a concentration when only 50% of KDR-Fc binding to the chip was observed.

#### 15 Reversible Refolding of A VEGFR Binding Polypeptide:

Differential scanning calorimetry (DSC) analysis was performed on M5FL protein in 100 mM sodium acetate buffer (pH 4.5). An initial DSC run (Scan 1) was performed in a N-DSC II calorimeter (Calorimetry Sciences Corp) by ramping the temperature from 5-95 °C at a rate of 1 degree per minute, followed by a reverse scan  
20 (not shown) back to 10 degrees, followed by a second run (Scan 2). Under these conditions, data were best fit using a two transition model ( $T_m = 77$  °C and 67 °C using Origin software (OriginLab Corp)). See Figure 10.

#### PEGylation of the M5FL Protein:

25 The C100-form of the M5FL protein, which has the complete sequence of M5FL with the Ser at position 100 mutated to a Cysteine including the additional C-terminal His-tag used to purify the protein. The purified M5FL-C100 protein was modified at the single cysteine residue by conjugating various maleimide-derivatized PEG forms (Shearwater). The resulting reacted proteins were run on a 4-12%  
30 polyacrylamide gel (Figure 11).

#### Construction of cell lines:

Plasmid construction. Plasmids, encoding chimeric receptors composed of the transmembrane and cytoplasmic domains of the human erythropoietin receptor (EpoR) fused to the extracellular domains of KDR, Flk-1, or human TrkB were constructed by a two-step PCR procedure. PCR products encoding the extracellular domains were amplified from plasmids encoding the entire receptor gene: KDR (amino acids 1 to 764) was derived from clone PR1371\_H11 (OriGene Technologies, Rockville, MD) with primers 5-RI-hKDR-1B/ 3-EPO/hKDR-2312B, flk-1 (amino acids 1 to 762) was derived from clone #4238984 (IMAGE) with primers 5-RI-mKDR-1/ 3-EPO/mKDR-2312, and human TrkB (from amino acids 1 to 430) from clone #X75958 (Invitrogen Genestorm) with primers 5-RI-hTrkB-1/ 3-EpoR/hTrkB-1310. PCR products encoding the EpoR transmembrane and cytoplasmic domains (amino acids 251 to 508) were amplified from clone #M60459 (Invitrogen Genestorm) with the common primer 3-XHO-EpoR-3066 and one of three gene-specific primers 5-hKDR/EPO-2274B (KDR), 5-mKDR/EPO-2274 (flk-1), and 5'hTrkB/EpoR-1274 (human TrkB), which added a short sequence complementary to the end of the receptor fragment PCR product. Second, PCR products encoding the two halves of the chimeric genes were mixed and amplified with 3-XHO-EpoR-3066 and the 5' primers (5-RI-hKDR-1B, 5-RI-mKDR-1, and 5-RI-hTrkB-1) specific for each gene used in the previous cycle of amplification. The resulting PCR products were digested with *EcoRI* and *XhoI* and cloned into pcDNA3.1(+) (Invitrogen) to generate the plasmids phKE8 (human KDR/EpoR fusion), pmKE2 (flk-1/EpoR fusion), and phTE (TrkB/EpoR fusion).

Construction of cell lines for flow cytometry. CHO-K1 cells (American Type Culture Collection, Manassas, VA) were stably transfected using Lipofectamine 2000 (Invitrogen) with either pcDNA 3.1 (Invitrogen) alone, pmKE2 alone, or a mixture of pcDNA 3.1 and a plasmid encoding full-length human KDR (Origene Inc., clone PR1371-H11). Stable transfectants were selected and maintained in the presence of 0.5 mg/ml of Geneticin (Invitrogen). The human KDR-expressing clone designated CHO-KDR and the murine VEGFR-2/EpoR-chimera-expressing population designated CHO-Flk were obtained by fluorescence activated cell sorting of the transfected population following staining with an anti-KDR polyclonal antiserum (R&D Systems). CHO-KDR and CHO-Flk cell lines were grown routinely in Dulbecco's modified Eagle's

medium (DMEM; Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS), 0.5 mg/ml Geneticin, 100 U/ml penicillin, 0.25  $\mu$ g/ml amphotericin B, 100  $\mu$ g/ml streptomycin and 2 mM L-glutamine.

- 5           Construction of Ba/F3 cell lines. Cell lines that would proliferate in response to VEGF binding by VEGFR-2 were constructed by transfection of the murine pre-B cell line Ba/F3 (DSMZ, Braunschweig, Germany) with phKE8 or pmKE2, receptor chimeras consisting of the extracellular domains of human or murine VEGFR-2 fused to the transmembrane and cytoplasmic domains of the human erythropoietin receptor
- 10 (see above). Ba/F3 cells were maintained in minimal Ba/F3 medium (RPMI-1640 (Gibco) containing 10% FBS, 100 U/ml penicillin, 0.25  $\mu$ g/ml amphotericin B, 100  $\mu$ g/ml streptomycin and 2 mM L-glutamine) supplemented with 10% conditioned medium from WEHI-3B cells (DSMZ; grown in Iscove's modified Dulbecco's medium (Gibco)/ 10%FBS/ 25  $\mu$ M  $\beta$ -mercaptoethanol) as a source of essential growth factors.
- 15 Following electroporation with the plasmids pmKE2 or phKE8, stable transfectants were selected in 0.75 mg/ml Geneticin. Geneticin-resistant populations were transferred to minimal Ba/F3 medium containing 100 ng/ml of human VEGF<sub>165</sub> (R&D Systems), and the resulting VEGF-dependent populations were designated Ba/F3-Flk and Ba/F3-KDR. Control cell line expressing a chimeric TrkB receptor (Ba/F3-TrkB)
- 20 that would be responsive to stimulation by NT-4, the natural ligand for TrkB was similarly constructed using the plasmid phTE and human NT-4 (R&D Systems).

Analysis of cell surface binding of fibronectin-based scaffold proteins:

- Binding of fibronectin-based scaffold protein to cell-surface KDR and Flk-1
- 25 was analyzed simultaneously on VEGF-R2-expressing and control cells by flow cytometry. CHO-pcDNA3 cells (control) were released from their dishes with trypsin-EDTA, washed in Dulbecco's PBS without calcium and magnesium (D-PBS<sup>-</sup>; Invitrogen), and stained for 30 minutes at 37 °C with 1.5  $\mu$ M CMTMR (5-(and-6)-(((4-chloromethyl)benzoyl)amino) -tetramethylrhodamine) (Molecular Probes). The cells
- 30 were washed in D-PBS<sup>-</sup> and incubated for a further 30 minutes at 37 °C, and then resuspended in blocking buffer (D-PBS<sup>-</sup>/10% fetal bovine serum) on ice. CHO-KDR or CHO-Flk cells were treated identically except that CMTMR was omitted. 75,000 of



CMTMR-stained CHO-pcDNA3 cells were mixed with an equal number of unstained CHO-KDR or CHO-Flk cells in each well of a V-bottom 96-well plate. All antibodies and fibronectin-based scaffold proteins were diluted in 25  $\mu$ l/well of blocking buffer, and each treatment was conducted for 1 hour at 4 °C. Cell mixtures were stained with His<sub>6</sub>-tagged fibronectin-based scaffold proteins, washed twice with cold D-PBS<sup>-</sup>, and then treated with 2.5  $\mu$ g/ml anti-His<sub>6</sub> MAb (R&D Systems), washed, and stained with 4  $\mu$ g/ml Alexa Fluor 488-conjugated anti-mouse antibody (Molecular Probes). For cells treated with an anti-KDR mouse monoclonal antibody (Accurate Chemical, Westbury, NY) or an anti-flk-1 goat polyclonal antibody (R&D Systems), the anti-His<sub>6</sub> step was omitted, and antibody binding was detected with the species-appropriate Alexa Fluor 488 conjugated secondary antibody (Molecular Probes). Following staining, cells were resuspended in 200  $\mu$ l/well D-PBS<sup>-</sup>/1%FBS/1  $\mu$ g/ml 7-aminoactinomycin D (7-AAD; Molecular Probes) and analyzed by flow cytometry on a FACSCalibur (Becton Dickinson, San Jose, CA) equipped with a 488 nM laser. Following gating to exclude dead cells (7-AAD positive), VEGFR-2-expressing cells and CHO-pcDNA3 cells were measured independently for Alexa Fluor 488 fluorescence by gating on the CMTMR-negative or -positive populations, respectively. Control experiments showed that staining with CMTMR did not interfere with the detection of Alexa Fluor 488-conjugated antibodies on the surface of the stained cells.

Cell-surface binding was also assessed by fluorescence microscopy using the secondary antibodies described above. For these studies, antibodies were diluted in D-PBS containing calcium and magnesium (D-PBS<sup>+</sup>)/10% FBS. Cells were grown on 24- or 96-well plates, and following staining were kept in D-PBS<sup>+</sup> for observation on an inverted fluorescence microscope.

25

#### Ba/F3 Cell Proliferation Assay:

Ba/F3 cells were washed three times in minimal Ba/F3 medium and resuspended in the same medium containing 15.8 ng/ml of proliferation factor (human VEGF<sub>165</sub>, murine VEGF<sub>164</sub>, or hNT-4 for Ba/F3-KDR, Ba/F3-Flk, or Ba/F3-TrkB cells, respectively), and 95  $\mu$ l containing  $5 \times 10^4$  Ba/F3-KDR cells or  $2 \times 10^4$  Ba/F3-Flk or Ba/F3-TrkB cells were added per well to a 96-well tissue culture plate. 5  $\mu$ l of serial dilutions of test protein in PBS was added to each well for a final volume of 100  $\mu$ l



Ba/F3 medium/5% PBS/15 ng/ml growth factor. After incubation for 72 hours at 37 °C, proliferation was measured by addition of 20  $\mu$ l of CellTiter 96® Aqueous One Solution Reagent (Promega) to each well, incubation for 4 hours at 37°C, and measurement of the absorbance at 490 nm using a microtiter plate reader (Molecular Dynamics).

#### HUVEC Cell Proliferation Assay:

HUVEC cells (Clonetics, Walkersville, MD) from passage 2-6 were grown in EGM-2 medium (Clonetics). 5000 cells/well were resuspended in 200  $\mu$ l starvation medium (equal volumes of DMEM (Gibco) and F-12K medium (ATCC), supplemented with 0.2% fetal bovine serum and 1x penicillin/ streptomycin/ fungizone solution (Gibco)), plated in 96-well tissue culture plates and incubated for 48 hours. Fibronectin-based binding proteins were added to the wells and incubated for 1 hour at 37°, and then human VEGF<sub>165</sub> was added to a final concentration of 16 ng/ml. After 48 hours incubation, cell viability was measured by addition of 30  $\mu$ l/well of a mixture of 1.9 mg/ml CellTiter96® AQueous MTS reagent (Promega) with 44  $\mu$ g/ml phenazine methosulfate (Sigma) and measurement of absorbance at 490 nm as described above for Ba/F3 cells.

#### 20 Example 12: Antibody Light Chain-Based VEGFR Binding Polypeptides

Figures 21A and 21B show amino acid sequences of VEGFR binding polypeptides (SEQ ID NOs:241-310) based on an antibody light chain variable region (VL) framework/scaffold.

Light chain variable domain proteins were generated using the PROfusion™ system, as described above for use with <sup>10</sup>Fn3-derived proteins.

All references cited herein are hereby incorporated by reference in their entirety.

Table 1 Preferred Specific Peptide Sequences

SEQ ID NO	Clone Name	N-terminus	BC Loop	DE Loop	FG Loop										Binding to 1 nM KDR, %	Kd KDR, nM	Binding to 1 nM FLK, %	Kd FLK, nM	
KDR Binders																			
6	K1	Del 1-8	RHPHFPTTR	LQPPT	M	G	L	Y	G	H	E	L	L	T	P	48	0.55		
7	K2	Del 1-8	RHPHFPTTR	LQPPT	D	G	E	N	G	Q	F	L	L	V	P	48	1.19		
8	K5	Del 1-8	RHPHFPTTR	LQPPT	M	G	P	N	D	N	E	L	L	T	P	47	1.54		
9	K3	Del 1-8	RHPHFPTTR	LQPPT	A	G	W	D	D	H	E	L	F	I	P	45	1.15		
10	K7	Del 1-8	RHPHFPTTR	LQPPT	S	G	H	N	D	H	M	L	M	I	P	40	2.2		
11	K4	Del 1-8	RHPHFPTTR	LQPPT	A	G	Y	N	D	Q	I	L	M	T	P	38	1.95		
12	K9	Del 1-8	RHPHFPTTR	LQPPT	F	G	L	Y	G	K	E	L	L	I	P	35	1.8		
13	K10	Del 1-8	RHPHFPTTR	LQPPT	T	G	P	N	D	R	L	L	F	V	P	33	0.57		
14	K12	Del 1-8	RHPHFPTTR	LQPPT	D	V	Y	N	D	H	E	I	K	T	P	29	0.62		
15	K6	Del 1-8	RHPHFPTTR	LQPPT	D	G	K	D	G	R	V	L	L	T	P	27	0.93		
16	K15	Del 1-8	RHPHFPTTR	LQPPT	E	V	H	H	D	R	E	I	K	T	P	25	0.35		
17	K11	Del 1-8	RHPHFPTTR	LQPPT	Q	A	P	N	D	R	V	L	Y	T	P	24	1.16		
18	K14	Del 1-8	RHPHFPTTR	LQPPT	R	E	E	N	D	H	E	L	L	I	P	20	0.57		
19	K8	Del 1-8	RHPHFPTTR	LQPPT	V	T	H	N	G	H	P	L	M	T	P	18	3.3		
20	K13	Del 1-8	RHPHFPTTR	LQPPT	L	A	L	K	G	H	E	L	L	T	P	17	0.58		
21	VR28	WT	RHPHFPTTR	LQPPT	V	A	Q	N	D	H	E	L	I	T	P	3	11		
22	159	WT	RHPHFPTTR	LQPPA	M	A	Q	S	G	H	E	L	F	T	P				
KDR and FLK Binders																			
24	E29	Del 1-8	RHPHFPTTR	LQPPT	V	E	R	N	G	R	V	L	M	T	P	41	44	1.51	0.91
25	E19	Del 1-8	RHPHFPTTR	LQPPT	V	E	R	N	G	R	H	L	M	T	P	38	40	1.3	0.66
33	E25	Del 1-8	RHPHFPTTR	LQPPT	L	E	R	N	G	R	E	L	M	T	P	41	28	1.58	1.3
45	E9	Del 1-8	RHPHFPTTR	LQPPT	E	E	R	N	G	R	T	L	R	T	P	24	34	2.37	1.4
50	E24	Del 1-8	RHPHFPTTR	LQPPT	V	E	R	N	D	R	V	L	F	T	P	24	29		
54	E26	Del 1-8	RHPHFPTTR	LQPPT	V	E	R	N	G	R	E	L	M	T	P	27	20	1.66	2.05
59	E28	Del 1-8	RHPHFPTTR	LQPPT	L	E	R	N	G	R	E	L	M	V	P	19	21	1.63	2.1
60	E3	Del 1-8	RHPHFPTTR	LQPPT	D	G	R	N	D	R	K	L	M	V	P	37	14	0.96	5.4
65	E5	Del 1-8	RHPHFPTTR	LQPPT	D	G	Q	N	G	R	L	L	N	V	P	26	10	0.4	3.2
91	E23	Del 1-8	RHPHFPTTR	LQPPT	V	H	W	N	G	R	E	L	M	T	P	36	7		

92	E8	Del1-8	RHPHFPTR	LQPPT	E	E	W	N	G	R	V	L	M	T	P	51	10	
93	E27	Del1-8	RHPHFPTR	LQPPT	V	E	R	N	G	H	T	L	M	T	P	37	9	
94	E16	Del1-8	RHPHFPTR	LQPPT	V	E	E	N	G	R	Q	L	M	T	P	35	0	
95	E14	Del1-8	RHPHFPTR	LQPPT	L	E	R	N	G	Q	V	L	F	T	P	33	11	
96	E20	Del1-8	RHPHFPTR	LQPPT	V	E	R	N	G	Q	V	L	Y	T	P	43	11	
97	E21	Del1-8	RHPHFPTR	LQPPT	W	G	Y	K	D	H	E	L	L	I	P	47	1	
98	E22	Del1-8	RHPHFPTR	LQPPT	L	G	R	N	D	R	E	L	L	T	P	45	3	
99	E2	Del1-8	RHPHFPTR	LQPPT	D	G	P	N	D	R	L	L	N	I	P	53	10	
100	E12	Del1-8	RHPHFPTR	LQPPT	F	A	R	D	G	H	E	I	L	T	P	36	1	
101	E13	Del1-8	RHPHFPTR	LQPPT	L	E	Q	N	G	R	E	L	M	T	P	38	1	
102	E17	Del1-8	RHPHFPTR	LQPPT	V	E	E	N	G	R	V	L	N	T	P	32	10	
103	E15	Del1-8	RHPHFPTR	LQPPT	L	E	P	N	G	R	Y	L	M	V	P	52	2	
104	E10	Del1-8	RHPHFPTR	LQPPT	E	G	R	N	G	R	E	L	F	I	P	53	3	
154	M2	WT	RHPHFPTR	LQPPA	W	E	R	N	G	R	E	L	F	T	P			
156	M3	WT	RHPHFPTR	LQPPA	K	E	R	N	G	R	E	L	F	T	P			
172	M4	WT	RHPHFPTH	LQPPA	T	E	R	T	G	R	E	L	F	T	P			
173	M8	WT	RHPHFPTH	LQPPA	K	E	R	S	G	R	E	L	F	T	P			
175	M6	WT	RHPHFPTH	LQPPA	L	E	R	D	G	R	E	L	F	T	P			
180	M7	WT	RHPHFPTR	LQPTT	W	E	R	N	G	R	E	L	F	T	P			
181	M1	WT	RHPHFPTR	LQPTV	L	E	R	N	D	R	E	L	F	T	P			
177	M5FL	WT	RHPHFPTR	LQPPL	K	E	R	N	G	R	E	L	F	T	P			

Table 2 KDR & FLK binders																							
SEQ ID NO	Clone Name	N-terminus	N-Terminus Framework 1	BC Loop	Framework 2	DE Loop	Framework 3	FG Loop											Framework 4	Blinding to 1 nM KDR, %	Blinding to 1 nM FLK-1, %	Kd KDR, nM	Kd FLK-1, nM
23	D12	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R K L M T P	ISINYRT	46	47												
24	E29	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L M T P	ISINYRT	41	44												
25	E19	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R H L M T P	ISINYRT	38	40												
26	D1	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R M L M T P	ISINYRT	38	38												
27	C6	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L M T P	ISINYRT	36	49												
28	EGE5	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L M T P	ISINYRT	32	47												
29	EGE2	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R Q L M T P	ISINYRT	42	33												
30	D4	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R T L F T P	ISINYRT	27	44												
31	E25	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L M T P	ISINYRT	41	28							1.58	1.3				
32	EGE6	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R L L N T P	ISINYRT	33	40												
33	C7	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L M T P	ISINYRT	32	40												
34	D9	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L F T P	ISINYRT	31	40												
35	EGE3	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R Q L Y T P	ISINYRT	34	38												
36	D3	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R A L M T P	ISINYRT	36	30												
37	D2	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R N L M T P	ISINYRT	35	30												
38	C8	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L I T P	ISINYRT	30	34												
39	EGE4	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L N T P	ISINYRT	26	41												
40	D7	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R K V L M T P	ISINYRT	39	27												
41	D5	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R T L M T P	ISINYRT	38	23												
42	B3	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L M T P	ISINYRT	33	27												
43	E9	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R T L R T P	ISINYRT	24	34							2.37	1.4				
44	D6	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R K T L M T P	ISINYRT	32	30												
45	EGE7	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L L T P	ISINYRT	31	30												
46	EGE1	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R K L M T P	ISINYRT	30	29												
47	F9	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L N T P	ISINYRT	32	23												
48	E24	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L K T P	ISINYRT	24	29												
49	B11	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L R T P	ISINYRT	29	21												
50	B12	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L M T P	ISINYRT	29	21												
51	B5	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L M T P	ISINYRT	27	24												
52	E26	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L M T P	ISINYRT	27	20							1.66	2.05				
53	C12	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L S V P	ISINYRT	24	20												
54	F4	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R T L R T P	ISINYRT	31	18												
55	E18	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L N T P	ISINYRT	17	29							1.2	0.53				
56	C11	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R V L I V P	ISINYRT	19	21												
57	E28	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L M V P	ISINYRT	19	21							1.63	2.1				
58	E3	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L M V P	ISINYRT	37	14							0.96	5.4				
59	F8	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R T S F T P	ISINYRT	33	13												
60	F3	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R K L Y T P	ISINYRT	27	15												
61	B10	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L N T P	ISINYRT	15	23												
62	E6	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R L L S I P	ISINYRT	36	7							0.35	7.1				
63	E5	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R L L N V P	ISINYRT	26	10							0.4	3.2				
64	G4	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R H L N I P	ISINYRT	21	12												
65	A3	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R K M L S V P	ISINYRT	33	7												
66	A4	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R L L F I P	ISINYRT	46	2												
67	A6	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R L L N I P	ISINYRT	18	2												
68	A7	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L I V P	ISINYRT	18	2												
69	A8	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R K Y L F V P	ISINYRT	38	4												
70	A9	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L F V P	ISINYRT	31	4												
71	A10	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L L T P	ISINYRT	34	4												
72	EGE11	Del 1-8	EVVAATPTSLISW	RHPHFPTIR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYTIITGYAVT	V E R N G R E L L I P	ISINYRT	50	0												

Table 2 KDR & FLK binders

SEQ ID NO	Clone Name	N-terminus	N-Terminus Framework 1	BC Loop	Framework 2	DE Loop	Framework 3	FG Loop	Framework 4	Binding to 1 nM KDR, %	Binding to 1 nM Flk-1, %	Kd KDR, nM	Kd Flk-1, nM
73	A11	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	L E W N N R V L M T P	ISINYRT	26	6		
74	A12	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E W N N G R V L M T P	ISINYRT	40	10		
75	B4	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	N E R N N G R E L M T P	ISINYRT	19	12		
76	B6	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	L E R N N G K E L M T P	ISINYRT	23	11		
77	B7, B8	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G R E L L T P	ISINYRT	18	10		
78	B11	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G R E L K T P	ISINYRT	29	21		
79	C1	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	Q E R N N G R E L R T P	ISINYRT	28	13		
80	C2	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G R E L L W P	ISINYRT	40	16		
81	C3	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	L E R N N G R E L M I P	ISINYRT	31	17		
82	C9	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G L V L M T P	ISINYRT	33	7		
83	C10	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G R V L I P	ISINYRT	24	17		
84	D11	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G H K L F T P	ISINYRT	24	3		
85	EGE8	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N E R V L M T P	ISINYRT	26	20		
86	EGE9	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	F G P N D R E L L T P	ISINYRT	32	1		
87	EGE10	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	M G P N D R E L L T P	ISINYRT	37	1		
88	EGE11	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	M G K N D R E L L T P	ISINYRT	32	1		
89	E23	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V H W N G R E L M T P	ISINYRT	36	7		
90	E8	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	E E W N G R V L M T P	ISINYRT	51	10		
91	E27	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G H T L M T P	ISINYRT	37	9		
92	E16	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G R Q L M T P	ISINYRT	35	0		
93	E14	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	L E R N N G Q V L F T P	ISINYRT	33	11		
94	E20	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R N N G Q V L Y T P	ISINYRT	43	11		
95	E21	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	W G Y K D H E L L T P	ISINYRT	47	1		
96	E22	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	L G R N D R E L L T P	ISINYRT	45	3		
97	E2	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	D G P N D R L L N T P	ISINYRT	53	10		
98	E12	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	F A R D G H E L L T P	ISINYRT	36	1		
99	E13	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	L E Q N G R E L M T P	ISINYRT	38	1		
100	E17	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E E N G R V L N T P	ISINYRT	32	10		
101	E15	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	L E P N G R Y L M V P	ISINYRT	52	2		
102	E10	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	E G R N G R E L F I P	ISINYRT	53	3		
103	F1	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	S G R N D R E L L V P	ISINYRT	18	2		
104	F5	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E R D G R E L N I P	ISINYRT	12	8		
105	F6	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E Q N G R V L M T P	ISINYRT	37	2		
106	F7	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E H N G R V L N I P	ISINYRT	30	7		
107	F10	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	M A P N G R E L L T P	ISINYRT	29	1		
108	F11	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	V E Q N G R V L N T P	ISINYRT	20	8		
109	F12	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	D G R N G H E L M T P	ISINYRT	17	1		
110	G1	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	E G R N G R E L M V P	ISINYRT	22	2		
111	G2	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	L E R N N R E L L T P	ISINYRT	25	9		
112	G3	Del 1-8	EVVAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPT	ATISGLKPGVDYITITGYAVT	M E R S G R E L M T P	ISINYRT	28	10		
113	MWF10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	R A L S I E L F T P	ISINYRT				
114	MWA10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	F A R K G T E L F T P	ISINYRT				
115	MWA2	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	L E R C G R E L F T P	ISINYRT				
116	MWC10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	R E R N G R E L F T P	ISINYRT				
117	MWB7	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	K E R N G R E L F T P	ISINYRT				
118	MWB8	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	C E R N G R E L F T P	ISINYRT				
119	MWA10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	L E R T G R E L F T P	ISINYRT				
120	MWB2	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	W E R T G K E L F T P	ISINYRT				
121	MWC3-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	I E R T C R E L F T P	ISINYRT				
122	MWG11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITITGYAVT	G G M I V R E L F T P	ISINYRT				



Table 2 KDR &amp; FLK binders

SEQ ID NO	Clone Name	N-terminus	N-Terminus Framework 1	BC Loop	Framework 2	DE Loop	Framework 3	FG Loop	Framework 4	Binding to 1 nM KDR, %	Binding to 1 nM FLK-1, %	Kd KDR, nM	Kd FLK-1, nM
123	MWG11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	F G R S S R E L F T P	ISINYRT				
124	MWD3-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	R H K S R G E L F T P	ISINYRT				
125	MWE11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	R H R D K R E L F T P	ISINYRT				
126	MWD10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	Y H R G R G E L F T P	ISINYRT				
127	MWC1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	R H R C R E L F T P	ISINYRT				
128	MWA12	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	S H R L R K E L F T P	ISINYRT				
129	MWB3-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	M H R Q R G E L F T P	ISINYRT				
130	MWA11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	F H R R R G E L F T P	ISINYRT				
131	MWG12	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	F H R R R G E L F T P	ISINYRT				
132	MWH11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	S H R R R N E L F T P	ISINYRT				
133	MWD12	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	L H R R V R E L F T P	ISINYRT				
134	MWH5	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	R H R R R G E L F T P	ISINYRT				
135	MWA1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W H R S R K E L F T P	ISINYRT				
136	MWG4-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	R H R T G R E L F T P	ISINYRT				
137	MWA12	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W H R V R G E L F T P	ISINYRT				
138	MWG11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W H R V R G E L F T P	ISINYRT				
139	MWC12	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W H R W R G E L F T P	ISINYRT				
140	MWF11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W H R S G G E L F T P	ISINYRT				
141	MWE11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W K R X N V E L F T P	ISINYRT				
142	MWD10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	R L X N V E L F T P	ISINYRT				
143	MWC4-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W R T P H A E L F T P	ISINYRT				
144	MWF3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	L S P H S V E L F T P	ISINYRT				
145	MWB2	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	V S R Q K A E L F T P	ISINYRT				
146	MWE10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	S Y S K L E L F T P	ISINYRT				
147	MWD9	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	L T D R G S E L F T P	ISINYRT				
148	MWH3-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	G T R T R S E L F T P	ISINYRT				
149	MWG10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	P V A G C S E L F T P	ISINYRT				
150	MWH11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W W Q T P R E L F T P	ISINYRT				
151	MWF11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W W Q T P R E L F T P	ISINYRT				
152	M2	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W E R N G R E L F T P	ISINYRT				
153	MWB09-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W E R N G R E L F T P	ISINYRT				
154	M3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	K E R N G R E L F T P	ISINYRT				
155	MWA3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	G A L N T S E L F T P	ISINYRT				
156	MWE10	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	F G R E R R E L F T P	ISINYRT				
157	MWG3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	S G R V S F E L F T P	ISINYRT				
158	MWD5	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	F H R R R G E L F T P	ISINYRT				
159	MWC3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	L I R M N T E L F T P	ISINYRT				
160	MWH3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	C L H L I T E L F T P	ISINYRT				
161	MWC2	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	V L K L T L E L F T P	ISINYRT				
162	MWE2	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	V L K L T L E L F T P	ISINYRT				
163	MWA2	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	V L K L T L E L F T P	ISINYRT				
164	MWD3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	A L M A S G E L F T P	ISINYRT				
165	MWE3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	S M K N R L E L F T P	ISINYRT				
166	MWB3	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	L R C L I P E L F T P	ISINYRT				
167	MWD2	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	V S R Q K A E L F T P	ISINYRT				
168	MWC11	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	W S R T G R E L F T P	ISINYRT				
169	MWH12	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	V W R T G R E L F T P	ISINYRT				
170	M4	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	T E R T G R E L F T P	ISINYRT				
171	M8	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	K E R S G R E L F T P	ISINYRT				
172	MWF10-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFTR	YRITYGETGNSPVQEFVTP	LQPPA	ATISGLKPGVDYITIGYAVT	L E R N D R E L F T P	ISINYRT				

Table 2 KDR & FLK binders																												
SEQ ID NO	Clone Name	N-terminus	N-Terminus Framework 1	BC Loop	Framework 2	DE Loop	Framework 3	FG Loop																Framework 4	Binding to 1 nM KDR, %	Binding to 1 nM Flk-1, %	Kd KDR, nM	Kd Flk-1, nM
								L	E	R	D	G	R	E	L	F	T	P	L	E	R	D	G					
173	M6	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	LQPPA	ATISGLKPGVDYTIITGYAVT	L	E	R	D	G	R	E	L	F	T	P	ISINYRT									
174	MWB6	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	LQPTT	ATISGLKPGVDYTIITGYAVT	Q	G	R	H	K	R	E	L	F	T	P	ISINYRT									
175	M5FL	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	LQPPA	ATISGLKPGVDYTIITGYAVT	K	E	R	N	G	R	E	L	F	T	P	ISINYRT									
176	MWG10-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	LQPPA	ATISGLKPGVDYTIITGYAVT	M	A	Q	N	D	H	E	L	I	T	P	ISINYRT									
177	JD08-f1; N4	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	LQPPA	ATISGLKPGVDYTIITGYAVT	M	A	Q	N	D	H	E	L	I	T	P	ISINYRT									
178	M7	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	LQPTT	ATISGLKPGVDYTIITGYAVT	W	E	R	N	G	R	E	L	F	T	P	ISINYRT									
179	M1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	LQPTV	ATISGLKPGVDYTIITGYAVT	L	E	R	N	D	R	E	L	F	T	P	ISINYRT									
180	MWA07-f1	WT	VSDVPRDLEVVAAATPTSLISW	RPPHFPTH	YRITYGETGGNSPVQEFVTP	LQPTV	ATISGLKPGVDYTIITGYAVT	L	E	R	N	D	R	E	L	F	T	P	ISINYRT									
181	MWH11-f1	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	PQPPA	ATISGLKPGVDYTIITGYAVT	K	E	R	S	G	R	E	L	F	T	P	ISINYRT									
182	NF09-f1; F4	WT	VSDVPRDLEVVAAATPTSLISW	RHPHFPTH	YRITYGETGGNSPVQEFVTP	PQPPA	ATISGLKPGVDYTIITGYAVT	L	E	R	N	D	R	E	L	F	T	P	ISINYRT									
183	MWG12-f1	WT	VSDVPRDLEVVAAATPTSLISW	CHPHFPTH	YRITYGETGGNSPVQEFVTP	LQPPA	ATISGLKPGVDYTIITGYAVT	M	A	Q	N	D	H	E	L	I	T	P	ISINYRT									



Table 3 KDR binders																	
SEQ ID NO	Clone Name	N-terminus	BC Loop	DE Loop	FG Loop										Binding to 1 nM KDR, %	Kd KDR, nM	
6	K1	Del 1-8	RHPHFPtr	LQPPT	M	G	L	Y	G	H	E	L	L	T	P	48	0.55
7	K2	Del 1-8	RHPHFPtr	LQPPT	D	G	E	N	G	Q	F	L	L	V	P	48	1.19
8	K5	Del 1-8	RHPHFPtr	LQPPT	M	G	P	N	D	N	E	L	L	T	P	47	1.54
9	K3	Del 1-8	RHPHFPtr	LQPPT	A	G	W	D	D	H	E	L	F	I	P	45	1.15
311	3'E9 PR4	Del 1-8	RHPHFPtr	LQPPT	V	E	Q	D	G	H	V	L	Y	I	P	44	
312	2'Del E6 PR4	Del 1-8	RHPHFPtr	LQPPT	M	G	K	N	G	H	E	L	L	T	P	43	
313	3'D3 PR4	Del 1-8	RHPHFPtr	LQPPT	P	G	P	G	D	R	E	L	I	T	P	42	
314	2'Del F8 PR4	Del 1-8	RHPHFPtr	LQPPT	A	G	P	G	A	H	E	L	L	T	P	42	
315	4'B3 PR4	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	N	N	R	E	L	L	T	P	42	
316	3'E3 PR4	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	Y	G	R	E	L	L	T	P	41	
10	K7	Del 1-8	RHPHFPtr	LQPPT	S	G	H	N	D	H	M	L	M	I	P	40	2.2
317	3'H11 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	H	N	G	N	E	L	L	T	P	39	
318	3'B4 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	W	N	G	H	E	L	M	T	P	38	
11	K4	Del 1-8	RHPHFPtr	LQPPT	A	G	Y	N	D	Q	I	L	M	T	P	38	1.95
319	2'Del F7 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	L	R	D	R	E	L	F	V	P	38	
320	2'Del D3 PR4	Del 1-8	RHPHFPtr	LQPPT	S	G	L	N	D	R	V	L	F	I	P	38	
321	3'C6 PR4	Del 1-8	RHPHFPtr	LQPPT	M	G	P	N	D	R	E	L	L	T	P	37	
322	3'F3 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	H	N	D	R	E	L	L	T	P	37	
323	3'H3 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	L	N	D	R	E	L	M	T	P	36	
324	1'Del G10 PR4	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	N	G	H	K	L	M	T	P	36	
12	K9	Del 1-8	RHPHFPtr	LQPPT	F	G	L	Y	G	K	E	L	L	I	P	35	1.8
325	2'DelE4 PR4	Del 1-8	RHPHFPtr	LQPPT	V	H	W	N	G	H	E	L	M	T	P	34	
326	2'Del C6 PR4	Del 1-8	RHPHFPtr	LQPPT	M	G	F	M	A	H	E	L	M	V	P	34	
327	2'Del C11 PR4	Del 1-8	RHPHFPtr	LQPPT	A	G	L	N	E	H	E	L	L	I	P	34	
328	2'Del D10 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	D	N	A	R	E	L	L	T	P	34	
329	2'Del H5 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	K	D	V	R	E	L	L	T	P	34	
330	3'A7 PR4	Del 1-8	RHPHFPtr	LQPPT	L	S	D	S	G	H	A	L	F	T	P	34	
331	2'Del E3 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	P	Y	E	H	E	L	L	T	P	33	
13	K10	Del 1-8	RHPHFPtr	LQPPT	T	G	P	N	D	R	L	L	F	V	P	33	0.57
332	2'Del B5 PR4	Del 1-8	RHPHFPtr	LQPPT	A	G	R	H	D	H	E	L	I	I	P	33	
333	3'C12 PR4	Del 1-8	RHPHFPtr	LQPPT	I	G	P	N	N	H	E	L	L	T	P	33	
334	2'Del G9 PR4	Del 1-8	RHPHFPtr	LQPPT	V	E	Q	N	G	R	E	L	I	I	P	33	
335	2'Del C1 PR4	Del 1-8	RHPHFPtr	LQPPT	A	G	L	D	E	H	E	L	L	I	P	32	
336	3'E1 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	P	N	G	H	E	L	F	T	P	32	
337	3'C3 PR4	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	N	G	H	A	L	F	T	P	32	
338	2'DelB7 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	Y	N	N	R	E	L	L	T	P	32	
339	3'F1 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	D	G	H	F	L	Y	T	P	31	
340	2'Del B4 PR4	Del 1-8	RHPHFPtr	LQPPT	S	G	H	N	G	H	E	V	M	T	P	31	
341	3'G3 PR4	Del 1-8	RHPHFPtr	LQPPT	F	D	Q	S	D	H	E	L	L	T	P	31	
342	2'DelH4 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	P	N	E	R	M	L	M	T	P	30	
343	3'D9 PR4	Del 1-8	RHPHFPtr	LQPPT	G	Y	Y	N	D	R	E	L	L	T	P	30	
344	3'G10 PR4	Del 1-8	RHPHFPtr	LQPPT	L	T	H	N	D	H	E	L	L	T	P	30	
345	3'B2 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	R	N	D	R	E	L	L	T	P	29	
346	2'DelC3 PR4	Del 1-8	RHPHFPtr	LQPPT	W	A	Q	N	G	R	E	L	L	T	P	29	
347	3'F2 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	K	N	D	H	E	L	L	T	P	29	
348	4'C9 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	P	N	D	H	E	L	M	T	P	29	
349	2'Del B2 PR4	Del 1-8	RHPHFPtr	LQPPT	T	G	W	N	G	N	E	L	F	T	P	29	
14	K12	Del 1-8	RHPHFPtr	LQPPT	D	V	Y	N	D	H	E	I	K	T	P	29	0.62
350	4'H7 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	H	N	D	H	E	L	L	T	P	29	
351	2'Del D1 PR4	Del 1-8	RHPHFPtr	LQPPT	L	E	Q	N	D	R	V	L	L	T	P	28	
352	2'Del H6 PR4	Del 1-8	RHPHFPtr	LQPPT	T	G	H	H	D	H	E	L	I	I	P	28	

Table 3 KDR binders																				Binding to 1 nM KDR, %	Kd KDR, nM
SEQ ID NO	Clone Name	N- terminus	BC Loop	DE Loop	FG Loop																
353	3'B12 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	H	E	N	R	E	L	L	T	P	28					
354	4'C5 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	L	N	D	H	E	L	I	T	P	27					
15	K6	Del 1-8	RHPHFPtr	LQPPT	D	G	K	D	G	R	V	L	L	T	P	27	0.93				
355	3'D8 PR4	Del 1-8	RHPHFPtr	LQPPT	A	G	P	N	D	H	Q	L	F	T	P	27					
356	3'C5 PR4	Del 1-8	RHPHFPtr	LQPPT	D	A	M	Y	G	R	E	L	M	T	P	27					
357	3'A8 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	W	D	D	H	E	L	L	T	P	27					
358	2'Del F11 PR4	Del 1-8	RHPHFPtr	LQPPT	M	G	Q	N	D	K	E	L	I	T	P	27					
359	4'D8 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	G	H	E	L	Y	T	P	26					
360	2'Del C5 PR4	Del 1-8	RHPHFPtr	LQPPT	P	G	H	N	D	H	E	L	M	V	P	26					
16	K15	Del 1-8	RHPHFPtr	LQPPT	E	V	H	H	D	R	E	I	K	T	P	25	0.35				
361	3'B1 PR4	Del 1-8	RHPHFPtr	LQPPT	E	A	R	N	G	R	E	L	L	T	P	25					
362	3'A9 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	H	N	D	R	E	L	L	T	P	25					
363	4'B11 PR4	Del 1-8	RHPHFPtr	LQPPT	M	A	H	N	D	H	E	L	L	T	P	25					
17	K11	Del 1-8	RHPHFPtr	LQPPT	Q	A	P	N	D	R	V	L	Y	T	P	24	1.16				
364	3D12 PR3	Del 1-8	RHPHFPtr	LQPPT	L	G	Q	N	D	R	Q	L	L	V	P	24					
365	2'Del H12 PR4	Del 1-8	RHPHFPtr	LQPPT	A	G	G	N	G	H	E	L	L	T	P	24					
366	3'H9 PR4	Del 1-8	RHPHFPtr	LQPPT	H	G	P	Y	D	Q	V	L	L	T	P	24					
367	3'F6 PR4	Del 1-8	RHPHFPtr	LQPPT	I	E	Q	S	G	L	Q	L	M	T	P	24					
368	1'DelE6 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	D	R	E	L	L	T	P	24					
369	3'E5 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	W	D	G	R	E	L	F	T	P	23					
370	3A3 PR3	Del 1-8	RHPHFPtr	LQPPT	L	A	Y	N	G	R	E	I	I	T	P	23					
371	3A2 PR3	Del 1-8	RHPHFPtr	LQPPT	W	S	Q	N	N	R	E	L	F	T	P	23					
372	3'B11 PR4	Del 1-8	RHPHFPtr	LQPPT	E	T	W	N	D	H	E	I	R	T	P	23					
373	1'DelA2 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	G	H	Q	L	F	T	P	23					
374	2'D6-PR4	WT	RHPHFPtr	LQPPT	V	T	H	N	G	H	P	L	M	T	P	22					
375	3'H1 PR4	Del 1-8	RHPHFPtr	LQPPT	F	A	Q	N	D	H	Q	L	F	T	P	22					
376	2'Del G11 PR4	Del 1-8	RHPHFPtr	LQPPT	G	G	Q	M	N	R	V	L	M	T	P	22					
377	2'Del F5 PR4	Del 1-8	RHPHFPtr	LQPPT	L	V	H	N	D	R	E	L	L	T	P	22					
378	1'DelE7 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	G	H	E	L	F	T	P	22					
379	2'E4-PR4	WT	RHPHFPtr	LQPPT	V	H	W	N	G	H	E	L	M	T	P	22					
380	2'Del F6 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	W	N	D	H	E	L	Y	I	P	22					
381	3'E10 PR4	Del 1-8	RHPHFPtr	LQPPT	A	G	H	K	D	Q	E	L	L	T	P	21					
382	4'A9 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	N	H	E	L	L	T	P	21					
383	4'G12 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	W	N	D	H	E	I	Y	T	P	21					
384	3'B10 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	T	G	R	E	L	L	T	P	21					
385	2'DelH9 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	W	S	G	H	E	L	F	V	P	20					
386	3'H8 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	H	N	D	R	E	L	I	T	P	20					
387	2'DelA5 PR4	Del 1-8	RHPHFPtr	LQPPT	W	N	Q	N	G	Q	E	L	F	T	P	20					
388	3B5 PR3	Del 1-8	RHPHFPtr	LQPPT	F	G	Q	N	G	H	A	L	L	T	P	20					
389	3C7 PR3	Del 1-8	RHPHFPtr	LQPPT	R	G	L	N	D	G	E	L	L	T	P	20					
390	3G2 PR3	Del 1-8	RHPHFPtr	LQPPT	F	G	P	S	D	H	V	L	L	T	P	20					
18	K14	Del 1-8	RHPHFPtr	LQPPT	R	E	E	N	D	H	E	L	L	I	P	20	0.57				
391	4'B12 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	N	H	E	L	L	T	P	20					
392	4'B8 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	D	H	K	L	F	I	P	20					
393	2'Del F1 PR4	Del 1-8	RHPHFPtr	LQPPT	R	D	Q	Y	E	H	E	L	L	T	P	20					
394	3'G1 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	L	N	G	H	E	L	F	T	P	19					
395	3'D2 PR4	Del 1-8	RHPHFPtr	LQPPT	V	E	S	N	G	H	A	L	F	V	P	19					
396	2'DelG5 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	Q	N	N	H	E	L	L	T	P	19					
397	2'DelC7 PR4	Del 1-8	RHPHFPtr	LQPPT	W	D	Q	N	G	H	V	L	L	T	P	19					
398	2'Del E5 PR4	Del 1-8	RHPHFPtr	LQPPT	E	G	L	N	D	H	E	L	I	I	P	19					
399	3'C8 PR4	Del 1-8	RHPHFPtr	LQPPT	E	G	L	N	D	H	E	L	M	I	P	19					

Table 3 KDR binders																	
SEQ ID NO	Clone Name	N-terminus	BC Loop	DE Loop	FG Loop										Binding to 1 nM KDR, %	Kd KDR, nM	
400	3'G7 PR4	Del 1-8	RHPHFPtr	LQPPT	E	G	Q	N	D	Q	L	L	F	I	P	19	
401	3'A6 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	G	H	E	L	L	T	P	19	
402	4'G4 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	D	R	E	L	L	T	P	19	
403	4'H5 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	G	H	E	L	F	T	P	18	
404	1'DelH12 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	E	R	E	L	F	T	P	18	
19	K8	Del 1-8	RHPHFPtr	LQPPT	V	T	H	N	G	H	P	L	M	T	P	18	3.3
405	2'Del D5 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	W	N	D	H	M	L	M	T	P	18	
406	3'F9 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	P	N	D	R	E	L	M	T	P	18	
407	2'H4-PR4	WT	RHPHFPtr	LQPPT	V	G	P	N	E	R	M	L	M	T	P	17	
408	4'H12 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	H	N	D	H	E	L	L	T	P	17	
409	1'DelD2 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	K	N	D	H	E	L	L	T	P	17	
410	4'E7 PR4	Del 1-8	RHPHFPtr	LQPPT	W	A	Q	N	D	H	E	L	L	T	P	17	
411	1'DelH10 PR4	Del 1-8	RHPHFPtr	LQPPT	F	A	Q	N	D	H	E	L	L	T	P	17	
20	K13	Del 1-8	RHPHFPtr	LQPPT	L	A	L	K	G	H	E	L	L	T	P	17	0.58
412	3C3 PR3	Del 1-8	RHPHFPtr	LQPPT	M	E	Q	N	G	H	E	L	F	T	P	17	
413	2'Del B3 PR4	Del 1-8	RHPHFPtr	LQPPT	D	A	P	N	G	R	E	L	M	V	P	17	
414	2'Del A2 PR4	Del 1-8	RHPHFPtr	LQPPT	G	G	R	N	G	H	T	L	L	T	P	17	
415	3'F12 PR4	Del 1-8	RHPHFPtr	LQPPT	L	S	Q	T	D	H	E	L	L	T	P	17	
416	3B4 PR3	Del 1-8	RHPHFPtr	LQPPT	V	G	Q	N	E	H	E	L	L	T	P	17	
417	3F8 PR3	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	G	H	E	L	K	T	P	17	
418	1'DelH5 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	D	R	E	L	F	T	P	17	
419	1'DelD5 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	Q	N	H	H	E	L	F	T	P	17	
420	3'E11 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	P	H	D	R	E	L	L	T	P	17	
421	2'C6-PR4	WT	RHPHFPtr	LQPPT	M	G	F	M	A	H	E	L	M	V	P	16	
422	4C9 PR3	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	D	H	E	L	L	T	P	16	
423	3C9 PR3	Del 1-8	RHPHFPtr	LQPPT	L	V	R	N	D	H	E	L	L	T	P	16	
424	3F10 PR3	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	D	D	H	E	L	L	T	P	16	
425	2'Del A11 PR4	Del 1-8	RHPHFPtr	LQPPT	E	D	I	R	V	L	W	L	N	T	T	16	
426	1'DelD1 PR4	Del 1-8	RHPHFPtr	LQPPT	V	T	Q	N	D	H	E	L	L	T	P	16	
427	1'DelE2 PR4	Del 1-8	RHPHFPtr	LQPPT	V	G	Q	N	D	H	E	L	L	T	P	16	
428	1'DelF3 PR4	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	N	D	H	K	L	F	T	P	16	
429	4'A5 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	D	H	E	L	L	T	P	16	
430	1'DelB8 PR4	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	N	D	H	E	L	L	T	P	16	
431	4'B7 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	N	H	E	L	L	T	P	16	
432	4F4 PR3	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	D	R	E	L	I	T	P	15	
433	4B11 PR3	Del 1-8	RHPHFPtr	LQPPT	V	G	Q	N	N	H	E	L	I	T	P	15	
434	3'G2 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	G	H	E	L	I	T	P	15	
435	2'Del C8 PR4	Del 1-8	RHPHFPtr	LQPPT	T	A	H	N	G	H	E	L	L	T	P	15	
436	3'B8 PR4	Del 1-8	RHPHFPtr	LQPPT	L	G	Y	H	D	H	A	L	F	T	P	14	
437	3'H10 PR4	Del 1-8	RHPHFPtr	LQPPT	W	A	W	N	D	H	E	L	M	T	P	14	
438	1'DelA1 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	D	H	E	L	L	T	P	14	
439	4'D6 PR4	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	N	D	H	E	L	M	T	P	14	
440	4F9 PR3	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	N	D	H	E	L	L	T	P	14	
441	4H5 PR3	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	N	G	H	E	L	I	T	P	14	
442	2D12 PR3	WT	RHPHFPtr	LQPPT	E	G	W	I	D	H	E	I	M	I	P	14	
443	3'F7 PR4	Del 1-8	RHPHFPtr	LQPPT	E	G	Q	N	G	S	E	L	I	V	P	14	
444	4C11 PR3	Del 1-8	RHPHFPtr	LQPPT	M	A	Q	N	D	R	E	L	I	T	P	14	
445	4B6 PR3	Del 1-8	RHPHFPtr	LQPPT	V	G	Q	N	D	H	E	L	F	T	P	14	
446	1'DelE12 PR4	Del 1-8	RHPHFPtr	LQPPT	V	A	Q	S	D	H	E	L	F	T	P	13	
447	1'DelC2 PR4	Del 1-8	RHPHFPtr	LQPPT	V	D	R	N	D	H	E	L	F	T	P	13	
448	1'DelA9 PR4	Del 1-8	RHPHFPtr	LQPPT	L	A	Q	N	D	H	E	L	M	T	P	13	

Table 3 KDR binders																
SEQ ID NO	Clone Name	N-terminus	BC Loop	DE Loop	FG Loop										Binding to 1 nM KDR, %	Kd KDR, nM
449	1'DelA4 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	D	H	E	L	F	T	P	13
450	3G5 PR3	Del 1-8	RHPHFPTR	LQPPT	L	G	E	N	D	R	K	L	I	T	P	13
451	4A12 PR3	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	D	H	E	L	L	T	P	13
452	2'Del E12 PR4	Del 1-8	RHPHFPTR	LQPPT	E	G	P	N	G	H	E	L	I	T	P	13
453	3G1 PR3	Del 1-8	RHPHFPTR	LQPPT	M	A	Q	N	V	R	E	L	L	T	P	13
454	4F12 PR3	Del 1-8	RHPHFPTR	LQPPT	V	T	Q	N	G	H	E	L	I	T	P	13
455	4B7 PR3	Del 1-8	RHPHFPTR	LQPPT	V	T	Q	N	D	H	E	L	F	T	P	13
456	4'G8 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	G	H	E	L	L	T	P	13
457	3'E8 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	D	R	Q	L	F	T	P	12
458	3'E4 PR4	Del 1-8	RHPHFPTR	LQPPT	V	G	P	N	D	R	E	L	I	V	P	12
459	1'DelC6 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	E	H	E	L	L	T	P	12
460	1'DelD3 PR4	Del 1-8	RHPHFPTR	LQPPT	L	A	Q	N	N	H	E	L	I	T	P	12
461	3A8 PR3	Del 1-8	RHPHFPTR	LQPPT	E	A	H	H	G	H	E	L	M	I	P	12
462	3C5 PR3	Del 1-8	RHPHFPTR	LQPPT	G	D	H	N	D	R	E	L	M	T	P	12
463	2'G11-PR4	WT	RHPHFPTR	LQPPT	G	G	Q	M	N	R	V	L	M	T	P	12
464	3'D4 PR4	Del 1-8	RHPHFPTR	LQPPT	L	A	H	N	D	R	E	L	I	T	P	12
465	3E6 PR3	Del 1-8	RHPHFPTR	LQPPT	V	P	Q	N	G	H	E	L	I	T	M	12
466	1'DelA11 PR4	Del 1-8	RHPHFPTR	LQPPT	L	A	Q	N	D	H	E	L	F	T	P	12
467	4'D12 PR4	Del 1-8	RHPHFPTR	LQPPT	V	D	Q	N	D	H	E	L	F	T	P	12
468	2'D5-PR4	WT	RHPHFPTR	LQPPT	V	A	W	N	D	H	M	L	M	T	P	11
469	2'A1-PR4	WT	RHPHFPTR	LQPPT	S	G	H	N	D	H	M	L	M	I	P	11
470	1'DelG11 PR4	Del 1-8	RHPHFPTR	LQPPT	L	A	Q	N	G	H	V	L	I	T	P	11
471	2'DelB10 PR4	Del 1-8	RHPHFPTR	LQPPT	V	T	H	N	D	H	E	L	L	T	P	11
472	2'DelB11 PR4	Del 1-8	RHPHFPTR	LQPPT	V	G	Q	N	D	H	E	L	M	T	P	11
473	1'DelC5 PR4	Del 1-8	RHPHFPTR	LQPPT	L	A	Q	N	D	H	E	I	M	T	P	11
474	4'B6 PR4	Del 1-8	RHPHFPTR	LQPPT	L	A	Q	N	D	H	E	L	I	T	P	11
475	3H9 PR3	Del 1-8	RHPHFPTR	LQPPT	V	S	Q	Q	N	H	E	L	L	T	P	11
476	4E10 PR3	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	D	H	E	L	M	T	P	11
477	3F5 PR3	Del 1-8	RHPHFPTR	LQPPT	V	A	Y	N	E	H	E	L	Y	T	P	11
478	4A9 PR3	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	H	D	H	E	L	L	T	P	11
479	1'DelH7 PR4	Del 1-8	RHPHFPTR	LQPPT	V	G	Q	N	D	Q	E	L	L	T	P	11
480	1'DelB10 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	R	N	D	H	E	L	M	T	P	11
481	2'DelB9 PR4	Del 1-8	RHPHFPTR	LQPPT	V	G	P	T	D	H	E	L	L	T	P	11
482	3F11 PR3	Del 1-8	RHPHFPTR	LQPPT	V	G	L	T	D	H	V	L	L	T	P	10
483	4C4 PR3	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	D	D	H	E	L	F	T	P	10
484	4B5 PR3	Del 1-8	RHPHFPTR	LQPPT	L	A	Q	N	D	H	E	L	F	T	P	10
485	3D4 PR3	Del 1-8	RHPHFPTR	LQPPT	V	G	W	N	D	H	E	L	I	T	P	10
486	4A4 PR3	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	D	H	E	L	F	T	P	10
487	3D11 PR3	Del 1-8	RHPHFPTR	LQPPT	L	G	Q	E	N	Q	E	L	I	T	P	10
488	2H10 PR3	WT	RHPHFPTR	LQPPT	L	A	P	S	A	R	E	L	M	T	P	10
489	3G10 PR3	Del 1-8	RHPHFPTR	LQPPT	V	V	H	N	G	H	E	I	L	T	P	10
490	3F4 PR3	Del 1-8	RHPHFPTR	LQPPT	M	G	Y	E	D	H	E	L	I	T	P	10
491	2H12 PR3	WT	RHPHFPTR	LQPPT	E	G	Y	Q	N	H	E	L	S	V	P	10
492	4C2 PR3	Del 1-8	RHPHFPTR	LQPPT	V	D	Q	N	D	H	E	L	F	T	P	10
493	1'DelG9 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	S	D	H	E	L	M	T	P	10
494	1'DelH9 PR4	Del 1-8	RHPHFPTR	LQPPT	V	G	Q	N	D	H	E	L	I	T	P	10
495	1'DelB3 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	D	H	E	L	M	T	P	10
496	1'DelH1 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	G	H	E	L	I	T	P	9
497	3'A3 PR4	Del 1-8	RHPHFPTR	LQPPT	R	A	Q	N	D	H	E	L	I	T	P	9
498	1'DelC4 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	S	N	H	E	L	M	T	P	9
499	1'DelE11 PR4	Del 1-8	RHPHFPTR	LQPPT	V	A	Q	N	D	R	E	L	I	T	P	9

[illegible]

Table 4: Sequences of characterized VEGF-R2 binding clones

Clone	BC loop (23-30)	DE loop (52-56)	FG loop (77-87)
VR28	RHPHFPTR	LQPPT	VAQNDHELITP
K1	RHPHFPTR	LQPPT	██████HEL██TP
K6	RHPHFPTR	LQPPT	██████L██TP
K9	RHPHFPTR	LQPPT	██████EL██P
K10	RHPHFPTR	LQPPT	████ND██L██VP
K12	RHPHFPTR	LQPPT	████NDHE██TP
K13	RHPHFPTR	LQPPT	██A██HEL██TP
K14	RHPHFPTR	LQPPT	████NDHEL██IP
K15	RHPHFPTR	LQPPT	████D██E██TP
159 (Q8L)	RHPHFPTR	LQPPA	MAQSCHELETP
E3	RHPHFPTR	LQPPT	████ND██L██P
E5	RHPHFPTR	LQPPT	██QN██L██P
E6	RHPHFPTR	LQPPT	████N██L██P
E9	RHPHFPTR	LQPPT	████N██L██TP
E18	RHPHFPTR	LQPPT	V██N██EL██TP
E19	RHPHFPTR	LQPPT	V██N██L██TP
E25	RHPHFPTR	LQPPT	████N██EL██TP
E26	RHPHFPTR	LQPPT	V██N██EL██TP
E28	RHPHFPTR	LQPPT	████N██EL██VP
E29	RHPHFPTR	LQPPT	V██N██L██TP
M1	RHPHFPTR	LQP██	████ND██ELFETP
M2	RHPHFPTR	LQPPA	████NG██ELFETP
M3 (D60)	RHPHFPT██	LQPPA	████NG██ELFETP
M4	RHPHFPT██	LQPPA	████G██ELFETP
M5FL	RHPHFPTR	LQPP██	████NG██ELFETP
M6	RHPHFPT██	LQPPA	████G██ELFETP
M7	RHPHFPTR	LQP██	████NG██ELFETP
M8	RHPHFPT██	LQPPA	████SG██ELFETP
WT	VSDVPRDLEVVAATPTSLLSW████DAPAVTVRYYRITYGETGGNSPVQEFV████GSKSTATISGLKPGVDYTTITVYAVT████GRGDSPPASSKEISINYRT		



Table 5: Affinities of the trinectin binders to KDR-Fc  
determined in radioactive equilibrium binding assay

Clone	KDR (Kd, nM)
VR28	11.0 $\pm$ 0.5
K1	<0.6 $\pm$ 0.1
K6	<0.9 $\pm$ 0.1
K9	<1.8 $\pm$ 0.4
K10	<0.6 $\pm$ 0.1
K12	<0.6 $\pm$ 0.1
K13	<0.6 $\pm$ 0.1
K14	<0.6 $\pm$ 0.1
K15	<0.4 $\pm$ 0.1



Table 6: Affinities of the trinectin binders to KDR and Flk-1  
determined in radioactive equilibrium binding assay

Clone	KDR (Kd, nM)	Flk-1 (Kd, nM)
VR28	11.0±0.5	nd*
E3	<1.0±0.2	5.4±1.5
E5	<0.4±0.1	3.2±0.3
E6	<0.4±0.1	7.1±1.1
E9	2.4±0.3	<1.4±0.1
E18	<1.2±0.2	<0.5±0.1
E19	<1.3±0.2	<0.7±0.1
E25	<1.6±0.4	<1.3±0.2
E26	<1.7±0.4	2.0±0.3
E28	<1.6±0.4	2.1±0.6
E29	<1.5±0.4	<0.9±0.2
nd* - binding is not detected at 100 nM of target		

Table 7: Determination of ka, kd and Kd by BIAcore assay				
Clone	Target	ka (1/M*s)x10 <sup>-4</sup>	kd(1/s)x10 <sup>+5</sup>	Kd (nM)
E6	KDR	89	6.7	0.08
	Flk-1	67	136.0	2.02
E18	KDR	26	12.1	0.46
	Flk-1	60	19.5	0.33
E19	KDR	30	1.7	0.06
	Flk-1	66	22.3	0.34
E25	KDR	25	5.2	0.21
	Flk-1	50	37.8	0.76
E26	KDR	11	5.8	0.51
	Flk-1	22	47.7	2.14
E29	KDR	36	7.0	0.19
	Flk-1	79	28.8	0.37
M5FL	KDR	10	9.2	0.89
	Flk-1	28	58.2	2.10
VR28	KDR	3	34	13
159(Q8L)	KDR	5	10	2

Table 8: Binding to KDR (CHO KDR) and Flk-1  
(CHO Flk-1) expressing cells

Clone	CHO KDR (EC50, nM)	CHO Flk-1 (EC50, nM)
E18	4.2±1.0	0.9±0.4
E19	7.6±1.7	5.3±2.5
E26	2.6±1.2	1.3±0.7
E29	2.3±1.0	0.6±0.1
WT	no	no

Table 9: Inhibition of VEGF-induced proliferation of KDR (Ba/F3-KDR) and Flk-1 (Ba/F3-Flk) expressing cells

Clone	Ba/F3-KDR (IC50, nM)	Ba/F3-Flk (IC50, nM)
E18	5.4±1.2	2.4±0.2
E19	12.3±2.6	5.8±1.0
E26	3.2±0.5	5.3±1.7
E29	10.0±2.1	4.7±1.2
M5FL	3.9±1.1	5.1±0.2
WT	no	no
Anti-KDR Ab	17.3±7.7	ND
Anti-Flk-1 Ab	ND	15.0±3.2

---

Table 10: Inhibition of VEGF-induced proliferation  
of HUVEC cells

---

Clone	(IC <sub>50</sub> , nM)
E18	12.8 $\pm$ 4.6
E19	11.8 $\pm$ 2.7
E26	14.0 $\pm$ 5.9
E29	8.4 $\pm$ 0.8
M5FL	8.5 $\pm$ 2.8
WT	no

---

Table 11

	hKDR			Flk-1		
	$k_a$ (1/Ms) $\times 10^{-4}$	$k_d$ (1/s) $\times 10^5$	$K_D$ (nM)	$k_a$ (1/Ms) $\times 10^{-4}$	$k_d$ (1/s) $\times 10^5$	$K_D$ (nM)
M5FL C100	7.4	6.7	0.9	14.6	30	2.1
M5FL 20K PEG	0.9	5.4	5.9	2.4	55	22.8
M5FL 40K PEG	0.5	5.9	1.3	1.0	54	57.1

## We Claim:

1. A substantially pure single domain polypeptide that binds to human KDR, the polypeptide comprising between about 80 and about 150 amino acids that have a structural organization comprising:
  - 5 a) at least five to seven beta strands or beta-like strands distributed among at least two beta sheets, and
  - b) at least one loop portion connecting two strands that are beta strands or beta-like strands, which loop portion participates in binding to KDR,wherein the single domain polypeptide binds to an extracellular domain of the human KDR protein with a dissociation constant ( $K_D$ ) of less than  $1 \times 10^{-6} M$ .
- 10 2. The single domain polypeptide of claim 1, wherein the single domain polypeptide comprises an immunoglobulin variable domain.
3. The single domain polypeptide of claim 2, wherein the immunoglobulin variable domain is selected from the group consisting of: a human  $V_L$  domain, a human  $V_H$  domain and a camelid  $V_{HH}$  domain.
- 15 4. The single domain polypeptide of claim 2, wherein the polypeptide comprises three loop portions that participate in binding to KDR, and wherein each of said loop portions connects two beta strands.
5. The single domain polypeptide of claim 1, wherein the single domain polypeptide comprises an immunoglobulin-like domain.
- 20 6. The single domain polypeptide of claim 5, wherein the immunoglobulin-like domain is a fibronectin type III (Fn3) domain.
7. The single domain polypeptide of claim 1, wherein the Fn3 domain comprises, in order from N-terminus to C-terminus,
  - 25 a) a beta strand or beta-like strand, A;
  - b) a loop, AB;
  - c) a beta strand, B;
  - d) a loop, BC;
  - e) a beta strand C;
  - 30 f) a loop CD;
  - g) a beta strand D;
  - h) a loop DE;



- i) a beta strand F;
  - j) a loop FG; and
  - k) a beta strand or beta-like strand, G.
8. The single domain polypeptide of claim 7, wherein the loop FG participates in KDR  
5 binding.
9. The single domain polypeptide of claim 7, wherein the loops BC, DE and FG  
participate in KDR binding.
10. The single domain polypeptide of claim 9, wherein each of the beta strands consists  
essentially of an amino acid sequence that is at least 80% identical to the  
10 sequence of a corresponding beta strand of SEQ ID NO:5.
11. The single domain polypeptide of claim 10, wherein each of the loops AB, CD and  
EF consists essentially of an amino acid sequence that is at least 80% identical  
to the sequence of a corresponding loop of SEQ ID NO:5.
12. The single domain polypeptide of claim 1, wherein the single domain polypeptide  
15 comprises an amino acid sequence that is at least 60% identical to the sequence  
of SEQ ID NO:5.
13. The single domain polypeptide of claim 5, wherein the polypeptide comprises three  
loop portions that participate in binding to KDR, each loop portion connecting  
two strands that are beta or beta-like strands.
- 20 14. The single domain polypeptide of any of claims 1-13, wherein a loop that  
participates in KDR binding has a sequence selected from the group consisting  
of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.
15. The single domain polypeptide of any of claims 1-13, wherein the polypeptide is  
attached to a moiety that reduces the clearance rate of the polypeptide in a  
25 mammal by greater than three-fold relative to the unmodified polypeptide.
16. The single domain polypeptide of claim 15, wherein the moiety that reduces the  
clearance rate is a polyethylene glycol moiety.
17. The single domain polypeptide of claim 16, wherein the polyethylene glycol moiety  
has a molecular weight of between 2 and 100 kDa.
- 30 18. The single domain polypeptide of claim 16, wherein the polyethylene glycol moiety  
is covalently bonded to a thiol moiety or an amine moiety in the single domain  
polypeptide.

19. The single domain polypeptide of claim 1, wherein the polypeptide is attached to a label moiety.
20. The single domain polypeptide of any of claims 1-13, wherein the single domain polypeptide binds to an extracellular domain of the human KDR protein with a dissociation constant ( $K_D$ ) of less than  $1 \times 10^{-7} M$  and inhibits KDR-mediated VEGF activity.
21. The single domain polypeptide of any of claims 1-13, wherein the single domain polypeptide binds KDR competitively with the VEGF<sub>165</sub> isoform of VEGF-A.
22. The single domain polypeptide of any of claims 1-13, wherein the single domain polypeptide binds KDR competitively with VEGF-A and VEGF-D.
23. The single domain polypeptide of any of claims 1-13, wherein the single domain polypeptide also binds to an extracellular domain of the mouse Flk1 with a  $K_D$  of less than  $1 \times 10^{-6}$ .
24. A polypeptide comprising the amino acid sequence of SEQ ID NO:192.
25. The polypeptide of claim 24, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:193.
26. A polypeptide of claim 24 comprising the amino acid sequence of SEQ ID NO:194.
27. The polypeptide of claim 26, wherein a polyethylene glycol moiety is covalently bound to the cysteine residue at position 93.
28. The polypeptide of claim 27, wherein the polyethylene glycol moiety has a molecular weight ranging from about 10 kDa to about 60 kDa.
29. A substantially pure polypeptide comprising an amino acid sequence that is at least 85% identical to the sequence of any of SEQ ID NOs: 1-4, wherein said polypeptide binds to KDR and competes for binding to KDR with VEGF-A.
30. A substantially pure polypeptide of claim 29, comprising an amino acid sequence at least 85% identical to the sequence of any of SEQ ID NOs: 6-183, 186-197, and 199.
31. The polypeptide of claim 30, wherein said polypeptide comprises the sequence of any of SEQ ID NOs: 6-183, 186-197, and 199.
32. The polypeptide of claim 29, wherein said polypeptide inhibits a biological activity of VEGF.

33. The polypeptide of claim 29, wherein said polypeptide binds said KDR with a  $K_D$  of 50 nM or less.
34. The polypeptide of claim 29, wherein the polypeptide binds to an extracellular domain of the human KDR protein with a dissociation constant ( $K_D$ ) of less than  $1 \times 10^{-7} M$  and inhibits KDR-mediated VEGF activity.
35. A therapeutic formulation comprising a polypeptide of any of claims 1-13 and 24-34, and a pharmaceutically acceptable carrier.
36. A method for inhibiting VEGF biological activity in a cell comprising contacting said cell with a polypeptide of claim 20 in an amount and for a time sufficient to inhibit said VEGF biological activity.
37. A method for treating a subject having a condition which responds to the inhibition of VEGF, said method comprising administering to said subject an effective amount of a polypeptide of claim 20, wherein said polypeptide inhibits a biological activity of VEGF.
38. The method of claim 37, wherein said condition is a condition characterized by inappropriate angiogenesis.
39. The method of claim 38, wherein said condition is a hyperproliferative condition.
40. The method of claim 38, wherein said condition is selected from the group consisting of: an autoimmune disorder, an inflammatory disorder, a retinopathy, and a cancer.
41. A method of detecting VEGFR-2 in a sample said method comprising
- contacting said sample with the polypeptide of any of claims 1-13 and 24-34, wherein said contacting is carried out under conditions that allow polypeptide-VEGFR-2 complex formation; and
  - detecting said complex, thereby detecting said VEGFR-2 in said sample.
42. The method of claim 41, wherein said detection is carried out using a technique selected from the group consisting of radiography, immunological assay, fluorescence detection, mass spectroscopy, or surface plasmon resonance.
43. The method of claim 41, wherein said sample is a biological sample.
44. The method of claim 41, wherein said biological sample is a sample taken from a human, and wherein said VEGFR-2 is KDR.


45. The method of claim 41, wherein said polypeptide is detectably labeled with a labeling moiety.
46. The method of claim 45, wherein said labeling moiety is selected from the group consisting of: a radioactive moiety, a fluorescent moiety, a chromogenic moiety, a chemiluminescent moiety, and a hapten moiety.
47. The method of claim 41, wherein said polypeptide is immobilized on a solid support.
48. A target-binding  $^{10}\text{Fn3}$  polypeptide with improved pharmacokinetic properties, the polypeptide comprising:
- a) an  $^{10}\text{Fn3}$  domain having from about 80 to about 150 amino acids, wherein at least one of the loops of said  $^{10}\text{Fn3}$  domain participate in target binding; and
  - b) a covalently bound polyethylene glycol (PEG) moiety,
- wherein said Fn3 polypeptide binds to the target with a  $K_D$  of less than 100 nM and has a clearance rate of less than 30 mL/hr/kg in a mammal.
49. The  $^{10}\text{Fn3}$  polypeptide of claim 48, wherein the PEG moiety is attached to a thiol group or an amine group.
50. The  $^{10}\text{Fn3}$  polypeptide of claim 48, wherein the PEG moiety is attached to the Fn3 polypeptide by site directed pegylation.
51. The  $^{10}\text{Fn3}$  polypeptide of claim 50, wherein the PEG moiety is attached to a Cys residue.
52. The  $^{10}\text{Fn3}$  polypeptide of claim 48, wherein a PEG moiety is attached at a position on the  $^{10}\text{Fn3}$  polypeptide selected from the group consisting of:
- a) the N-terminus;
  - b) between the N-terminus and the most N-terminal beta strand or beta-like strand;
  - c) a loop positioned on a face of the polypeptide opposite the target-binding site;
  - d) between the C-terminus and the most C-terminal beta strand or beta-like strand; and
  - e) at the C-terminus.
53. The  $^{10}\text{Fn3}$  polypeptide of claim 48, wherein the PEG moiety has a molecular weight of between about 2 kDa and about 100 kDa.
54. The  $^{10}\text{Fn3}$  polypeptide of claim 48, wherein the  $^{10}\text{Fn3}$  polypeptide comprises an amino acid sequence that is at least 60% identical to SEQ ID NO:5.

55. A method of administering a  $^{10}\text{Fn3}$  polypeptide to a patient so as to achieve a delayed release relative to intravenous administration, the method comprising: administering the  $^{10}\text{Fn3}$  polypeptide subcutaneously, thereby achieving a delayed release into the bloodstream relative to intravenous administration.
- 5 56. The method of claim 55, wherein the subcutaneous administration of the  $^{10}\text{Fn3}$  polypeptide achieves a maximum serum concentration of the  $^{10}\text{Fn3}$  polypeptide that is less than half the maximum serum concentration achieved by intravenous administration of an equal dosage.
57. The method of claim 55, wherein the  $^{10}\text{Fn3}$  polypeptide is attached to a moiety that  
10 increases the serum half-life of the  $^{10}\text{Fn3}$  polypeptide.
58. The method of claim 57, wherein the moiety is a polyethylene glycol moiety.
59. The method of claim 55, wherein the  $^{10}\text{Fn3}$  polypeptide comprises an amino acid sequence that is at least 60% identical to SEQ ID NO:5.
60. A substantially pure single domain polypeptide that binds to a preselected human  
15 target protein and a homolog thereof from a non-human species, the polypeptide comprising between about 80 and about 150 amino acids that have a structural organization comprising:
- a) at least five to seven beta strands or beta-like strands distributed among at least two beta sheets, and
  - 20 b) at least one loop portion connecting two strands that are beta strands or beta-like strands, which loop portion participates in binding to the preselected human target protein and the homolog thereof,
- wherein the single domain polypeptide binds to the preselected human target protein and to the homolog thereof with a dissociation constant ( $K_D$ ) of less than  
25  $5 \times 10^{-8}\text{M}$ , and wherein the homolog is at least 80% identical across a sequence of at least 100 amino acids to the preselected human target protein.
61. The single domain polypeptide of claim 60, wherein the single domain polypeptide comprises an immunoglobulin variable domain.
62. The single domain polypeptide of claim 61, wherein the immunoglobulin variable  
30 domain is selected from the group consisting of: a human  $V_L$  domain, a human  $V_H$  domain and a camelid  $V_{HH}$  domain.

63. The single domain polypeptide of claim 61, wherein the polypeptide comprises three loop portions that participate in binding to the preselected human target protein and the homolog thereof, each loop portion connecting strands that are beta strands or beta-like strands.
- 5 64. The single domain polypeptide of claim 60, wherein the single domain polypeptide comprises an immunoglobulin-like domain.
65. The single domain polypeptide of claim 64, wherein the immunoglobulin-like domain is a fibronectin type III (Fn3) domain.
66. The single domain polypeptide of claim 65, wherein the Fn3 domain comprises, in  
10 order from N-terminus to C-terminus,  
a) a beta strand or beta-like strand, A;  
b) a loop, AB;  
c) a beta strand, B;  
d) a loop, BC;  
15 e) a beta strand C;  
f) a loop CD;  
g) a beta strand D;  
h) a loop DE;  
i) a beta strand F;  
20 j) a loop FG; and  
k) a beta strand or beta-like strand, G.
67. The single domain polypeptide of claim 66, wherein the loop FG participates in target protein binding.
68. The single domain polypeptide of claim 66, wherein the loops BC, DE and FG  
25 participate in target protein binding.
69. The single domain polypeptide of claim 66, wherein each of the beta strands or beta-like strands consists essentially of an amino acid sequence that is at least 80% identical to the sequence of a corresponding beta strand of SEQ ID NO:5.
70. A nucleic acid comprising a sequence encoding the polypeptide of claim 1.
- 30 71. The nucleic acid of claim 70, wherein said nucleic acid encodes a polypeptide selected from the group consisting of any of SEQ ID Nos. 6-183, 186-197, 199 and 241-310.

72. A nucleic acid comprising a nucleic acid sequence that hybridizes in stringent conditions to a nucleic acid sequence of SEQ ID NO: 184 and encodes a polypeptide that binds to human KDR with a  $K_D$  of less than  $1 \times 10^{-6} M$ .
73. The nucleic acid sequence of claim 72, wherein said nucleic acid comprises a  
5        nucleic acid sequence selected from the group consisting of SEQ ID NO:184 and SEQ ID NO:185.
74. An expression vector comprising the nucleic acid of claim 71 operably linked with a promoter.
75. A cell comprising the nucleic acid of claim 72.
- 10    76. A method of producing the polypeptide that binds KDR, comprising: expressing a nucleic acid comprising a sequence encoding the polypeptide of claim 1.
77. The method of claim 76, wherein the nucleic acid comprises a sequence that encodes a polypeptide selected from the group consisting of any of SEQ ID Nos. 6-183, 186-197, 199 and 241-310.
- 15    78. The method of claim 76, wherein the nucleic acid comprises a sequence that hybridizes in stringent conditions to a nucleic acid sequence of SEQ ID NO: 184
79. The method of claim 76, wherein the nucleic acid is expressed in a cell.
80. The method of claim 76, wherein the nucleic acid is expressed in a cell-free system.





Figures 1A-1D






Figure 2

3A



3B



Figures 3A-3B






Figure 4

5A




5B

Figures 5A-5B




Figures 6A-6B




Figures 7A-7B



8A



8B



Figures 8A-8B






Figure 9


Figure 10

M5FL in 100 mM NaOAc, pH 4.5

Scan 1: T<sub>m</sub> = 67 deg (40%), 77 deg (60%)Scan 2: T<sub>m</sub> = 67 deg (34%), 77 deg (66%)

$$\Delta H_{\text{scan2}} / \Delta H_{\text{scan1}} = 99\%$$

Figure 11

Samples

M: Marker  
-: Starting M5FL  
20: M5FL-PEG20  
40: M5FL-PEG40

Figure 12




Figure 13. CT-01 Blocks VEGFR-2 Signaling in Human Endothelial Cells




Figure 14. Blocking VEGF with Fibronectin-based KDR Binders (M5FL, F10, CT-01)








Figure 15. Comparison of <sup>125</sup>I native, PEGylated CT-01 administered iv & ip.




**Figure 16. Pharmacokinetics of CT-01**  
**Tissue distribution of <sup>125</sup>I-CT01PEG40 in normal rats**



## Figure 17. Miles Assay Measures Vascular Permeability


### 1. Treat mice with test article i.p.

Treatment is hours prior to assessment of VEGF blocking activity




### 2. Inject Evans blue i.v.


Let it circulate for 10 min



### 3. Inject VEGF<sub>165</sub> intradermally to induce vascular permeability




### 4. Sacrifice mice and skin the back



Flipped back skin

### 5. Extract the Evans blue and quantify by A<sub>620</sub>

Figure 18. CT-01 Blocks VEGF In Vivo



\*- Statistical difference from VEGF-induce leakage in control mice (P < 0.05)

Figure 19. CT-01 Inhibits Tumor Growth  
B16-F10 Murine Melanoma Tumor Assay





Figure 20. CT-01 Inhibits Tumor Growth  
U87 Human Glioblastoma, i.v EOD



Treatment was initiated on ~day 22 after the establishment of measurable tumors

VL-KDR selection

PR7 VLE/KDR sequences

SEQ ID NO:		
241	A1-1	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
242	C1-3	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
243	H1-8	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
244	F1-6	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
245	G1-7	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
246	H4-32	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
247	E2-13	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
248	B2-10	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
249	H3-24	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
250	F4-30	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
251	F2-14	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
252	B3-18	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
253	A2-9	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
254	C2-11	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
255	D1-4	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
256	A4-25	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
257	B4-26	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
258	C4-27	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
259	G4-31	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
260	H2-16	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
261	E4-29	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
262	F3-22	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
263	G3-23	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
264	D3-20	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
265	E1-5	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
266	A3-17	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
267	D4-28	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
268	C3-19	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA
269	E3-21	EIVMTQSPGTLSPGERATLSCRASQS-VSSNS-----VAWYRKKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYVCATVAGDH-VEDHWGQGTKEIKADGSDYKDDDDKASA


PR8 VLE/KDR 5 nm pool sequences

270	A5-33	EIVMTQSPGTLSPGERATLSCRASQS-VSSSS-----LAWYRQKPGQAPRLLIYGASNATGIPDRFSGSGSGTDFTLTISLQPEDFAVYVCATVAGC-SSGRNWGQGTKEIKADGSDYKDDDDKASA
271	C5-35	EIVMTQSPGTLSPGERATLSCRASQS-VSSSS-----LAWYRQKPGQAPRLLIYGASNATGIPDRFSGSGSGTDFTLTISLQPEDFAVYVCATVAGC-SSGRNWGQGTKEIKADGSDYKDDDDKASA
272	B5-34	EIVMTQSPGTLSPGERATLSCRASQS-SSSS-----LAWYRQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTISLQPEDFAVYVCATVAGC-SSGRNWGQGTKEIKADGSDYKDDDDKASA


Figure 21A







Immunoglobulin VH



Fibronectin type III





Figure 22